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ABSTRACT
Pseudomonas aeruginosa is one of the main causes of healthcare-associated
infections among hospitalized patients. Healthcare-associated infections predominantly lead
to pneumonia, urinary tract infections, as well as skin and soft-tissue infections. This
organism is commonly multiresistant and leads to morbidity and mortality. In this study,
the resistance mechanisms of 88 clinical P. aeruginosa isolates from the Department of
Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur,
Malaysia were evaluated. The antibiotics resistance profiles of these isolates were
determined and this was followed by evaluating the expression levels of AmpC
cephalosporinase, the multidrug efflux pumps, the OprD outer membrane porin and the
penicillin binding protein (PBP2, PBP3). Selected clinical isolates that were resistant to
imipenem and meropenem were evaluated for metallo--lactamase (MBL) and extended
spectrum β-lactamases (ESBL) production. The antimicrobial agents tested in this work
were piperacillin/tazobactam, ceftazidime, aztreonam, amikacin, gentamicin, ciprofloxacin,
imipenem, meropenem and colistin. These agents were selected as representatives of the
primary antibiotic classes used to treat P. aeruginosa infections.
The clinical specimens of P. aeruginosa isolates were isolated from urine (53.4%),
wound (21.6 %), sputum (5.7%), blood (5.7%) and in dwelling medical devices (13.6 %) as
shown in Table 3.1a. Samples were collected from patients hospitalized in the surgical (31),
medical (20), orthopedic (13), paediatric (7), neurosurgery (7), intensive care unit (ICU)
(5), otorhinolaryngology (ENT) (3) and gynaecology wards (2). Of these isolates, 47 were
from urine, 19 from wounds, 12 from in dwelling medical devices, 5 from blood, and 5
from sputum.
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In the isolates tested. The highest resistance was observed for gentamicin (94.0%),
ciprofloxacin and ceftazidime (92%), imipenem (74.0%), meropenem (78%), amikacin
(66.0%), piperacillin/tazobactam (58.0%), aztreonam (56.0%) and colistin (7.0%), with the
surgical department having the highest of numbers of isolates resistant for all antibiotics
except colistin with urine and wound specimens being most resistant to the antibiotics
except for colistin.
The gene expression analysis of 88 P. aeruginosa isolates showed overexpression of efflux
pump genes for MexY (82.0%, from 2.0 to 1731.0 fold), MexB (73.0%, from 2.0 to 50.0
fold), MexEF (68.0%, from 2.9 to 371), MexZ (66.0%) and MexCD (48.0%, from 2.0 to
522), while for AmpC overexpression it was 65.0% (from 10.4 to 1806.0 fold). Down
regulation were noted for OprD (97.0%, from 0.2 to 0.7 fold), PBP2 (77.0%, from 0.1 to
0.7 fold), PBP3 (84.0%, from 0.01 to 0.7 fold) and OprM (65%, from 0.2 to 0.7) as
compared to those of P. aeruginosa ATCC 27853.
Among the resistant isolates overexpressed for the MexB and MexY efflux gene, the lowest
mRNA expression was noted for isolates resistant to colistin, whereas the highest mRNA
expression was noted for isolates resistant to ciprofloxacin and amikacin respectively. For
the overexpression of MexCD and MexEF genes, the lowest mRNA expression was seen
with isolates resistant to piperacillin/tazobactam. However, the highest overexpression for
MexCD was seen with isolates resistant to meropenem and aztreonam while the highest
overexpression for MexEF gene was noted with isolates resistant to colistin. For the
overexpression of AmpC gene, the lowest mRNA expression was seen with isolates
resistant to colistin and the highest mRNA expression was noted with isolates resistant to
piperacillin/tazobactam. All isolates resistant to meropenem, imipenem and colistin
demonstrated lower mRNA expression for OprD gene while as for OprM gene, the lowest
vmRNA expression was observed in isolates resistant to amikacin. For the PBP gene,
isolates resistant to colistin had lower mRNA expression for PBP2, PBP3 while those
resistant to imipenem had higher mRNA expression. With regard to the significance of the
above results, the overexpressions of MexY gene were significantly different in isolates
resistant to amikacin, gentamicin and ciprofloxacin as compared to other antibiotics (p <
0.05), while, for the AmpC gene, mRNA expression in P. aeruginosa isolates demonstrated
high significant differences towards piperacillin/tazobactam antibiotics as compared to
other antibiotics (p < 0.05).
Sixty-five of the clinical P. aeruginosa isolates that were resistant to imipenem and
meropenem were then evaluated for detection of 6 different metallo-beta-lactamase (MBL)
genes (blaIMP, blaVIM, blaGIM, blaSIM, blaSPM and blaNDM). In addition, these isolates were
tested for the extended spectrum beta-lactamase (ESBL) production genes (blaVEB, blaTEM,
blaCTX-M, blaSHV and blaPER) using PCR. Among the 65 imipenem and meropenem resistant,
41 isolates were metallo-β-lactamase (MBL) producers and these genes blaIMP, blaVIM,
blaGIM, blaNDM and blaSIM were detected in 20, 14, 4, 2, and in 1 isolates respectively.
Thirty-three of these 65 isolates tested positive for 3 ESBL genes out of which PCR
positive isolates were present in 25 isolates for the blaVEB gene, 5 isolates for the blaTEM
gene and 3 isolates for the blaCTX-M gene respectively.
Most of the P. aeruginosa clinical isolates had a high level of resistance to
examined antibiotics except colistin. Multidrug resistance phenotype in these clinical
isolates was caused by the interaction of several different resistance mechanisms occurring
within the same strain such as overexpression of efﬂux, AmpC overproduction or decreased
outer membrane porin OprD, alteration of penicillin binding protein. Additionally, these
strains highlight the ability of P. aeruginosa to develop dual resistance to different classes
vi
of antimicrobial agents through independent mechanisms of resistance and highlight the
need for the judicious use of therapy when dealing with P. aeruginosa to prevent multidrug
resistance. The clinical P. aeruginosa isolates that were resistant to imipenem and
meropenem demonstrated high efflux overproduction, MBL and ESBL production that
confirm these resistance genes has the ability to increase the resistance to imipenem and
meropenem among P. aeruginosa.
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1Chapter 1
Introduction
21.1 Introduction
P. aeruginosa is one of the main causes of healthcare-associated infections among
hospitalized patients. Healthcare-associated infections predominantly lead to
pneumonia, urinary tract infections as well as, skin and soft-tissue infections. This
organism commonly demonstrates multiresistant isolates, which leads to morbidity and
mortality (Aloush et al., 2006; Giske et al., 2008b; Park et al., 2011). P. aeruginosa is a
therapeutic challenge for the treatment of healthcare-associated infections. The choice
of suitable antipseudomonal agents for treatment is significant in optimizing clinical
effects (Micek et al., 2005).
The extensive use of antimicrobial agents and the evolution of antimicrobial resistance
strategies of bacteria have resulted in the emergence of nosocomial bacterial pathogens
with acquired resistance to almost all available antimicrobial agents. These ‘Superbugs’,
have severely threatened therapeutic choices in the last few decades (Livermore et al.,
2001). P. aeruginosa is considered multidrug resistant (MDR) if the isolate is resistant
to more than two of the following drugs: piperacillin/tazobactam, ceftazidime,
aztreonam, amikacin, gentamicin, ciprofloxacin, imipenem, meropenem and colistin
(Mangoni et al., 2008; Kiser et al., 2010). These agents are representatives of the
primary antibiotic classes used to treat P. aeruginosa infections. P. aeruginosa uses
distinctive mechanisms to become resistant to a wide range of antimicrobials agents.
Several mechanisms contribute to P. aeruginosa acquiring resistance. These include the
up-regulation of efflux systems, decreased outer membrane permeability and β-
lactamase production. However, acquired extended spectrum β-lactamase (ESBL) and
Metallo β-lactamase (MBL) mediated resistance is important in emerging resistance
mechanisms in P. aeruginosa (Dumas et al., 2006; Strateva & Yordanov, 2009). P.
aeruginosa has been reported to have constitutive expression of multidrug efflux pumps
and AmpC β-lactamase, associated with loss in permeability of the outer membrane (De
3Kievit et al., 2001). A number of broadly specific efflux pump systems, including
MexB-OprM and MexXY-OprM that belong to the resistance-nodulation-division
family, supplies the main role to this intrinsic multidrug resistance. These systems are
able to pump out multiple antipseudomonal compounds and reduce its susceptibility
(Hocquet et al., 2006).
Several studies on the MexAB-OprM mutants showed that this multidrug efflux pump
extrudes aminoglycosides, macrolides, quinolones and most β-lactams but not
imipenem (Xavier et al., 2010). MexXY-OprM is however capable of extruding
amikacin, ciprofloxacin, gentamicin, cefotaxime, meropenem, cefepime and
erythromycin (Poole & Srikumar, 2001). P. aeruginosa also possesses inducible
chromosome-encoded AmpC β–lactamase that belongs to the molecular class C that
confers resistance to β-lactams (cephalosporins, penicillins). The up-regulation of efflux
pumps coupled with overexpression of β-lactamase in addition to porin loss, may
increase the pump rate and co-resistance phenotypes that could critically influence
antimicrobial therapy in clinical settings (Poole, 2007; Quale et al., 2006). In
Enterobacteriaceae and P. aeruginosa, ESBLs are commonly known to mediate
resistance to penicillin, cephalosporins, and monobactams (Tenover et al., 2003). ESBL
of Ambler class A enzymes are naturally able to hydrolyze 3rd generation
cephalosporins and/or several carbapenems such as CTX-M, TEM ,VEB, GES, SHV and
PER (Bonnet, 2004). The appearance of ESBL-producers associated with multiple
resistant isolates pose a serious problem in the hospital setting. The factors that
contribute to the increase in antibiotic resistance in bacterial pathogens are the extensive
use of antibiotics coupled with the transmissibility of resistance determinants mediated
by plasmids, transposons, and gene cassettes in integrons (Kang et al., 2005).
4The metallo β-lactamases (MBLs) class B is encoded by genes such as IMP, VIM, SPM,
GIM and the recently reported NDM. The IMP and VIM types are the most common and
widespread as they exhibit a worldwide distribution for which several allelic variants
are known (Pagani et al., 2005; Walsh et al., 2005; Aggarwal et al., 2008). The
occurrence of ESBLs and MBL-producing P. aeruginosa are increasingly being
reported worldwide (Gibb et al., 2002; Pagani et al., 2004; Lee et al., 2005; Aggarwal et
al., 2008). The expression of the genes involved in the various mechanisms of the drug
resistance were evaluated using the conventional method of detecting proteins by
western blotting, which is complex and time consuming (Poole, 2007; Dumas et al.,
2006; Quale et al., 2006; Hocquet et al., 2006; Savli et al., 2003). Current methods
include real time PCR her quantification of mRNA expression of the target gene
(Dumas et al., 2006).
1.2    Characteristics of P. aeruginosa
P. aeruginosa is an aerobic Gram-negative rod (Figure 1.1), with the remarkable
adaptable capacity to stay alive and continue under a wide range of environmental
situations. This organism is usually 1.5-5 µm in length, 0.5-1.0 µm in width, and is
motile due to the presence of flagella. P. aeruginosa was first isolated from a range of
environmental resources by Schroeter in 1872 (Palleroni, 1984). In addition, this
organism was first isolated from wound infections of soldiers whose bandages had a
blue and green color by Carle Gessard in 1882 (Gessard, 1984). P. aeruginosa belongs
to the Pseudomonadaceae family in the category of Gammaproteobacteria. Typical
features of P. aeruginosa isolates include positive oxidase tests, the ability to be
cultivated at temperatures of 42°C and (although it is classified as strictly aerobic) the
ability to grow under anaerobic conditions by the presence of an alternative terminal
electron acceptor such as nitrite or arginine, while utilizing more than eighty organic
compounds as carbon and energy sources (Dworkin & Falkow, 2006).
5Figure 1.1: Gram stain of P. aeruginosa cells (takes from http:// textbook of
bacteriology.net/pseudomonas.html).
P. aeruginosa is equipped with an equally large repertoire of pathogenic mechanisms
and is able to infect eukaryotic organisms ranging from amoeba to humans. P.
aeruginosa is a glucose and lactose non-fermenting bacterium that is commonly isolated
from hospitalized patients and may be found in a variety of aqueous solutions, including
disinfectants, soaps and eye drops. It can also be found in sinks, hot tubs, respiratory
equipment, showerheads, and has the ability to produce the water-soluble pigments
pyoverdine and pyocyanin, which together confer the bright green color characteristic of
the organism when grown on Pseudomonas isolation agar (King et al, 1954; Todar,
2006).
P. aeruginosa can cause a variety of diseases and can be isolated from almost any type
of specimen. Infections can be acquired from the community or during a stay in a
healthcare facility. P. aeruginosa is rarely part of the microbial flora of healthy
individuals, but may colonize the gastrointestinal tract of hospitalized patients,
particularly those who have received previous antibiotic therapy (Dworkin & Falkow,
2006). The colony morphology, pigmentation of P. aeruginosa can be quite
substantially heterogeneous. On a simple agar culture at 37ºC, the morphological colony
6is smooth and large with an elevated center giving it the appearance of a fried egg.
Colonies are usually pigmented and in actuality, the species designation, coming from
the aeruginous meaning “the color of copper rust,” reﬂects the feature blue green color
reported on colonies by the phenazine pyocyanin pigment. The rusty-brown phenazine
pyorubin and fluorescent yellow-green siderophore pyoverdin are other common
pigments, which are included in this bacterium (Palleroni, 1984). As pointed out by Lau
et al. (2004) pyocyanin is a compound with a redox-active effect and has multiple
cytopathic influences on mammalian cells (Lau et al., 2004). P. aeruginosa has different
forms of motility, which can be identiﬁed as swimming, twitching and swarming.
Versatile, with motility chemotaxis that may allow it to move either in fluid and/ solid
surfaces, P. aeruginosa swims in aqueous environments with single polar ﬂagella
movements. However, it can also move by twitching and swarming on solid surfaces.
Flagella and type IV pili are needed for swarming whereas; twitching is powered by the
sequential extension and retraction of type IV pili (Kohler et al., 2000; Merz et al.,
2000). Many chemicals can be demonstrated to result in chemotactic responses due to
the twitching and swimming of the P. aeruguinosa (Kato et al., 2008).
The increasing use of the antimicrobial and environmental stresses leading to chronic
infections of individual airways is due to change in colony morphology that arises
during bioﬁlm production (von Gotz et al., 2004; Häußler et al., 2003; Drenkard &
Ausubel, 2002). According to von Gotz et al. (2004) and Boles et al. (2004) various
types of colonial morphology in P. aeruginosa displays phenotypic modifications in
motility, antibiotic resistance, bioﬁlm formation, adherence properties, and virulence
gene expression. The creation of various phenotypic properties may possibly contribute
to the persistence and pathogenic achievement of P. aeruginosa (von Gotz et al., 2004;
Boles et al., 2004).
71.3 Clinical infection caused by P. aeruginosa
P. aeruginosa can cause infection in almost any part of the body, although it does not
typically cause infection in a healthy host. This bacterium is an opportunistic pathogen
that causes respiratory system infections, urinary tract infections, dermatitis, bacteremia,
soft tissue infections and a variety of systemic infections. It is found mainly in patients
with severe burns, cancer, and AIDS patients who are immunocompromised. Outbreaks
caused by this organism have been reported in diverse settings (Pirnay et al., 2003). P.
aeruginosa causes bacteremia mainly in immunocompromised patients and other
diseases such as diabetes mellitus, hematologic malignancies, neutropenia and severe
burns. The majority of Pseudomonas bacteremia is acquired in hospitals and nursing
homes, which accounts for 25% of all healthcare-associated Gram-negative bacteremia.
P. aeruginosa causes meningitis and brain abscesses due to the organism invading the
central nervous system (CNS) from the paranasal sinus or inner ear, or if it is inoculated
directly by means of surgery or invasive diagnostic procedures, or if it spreads from a
distant site of infection such as the urinary tract. P. aeruginosa causes ear infection as a
predominant bacterial pathogen in some cases of external otitis, including swimmer's
ear. This bacterium is also found in the normal ear, but often inhabits the external
auditory canal in association with inflammation, injury, maceration, or simply wet and
humid conditions. P. aeruginosa is also a common cause of eye infections including
keratitis, and has been isolated as the etiologic agent of neonatal ophthalmia (Martin et
al., 2003). P. aeruginosa also causes chronic contiguous osteomyelitis, usually resulting
from direct inoculation of bone and is the most common pathogen implicated in
osteochondritis after puncture wounds of the foot. P. aeruginosa can produce disease in
any part of the gastrointestinal tract from the oropharynx to the rectum (Driscoll et al.,
2007).
8The infection caused by P. aeruginosa varies depending on whether the person has an
underlying disease, or has had some type of healthcare intervention (Weinstein, 1998).
As reported by System, (2003) P. aeruginosa is considered the most common cause of
healthcare-associated pneumonia (17%), urinary tract infection (7%), surgical site
infection (8%), blood pathogen (2%) and is the ﬁfth most common isolate from all sites
(9%) (System, 2003). P. aeruginosa is lately known as a common source of many
community and healthcare-associated infections. In the community, the incidence of P.
aeruginosa can cause community-acquired pneumonia (CAP) which is increased in
patients with chronic obstructive pulmonary disease, nursing home residents and
patients recently discharged from the hospital (Ruiz et al., 1999). It is commonly spread
in natural environments and is usually found in soil and water. It can grow in distilled
water due to gaseous dissolved nutrients (Niederman, 2010; Lim et al., 2003). Most
aqueous solutions including disinfectants, antiseptics, intravenous fluids and eyewash
solutions are considered as reservoirs of P. aeruginosa. It is common in hospital settings
and persists in respiratory equipments, sinks, tubs and hydropathy baths. Because of
their presence in soil they are frequently recovered from fresh vegetables and plants
(Weinstein & Hota, 2004).
The infections caused by P. aeruginosa range from self-limiting folliculitis to life-
threatening bacteremia. These infections occupy the cornea, respiratory tract, urinary
tract, blood stream, surgical sites and skin infections in the setting of burn injuries, even
though infections may occur effectively in every anatomical site. It also leads to urinary
tract infections and ventilator-associated pneumonia in the intensive care unit (Speert et
al., 2002; Mittal et al., 2009). The infections resulted by P. aeruginosa can be divided
into acute or chronic. It has been quoted that acute infections, such as ventilator-
associated pneumonia, are invasive, cytotoxic and commonly lead to systemic infection,
9septic shock and mortality (Martin & Yost, 2011; Agodi et al., 2007; Martínez-Solano
et al., 2008). On the contrary, the chronic respiratory infections linked with cystic
fibrosis, although heavy in colonization of the sputum (>108 colony-forming units
cfu/g), are non-invasive, noncytotoxic and infrequently develop to systemic infection.
These chronic infections may continue for decades and in the end lead to lung
deterioration and mortality (Speert et al., 2002; Scheetz et al., 2009).
P. aeruginosa colonization plays a main role within intensive care units (ICUs), and it
has the capability to colonize in-patients, with ICUs clearly established as endemic
settings (Erbay et al., 2003). A deep understanding and knowledge of the mechanisms
of P. aeruginosa is therefore critical. Risk factors considerably related with the
acquisition of this bacterium in ICUs include: period of stay, mechanical ventilation
(Talon et al., 1998), long-term use of antibiotics (Blanc et al., 1998; Baddour et al.,
1995; Carmeli et al., 1999a), alcoholism (Blanc et al., 1998; Talon et al., 1998) and the
utilization of indwelling urinary catheters (Blanc et al., 1998). P. aeruginosa is
infrequently found as a part of the human microflora of healthy individuals as this
organism dies in the dry skin of healthy individuals (Bellais et al., 1999). P. aeruginosa
has a vast array of virulence factors and is universally distributed in natural
environments. This organism is rarely responsible for community-acquired infections in
healthy individuals. On the other hand, the incidence of P. aeruginosa associated
infection is high in a hospital environment particularly in immune compromised
individuals, epithelium compromised cystic fibrosis patients, and individuals with
severe burns, ulcerations and mechanical abrasions caused by catheterization. P.
aeruginosa is the main cause of death in cystic fibrosis patients (Thuong et al., 2003).
Infections caused by P. aeruginosa not only become increasingly resistant to one drug,
as multi-drug resistance is also increasing and have been difficult to treat (Flamm et al.,
2004). Due to increasing rates of antibiotic resistance in P. aeruginosa, the treatment of
10
infections is still a serious medical challenge. Infection with MDR P. aeruginosa is
associated with risk factors including severity of illness, invasive devices, a bedridden
state, and in hospitalized patients, lead to increased length of stay and increased
therapeutic costs as well as significant morbidity and mortality (Defez et al., 2004;
Paramythiotou et al., 2004; Moore & Flaws, 2011b). P. aeruginosa has been a well
known cause of infections for almost 130 years and will probably remain a leading
cause of infections in humans for many years to come for various reasons (Moore &
Flaws, 2011c); P. aeruginosa is ubiquitous in nature, increasing the probability of
exposure, patients with chronic disease and immunosuppression for long periods are
susceptible hosts for infection with P. aeruginosa. In addition, P. aeruginosa has many
resistant mechanisms to antipseudomonal agents that are not always used judiciously
and when overprescribed drive the development of resistance.
1.4 Pathogenicity of P. aeruginosa
P. aeruginosa is an opportunistic pathogen that causes acute and chronic infections that
can be acquired from the environment. It colonizes the respiratory epithelium in patients
with predisposing conditions such as cystic fibrosis, mechanical ventilation,
immunodeficiency or preexisting respiratory disease. The P. aeruginosa pathogenicity
is mainly caused by various bacterial virulence factors and genetic flexibility, enabling
it to survive in varied environments. Lung injury associated with P. aeruginosa
infections result from both the direct destructive effects of the organism on the lung
parenchyma, and the exuberant host immune responses. The factors that contribute to
the pathogenesis of P. aeruginosa are based on the health status of the host.
Hospitalized patients with underlying disease, particularly those who are on a ventilator
are most at risk for pneumonia caused by P. aeruginosa. In addition, pathogenesis
comes from the organism itself. In order for P. aeruginosa to cause any type of
infection it must first enter the host and colonize. Entry is often through inhalation into
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the respiratory tract, but the organism is so ubiquitous that is hard to tell exactly how the
organism is acquired in all cases.
The virulence factors produced by P. aeruginosa are listed and summarized in Table 1.1
(Sadikot et al., 2005; Driscoll et al., 2007). All of the virulence factors used by P.
aeruginosa are also produced by other microorganisms except for pyocyanin, which is
uniquely produced by P. aeruginosa. Many of these factors assist colonization, whereas
others facilitate bacterial invasion. Several factors are required in bacterial colonization,
including, pili or ﬁmbriae, ﬂagella and surface polysaccharides. Virulence factors can be
divided into two functional groups: factors that assist in the attachment of the organism
to host cells, which are the fimbriae and flagella; and factors that support in the invasion
of tissue and the inhibition of the immune response. These virulence factors include pili,
and flagella, which play an initial role in motility and adhesion to the epithelium, as
well as the endotoxin lipopolysaccharide (LPS). These factors then perform a main
function in the irreversible adhesion to epithelial cells, which is the first significant step
in colonization of the respiratory epithelium. Upon cell contact, the type III secretion
system, a major virulence determinant is activated. The type III secretion system
permits P. aeruginosa to produce toxins into the host cell. The type III secretion system
is coupled with acute invasive infections and requires pilin-mediated bacterial-epithelial
contact (Feldman et al., 1998; Hauser et al., 1998). This system is activated on contact
with eukaryotic cell membranes and interferes with signal transduction, leading to cell
death or changes in host immune responses. The type III secretion system includes three
apparatus: the secretion, the translocation or targeting apparatus, and the secreted toxins
(effector proteins) and cognate chaperones (Gauthier et al., 2003).
P. aeruginosa produces a number of secreted toxins by the single type III secretion
system, which include exoenzyme S (ExoS), exoenzyme U (ExoU), exoenzyme T
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(ExoT), and exoenzyme Y (ExoY). They contribute at differing levels in the
cytotoxicity leading to invasion and dissemination of bacterium (Epelman et al., 2004).
Among these exoenzymes, ExoU may be responsible for the highest virulence (Hauser
et al., 2002; Schulert et al., 2003). The expression of the type III secretion system in P.
aeruginosa isolates has been associated with increased mortality in patients with
pneumonia, sepsis, respiratory failure, and more severe diseases (Hauser et al., 2002;
Roy-Burman et al., 2001). Aside from the type III secreted proteins; P. aeruginosa
produces additional virulence factors that contribute to its pathogenicity. These
virulence factors are produced by the type II secretion system into the extracellular
space. These include exotoxin A, alkaline phosphatase, elastase and phospholipase C,
which contribute in the invasion via destroying the protective glycocalix of the
respiratory epithelium and exposing epithelial ligands to P. aeruginosa (Lau et al.,
2005; Hauser et al., 2002). These proteins encourage invasion by causing cytotoxic
effects on host cells (Wilson et al., 1987). A similar function also exists for pyoverdine
and pyocyanin.
P. aeruginosa strains mainly produce pyocyanin (N-methyl1-hydroxyphenazine), the
pigment that gives the blue-green color to the bacterial colonies. It has been found to
have various pathogenic effects such as increasing production IL-8, depressing host-
response (Denning et al., 1998; Leidal et al., 2001) and inducing apoptosis in
neutrophils (Allen et al., 2005). In animal models of acute and chronic lung infection,
pyocyanin was shown to be necessary to P. aeruginosa virulence (Lau et al., 2004). In
acute infections, invasion, dissemination and extensive tissue damage predominate. In
chronic infections, primarily in cystic fibrosis patients, P. aeruginosa may also adjust,
by losing its most immunogenic features such as flagella and pili to prevent clearance,
and by isolating itself from host defenses and adhering to the respiratory epithelium by
forming biofilms. A persistent inflammatory state is maintained by extracellular
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secreted virulence factors (Landsperger et al., 1994). Whether in acute or chronic
infections, P. aeruginosa possesses a multiplicity of regulatory systems allowing it to
adapt to its environment and notably to host defenses (Mahenthiralingam et al., 1994).
Among these systems, quorum sensing (QS) displays P. aeruginosa adaptability (Finch
et al.,1998). Quorum sensing systems are complex bacterial cell-to-cell signaling
systems that allow the bacteria to sense their own cell density and to communicate with
each other resulting in coordinated production of virulence factors depending on
bacterial density (Kaufmann et al., 2008). QS has been shown to be critical in
maintaining airway inflammation through virulence factor production and to the
formation of biofilm in chronic infections (Hentzer et al., 2003).
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Table 1.1: Virulence factors of P. aeruginosa and their function
Virulence Factor Function
Fimbriae Attachment to host cells and activation of pro
inflammatory gene expression
Polar flagella Motility, attachment to host cells and activation of
lnterleukin-8
Type III secretion system Injects toxins (ExoS, ExoT, ExoU, ExoY) into host
cells
ExoS Stimulates tumor necrosis factor alpha production
ExoT Activates GTPase
ExoU Cytotoxin
ExoY Adenylate cyclase activity
Quorum-sensing molecules Coordinate expression of genes among other
pseudomonal cells and promotes the formation of
biofilms
Pyochelin and pyoverdin Bind iron
Elastase, proteases, hemolysins,
and leukocidin
Aid in tissue invasion and lyse host cells
Pyocyanin Inhibits lymphocyte proliferation and cilia function
and produces reactive oxygen intermediates
Exotoxin A Inhibits protein synthesis in host cells and helps
organism disseminate
Lipopolysaccharide Endotoxin
Alginate Free radical scavenger; inhibits phagocytosis,
neutrophils chemotaxis and activation of complement
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1.5 Treatment of P. aeruginosa
P. aeruginosa is often resistant to a wide range of antimicrobial agents, including
fluoroquinolones, tetracycline, aminoglycoside, β-lactams, macrolides, rifampicin,
cotrimoxazole (trimethoprim/sulfamethoxazole) and chloramphenicol. Several
indigenous resistance mechanisms elucidate this pattern, such as active efflux pumps,
low membrane permeability and production of β-lactamases (Hancock, 1998). In vitro
susceptibility data are essential guides for the choice of a proper antibiotic for P.
aeruginosa infections, due to the incidence and diverse acquired resistance found by
clinical isolates. Antimicrobials that are typically considered effective toward P.
aeruginosa can be generally classified into the following seven groups:
First are the penicillins, such as ticarcillin and piperacillin, β-lactam/β-lactamase
inhibitor combinations including ticarcillin/clavulanic acid, and piperacillin/tazobactam
(Lister, 2000). Lodise et al. (2007) showed that extended infusion of
piperacillin/tazobactam (4 hours vs 1 hour) might target pharmacodynamic targets more
proficiently in severely ill patients (Lodise et al., 2007). In contrast, the Clinical
Laboratory Standards Institute resistance breakpoint for piperacillin/tazobactam
suspicions have expressed concern that suitability of this drug (Tam et al., 2008) may
lead to  therapeutic failures due to the false-susceptibility results.
Second are the cephalosporins, which include ceftazidime, cefoperazone and cefepime
(Bush, 2002). From all third generation cephalosporins, ceftazidime is the only one
active against P. aeruginosa. Among fourth generation cephalosporins, cefepime is the
only one that is accepted in the United States for utilization in human beings and has an
extended range. Cefepime is active toward Gram-positive and Gram-negative bacteria,
including P. aeruginosa. The fourth generation cephalosporins exhibit chemical
properties that can result in increased resistance by Gram-negative microorganisms
(Zuanazzi et al., 2010).
16
Third are the monobactams, this class of drugs is only represented by aztreonam (Jones
et al., 2002). Aztreonam is mainly used against gram-negative aerobic microorganisms,
as well as P. aeruginosa and Klebsiella. It is also recommended for use in urinary tract
infections, soft-tissue infections, intra-abdominal and pelvic infections and pneumonia
(Ennis & Cobbs, 1995).
Fourth are the carbapenems, which include ertapenem, doripenem, imipenem and
meropenem. Meropenem is fast becoming more effective than imipenem with regard to
resistance (Livermore, 2001b). Extended infusions of meropenem (3 hours) have been
found to results in positive outcome (Santos Filho et al., 2007). In vitro data proposes a
two-fold advantage for doripenem above meropenem, a four-fold advantage to
imipenem (Jones et al., 2004b) and decreased possibility for resistance selection
(Mushtaq et al., 2004). In addition, sustained infusions may increase the
antipseudomonal efficacy of doripenem in infections sourced by less susceptible strains
(Bhavnani et al., 2005).
Fifth are the fluoroquinolones, levofloxacin and ciprofloxacin. As judged by MIC,
ciprofloxacin is more potent than levofloxacin. However, maximum doses of
levofloxacin have superior pharmacokinetics, which lead to balance the decreased
potency. Therefore, these two fluoroquinolones are pharmacodynamically effective
against P. aeruginosa (Tennenberg et al., 2006).
Sixth are the aminoglycosides, which include amikacin, tobramycin, gentamicin, and
netilmicin. In their in vitro study, Giamarellou et al. (1984) found that aminoglycosides
when combined with β-lactams has a synergistic role (Giamarellou et al., 1984),
particularly, with amikacin combinations as stated by Giamarellos-Bourboulis et al.
(2005) (Giamarellos-Bourboulis et al., 2005).
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Finally the polymyxin (colistin), which has lately re-appeared as an effective solution to
treat MDR P. aeruginosa (Giamarellou & Kanellakopoulou, 2008; Falagas et al.,
2005c; Michalopoulos & Falagas, 2008; Kasiakou et al., 2005; Falagas et al., 2005b).
The toxicity of this drug (nephrotoxicity, but also neuromuscular blockade and
ototoxicity) has been much discussed but has been reported to be controllable and lower
than initially thought (Falagas et al., 2005b). Primary experimental data recommends
that colistin can be managed even in an aerosolized form to mechanically ventilated,
non-cystic fibrosis patients with pseudomonal infections (Horianopoulou et al.,2005).
Currently, colistin is becoming the foremost curative choice for strains with complicated
MDR patterns (Falagas et al., 2006a; Kallel et al., 2007; Hachem et al., 2007). Some
confusion still exists concerning the different formulations used (Falagas & Kasiakou,
2006). Polymyxin B belongs to this group, while clinical knowledge on this drug is
usually limited. It has been reported that Polymyxin B has been used as a rescue therapy
in a series of patients with healthcare-associated pneumonia caused by MDR P.
aeruginosa (Furtado et al., 2007). As a part of these antimicrobial classes, rifampicin
has been suggested to be used in combination with this agent due to the potential
synergistic results observed (Giamarellos-Bourboulis et al., 2003). Fosfomycin is an
additional agent that in vitro shows some efficacy for use in pseudomonal infections,
while relevant research has been limited (Falagas et al., 2010; Falagas et al., 2009).
P. aeruginosa is considered a serious therapeutic challenge for the treatment of both
health care and community associated infections. To optimize the clinical outcome the
choice of a suitable antipseudomonal drugs at the start of therapy is important (Bisbe et
al., 1988; Micek et al., 2005). Unfortunately, the choice of the most proper
antipseudomonal is difficult due to the capability of P. aeruginosa to develop resistance
to various groups of antipseudomonal drugs, even through the course of treating an
infection. Epidemiological reports have found that the rise in morbidity and mortality
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are associated with infections caused by drug-resistant P. aeruginosa. The early
treatment is significant to the outcome of the infection and adequate empirical regimens
for P. aeruginosa treatment should be started before receipt of the results of cultures
and susceptibility testing.  Numerous aspects should be considered in the case of
selection. These include the empirical treatment, including  the source and nature
(community-acquired vs. healthcare-associated infections) of the infection, diseases,
underlying risk factors (e.g., length of hospitalization, ICU admissions, previous
antimicrobial chemotherapy), data  about the epidemiology of resistance phenotypes in
the individual setting, hospital prescription policies, pharmacokinetic parameters and
overall cost of treating the infection (Aloush et al., 2006; Carmeli et al., 1999b; Gasink
et al., 2006).
The drug resistance development leads to limited therapeutic choices for treatment of
severe infections. In recent years, infections caused by MDR P. aeruginosa have
become a serious problem, especially in the healthcare-associated settings (Bassetti et
al., 2011). The World Health Organization (WHO) has identiﬁed antimicrobial
resistance as one of the three most important problems to human health (Rice, 2008),
and as a consequence the theme of World Health Day, on April 7, 2011, was
“Antimicrobial Resistance: no action today and no cure tomorrow” (Piddock, 2011).
Resistance to the current library of antimicrobial agents is a serious problem worldwide
including Europe, Latin America, North America and the Asia-Paciﬁc region (Dupont et
al., 2001; Kollef, 2006; Livermore, 2012). The use of common antipseudomonal agents
that are mentioned above in the treatment of P. aeruginosa infections is a challenging
task for clinicians. This is because most studies show signiﬁcant differences in their
efficacy and increased rates of resistance for these agents that lead to therapeutic failure
(Surveillance, 2004; Lepper et al., 2002; Driscoll et al., 2007; Obritsch et al., 2005;
Moore & Flaws, 2011c; Dupont et al., 2001; Kollef, 2006; Livermore, 2012).
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Consequently, clinicians are forced to rediscover old drugs, such as polymixins and
fosfomycin (Bassetti et al., 2011). The antibiotic monotherapy for urinary tract
infections caused by P. aeruginosa is usually recommended. However, it is not advised
for the treatment of upper tract infections complicated by abscess formation, or
whenever there is a suspicion of bacteraemia, or for infections in neutropenic patients.
In contrast, a combination chemotherapy including at least two different anti-
pseudomonal agents is usually recommended for the treatment of healthcare-associated
pneumonia infection, endocarditis, bacteraemia and severe P. aeruginosa infections
(Young et al., 2000). The rationale for combination chemotherapy is essentially to
reduce the chances of selection of resistant mutants during therapy, as well as to exploit
the potential synergistic activity of some agents. The preferred combination is still the
aminoglycosides and β-lactams, as synergism between these drugs has been
demonstrated by in vitro studies (Giamarellou et al., 1984; Giamarellos-Bourboulis et
al., 1996; Burgess & Hastings, 2000). Controversy revolves around the issue as to
whether combination or monotherapy is more appropriate in the treatment of P.
aeruginosa infections. There have been several retrospective studies and Meta analyses
published in recent years in favour of both sides. One multicenter, retrospective study
conducted by Garnacho-Montero and colleagues in 2007 sought to evaluate whether one
antibiotic achieved equal outcomes compared to combination therapy in patients with
ventilator-associated pneumonia (VAP) caused by P. aeruginosa (Garnacho-Montero et
al., 2007). They found that more patients on monotherapy were inappropriately treated
than those who were on combination therapy. In addition, the mortality rate was higher
amongst patients treated with only one drug. They concluded that combination therapy
be used at least initially in order to increase the chances that at least one drug is
effective before the organism is identification and susceptibility are known. According
to consensus guidelines suggested by the Infectious Disease Society of America (IDSA)
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and the American Thoracic Society (ATS), for empiric management of community or
hospital-acquired pneumonia, the following combination is recommended in patients
who have risk factors for P. aeruginosa: Use of an antipseudomonal quinolone plus an
anti-pseudomonal beta-lactam, an aminoglycoside plus an anti-pseudomonal beta-
lactam (the most common combination reported in the literature) and an aminoglycoside
plus an anti-pseudomonal quinolone.
Selection of antibiotics should include consideration of local antimicrobic resistance
patterns as well as institutional antibiograms. The consensus suggests a recommended
therapy of two weeks, but state that the duration of therapy should be adapted to the
patient’s signs and symptoms of clinical improvement (Mandell et al., 2007). The main
reason behind the combined empirical therapeutic course is not the potential for
synergy, but the improved opportunity of covering the responsible strain. For instance,
in the case of monotherapy by using a quinolone as, for an average 80% susceptibility,
there is a 1: 5 ability of a resistant strain and, therefore, therapeutic failure. When
administering a combination dosage, the chances of curative failure are decreased
because MDR is not as frequent as isolated resistance (Fish et al., 1995). Most studies
favor combination therapy for first treatment and management of P. aeruginosa
infections. Those requiring an antimicrobial β-lactam and either ﬂuoroquinolone or
aminoglycoside, have long been considered to comprise a proper antipseudomonal
treatment for infection caused by P. aeruginosa (Siegman-Igra et al., 1998;
Giamarellou, 2002; Kanj & Kanafani, 2011). Combination therapeutic regimens have
many advantages: it is economically safer, has rapid bacterial killing capabilities and
has lower pressure for selection of resistance (Amari et al., 2001; Safdar et al., 2004). In
addition, combining two drugs in vitro, enhances clinical efficacy and prevents the
emergence of resistant strains. The combination therapy is beneficial to the patient
because of the potential for synergy, having the increased chance that at least one agent
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will be effective, and the reduction of the emergence of resistant strains. The
disadvantages of the combination therapeutic regimens are: increased frequency of
adverse events (mainly as a result of the aminoglycoside component), increased risk for
fungal super-infections, and increased cost (Paul et al., 2004). However, there are
benefits associated with monotherapy that should not be dismissed. These include lower
health care costs and fewer adverse events especially when aminoglycosides are not
administered. There is also the utilization of a narrower spectrum of treatment and the
possibility of reducing the probability the patient could develop an infection with a
multidrug resistant strain of P. aeruginosa.
A meta-analysis conducted by Safdar et al. (2004), found a mortality beneﬁt of
combination therapy for P. aeruginosa infection, which included activity in lung and
abscesses and improved safety proﬁle (Safdar et al., 2004). The analysis recommended
that a combination therapy comprising of a β-lactam with a quinolone might be better
compared to a combination with aminoglycosides. This observation is supported by an
in vitro pharmacokinetic mode (Lister & Wolter, 2005). Besides the effects of
combination therapy mentioned above, an additional important feature of dual therapy is
the widening of the empirical coverage. An MDR phenotype can be expected in special
conditions such as in the case of a patient with VAP and a history of previous antibiotic
administration, particularly carbapenems that may have chosen resistance. In this case,
it allows for the empirical therapy use of colistin (Rios et al., 2007; Falagas et al.,
2006b). To reduce the incidence of P. aeruginosa infection, the identification of patients
at risk for infection and prevent exposure to the organism would be needed as well as to
prevent the further development of resistance by analyzing resistance trends and
adjusting therapeutic regimens regularly (Falagas et al., 2006b). Studies have shown
that antimicrobial pressure leads to the development of resistance, and in the absence of
that pressure, the organism reverts to being susceptible. The assess resistance should be
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continually needed, recognize trends and implement change as necessary. Only then
could be come close to winning the war against such a powerful adversary (Moore &
Flaws, 2011c). In the last decade, there have been no new antibacterial agents, effective
toward MDR strains of P. aeruginosa that have been introduced (Rossolini &
Mantengoli, 2005; Boucher et al., 2009). The Infectious Diseases Society of America
announced their “Bad Bugs No Drugs-10 by 20” initiative to support the development
of ten new antibiotics by 2020 (Spellberg et al., 2011; Boucher et al., 2009). This
initiative supports strengthening current approaches to minimize antimicrobial
resistance, protecting effectiveness of the drugs currently available by maximizing
hospital infection control practices, and limiting the spread of resistance (Kuehn, 2011).
1.6 Emergence of antibiotics resistance in P. aeruginosa
Hughes & Datta (1983) found low rate antibiotic resistance when screening
Enterobacteriaceae strains collected in different parts of the world from 1917 to 1954.
When a new antibiotic is established, a lot of bacteria are initially susceptible, however
resistance development is often observed after a short time (Hughes & Datta, 1983). In
the 1960s, P. aeruginosa emerged as a main human pathogen owing to its use for
wound and burn victims, in addition to neutropenic, cystic fibrosis and surgical patients
(Doggett & Aduan, 1979). In spite of the activity of anti-pseudomonal agents being one
of the holy grails of pharmaceutical drug discovery for many decades, it remains one of
the main recalcitrant and difficult to treat organisms. As therapeutic options run out, P.
aeruginosa has attained “superbug” status. Antimicrobial resistance, which has become
widespread today, seems to have been rare in the pre-antibiotic era (Moore & Flaws,
2011a). Antibiotic resistance among P. aeruginosa infection is an increasing global
problem and a public health threat, posing many therapeutic challenges. Additionally,
the susceptible strains of P. aeruginosa can acquire drug resistance during treatment,
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commonly with a relatively high frequency (Quinn et al.,1986; Lolans et al.,2008;
Mesaros et al., 2007). The emergence of resistance in P. aeruginosa has been reported
with all classes of antimicrobial agents including penicillins, cephalosporins,
carbapenems, aminoglycosides and fluoroquinolones (Livermore, 2002; Lister et al.,
2009).
This emergence of resistance has limited the opportunity of therapeutic options and is
leading to increased rates of morbidity and mortality and increased costs of treating
patients with P. aeruginosa infection (Livermore, 2002; Moore & Flaws, 2011a). P.
aeruginosa is considered the third most common healthcare-associated infections in our
society giving rise to a wide range of opportunistic infections. Its high intrinsic
resistance to antibiotics and ability to develop multidrug resistance poses serious
therapeutic problems (Zuanazzi et al.,2010; Cao et al., 2004a). The resistance of
antimicrobial agents is constantly increasing with geographical differences frequently
linked to local antibacterial strategies. The emergence of drug-resistance occurs
frequently in the ICU and raised resistance is mainly a dilemma in ICUs, particularly in
Europe (Jones et al., 2004a). Generally, the fluoroquinolones are the antimicrobial class
where the resistance rates are rising quickly (though, geographical difference subsists)
with resistance to β-lactams and aminoglycosides. In Europe, this is more important,
even though the emergences of colistin-resistant strains are being reported (Matthaiou et
al., 2008; Walkty et al., 2008; Denton et al., 2002). A review (Bonomo & Szabo, 2006)
described MDR as the decreased susceptibility to more than one of the following
antimicrobial agents: quinolones, carbapenems, cephalosporins, β-lactam inhibitor
combinations and aminoglycosides. Based on this description, a strain resistant to
amikacin and ceftazidime will be considered MDR, while there are sufficient treatment
options. Multidrug-resistant strains were isolated more frequently from ICU and nursing
home patients.  Manian et al. (1996) analyzed resistance rates among P. aeruginosa
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isolated from an ICU and found that the rates of resistance to penicillins and
cephalosporins was statistically related to prior treatment with third generation
cephalosporins (Manian et al., 1996). Overall, MDR rates for Europe are 5%, Asia and
the US are 2%, while MDR rates for Latin America is more frequent at 8% of total
isolates. When ICU isolates only are assessed, the pattern is diverse; in US resistance
frequencies in ICU isolates are 20%, and in Asian ICUs they are 30%. There have also
been growing numbers of reports of occurrences of widely resistant isolates (Rossolini
& Mantengoli, 2005).
Numerous reports have found that multidrug-resistant strains of P. aeruginosa usually
arise after prolonged exposure to antipseudomonal therapies (Georges et al., 2006;
Nadeem Sajjad Raja, 2007; Livermore, 2012) or after empirical treatment (Zavascki et
al., 2006; Arancibia et al., 2002; Mesaros et al., 2007). A number of P. aeruginosa
strains which showed resistance to beta-lactams, reflect a previous treatment history of
the patients with wide-range beta-lactams. For example, a considerable association was
observed in a single medical center between the antecedent use of ceftriaxone,
piperacillin, ceftazidime and cefotaxime. There was resistance to these drugs among P.
aeruginosa strains that usually produce chromosomal AmpC beta-lactamase, including
155 isolates of P. aeruginosa (Lolans et al., 2008). A study of the occurrence of P.
aeruginosa resistance to β-lactam antibiotics in ICU patients found a high risk emerging
with imipenem, piperacillin/tazobactam and cefotaxime during treatment (Georges et
al., 2006). A previous randomized assessment comparing imipenem to ciprofloxacin for
the treatment of healthcare-associated pneumonia also illustrated a higher risk of
emergence of resistance in the carbapenem arm (Aarts et al., 2008). Several factors may
lead to the increase in antibiotic resistance, such as hospital stay and period of
hospitalization before ICU admission, surgical ICU stay, the type of operation, length of
ICU stay,  previous antibiotic use, and inappropriate use of antipseudomonal  drugs and
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inadequate adherence to infection control practices (Fridkin et al., 2002; Neuhauser et
al., 2003; Siegel et al., 2007). MDR has been associated with a two-fold prolongation of
duration of hospitalization, a nine-fold elevation in secondary bacteraemia, a three-fold
raise in mortality and major increases in healthcare costs (Carmeli et al., 1999b).
Significant data from ICU isolates of P. aeruginosa resulting from Europe are even
worse. From 1990 to 1999 resistance to ceftazidime reached 57%, resistance to
aminoglycosides reached 37-70%, resistance to imipenem reached 52%, resistance to
ciprofloxacin reached 56% and resistance to piperacillin/tazobactam reached 53%
(Rossolini & Mantengoli, 2005). The prevalence of MDR P. aeruginosa in the US was
recently reported to have increased from 1% to 16% (D'Agata,2004). A multi-fold
increase was noted by Jung et al. (Jung et al., 2004) which reported 22% of P.
aeruginosa isolates were resistant to any antipseudomonal agent in 1998, and  32% of
isolates were resistant to at least three agents by 2002. In 2004 from the US National
Nosocomial Infection Surveillance System (NNIS) published a report, which
demonstrated the resistance rates with P. aeruginosa isolates to quinolones at 29.5%
and imipenem at 21.1%. In ICU isolates, the particular rates of resistance were even
higher- up to 23.6% for ceftazidime, 31.4% for piperacillin/tazobactam, 38% for
imipenem and 51.6% for ciprofloxacin (Cardo et al., 2004). Other studies in the
intensive care unit surveillance study (ISS) database exhibited that P. aeruginosa, over a
ten year period was becoming increasingly more resistant to antimicrobial agents
(Georges et al., 2006; Obritsch et al., 2004; Kallel et al., 2008).
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1.7 Mechanisms of the antibiotic resistance in P. aeruginosa
Resistance of P. aeruginosa to antimicrobial agents arises through a variety of
mechanisms, such as intrinsic resistance to antibiotics by a large selection of genetically
encoded resistance mechanisms, acquisition of additional resistance mechanisms from
other bacterial organisms in the form of plasmid-encoded genes and mutations in
chromosomal genes (Tenover, 2006). P. aeruginosa is intrinsically resistant to certain
antipseudomonal agents via three different mechanisms including antibiotics cleavage
by β-lactamase enzymes, antibiotic ejection by chromosomally encoded efflux
mechanisms and decreased drug uptake due to loss of outer membrane porin protein
(Poole, 2004b; Pfeifer et al., 2010). It has been observed that P. aeruginosa acquires
resistance to antipseudomonal agents either by mutations to chromosomal genes or via
the acquisition of plasmids encoding genes contributing resistance. Firstly, mutation of
the gyrA gene alters the structure of DNA gyrase, which is the target of the quinolones
(Lambert, 2002). When mutations occur in the respective genes, certain penicillin-
binding proteins (PBPs) confer resistance to beta-lactams (Lambert, 2002). PBPs are
important in the last steps of the synthesis of peptidoglycan, which is the most important
constituent of bacterial cell walls. The name PBP is derived from their affinity for the
binding of penicillin. PBPs catalyze a number of reactions required in peptidoglycan
cross-linking from lipid intermediates and also the elimination of terminal D-alanine
from the precursor of peptidoglycan (Spratt, 1977). Few studies have concentrated on
the recognized role of alterations of penicillin-binding proteins in relation to the
carbapenem resistance in Gram-negative bacteria (Ayala et al., 2005; Giske et al.,
2008a).
Bellido et al. (1990) depicted a case of treatment failure, where the P. aeruginosa
resistant isolates exhibited diminished binding of radioactively labeled imipenem to
PBP-4. In addition, the authors detected that, following several routes in an antibiotic-
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free broth, the isolate regained its capability to bind imipenem, and the MIC was
reduced from 32 to 8 mg/L (Bellido et al., 1990). Almost no follow-up studies have
been carried out on the P. aeruginosa clinical isolates, and it is still unclear whether
PBP alters in significant mechanisms of carbapenem resistance. One study has been
done on other Gram-negative bacilli, as well as on the clinical isolates of Acinetobacter
baumannii, which showed down-regulation of PBP-2 associating well with reduced
susceptibility to the carbapenems (Fernández-Cuenca et al., 2003). Neuwrith et al.
(1995) found that an imipenem-resistant Proteus mirabilis isolate would carry PBP-2
with reduced affinity to imipenem (Neuwirth et al., 1995). Besides this, a PBP-2 mutant
was found in E. coli, with increased imipenem MIC, however meropenem MIC was not
affected, and this suggested that meropenem also binds to PBP-3 (Sumita & Fukasawa,
1995). In addition, Ayala et al. (2005) demonstrated that alterations of PBP-3 might
possibly reduce susceptibility to imipenem in Bacteroides fragilis (Ayala et al., 2005).
Alterations of PBP-2 and PBP-3 can be speculated as a carbapenem resistance
mechanism in P. aeruginosa. Theoretically, down-regulation and the existence of amino
acid changes occur in the area of the three conserved motifs S-X-N, K-T-G and S-X-X-
K as shown in Figure 1.2 (Ghuysen, 1994). Mutations in active sites of PBP-2 and PBP-
3 can be essential for carbapenem resistance, and more studies are required to
concentrate on this issue. Mutations in genes that regulate the expression of genes
involved in the resistance of the organism to antimicrobial agents can also increase the
resistance of the organism. Mutations in ampR, the gene that regulates the expression of
AmpC, results in the overexpression of AmpC and thereby increases resistance to beta-
lactams (Lister et al., 2009). A number of different resistance genes are encoded on
plasmids that have been shown to be acquired by P. aeruginosa. These genes either
contribute to resistance to the aminoglycosides or to betalactams.
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Figure 1.2: The position of the three conserved motifs the active sites of PBP-2 and
PBP-3 is demonstrated. Numbers denote amino acid locations in the
respective proteins, and letters denote amino acids (S = serine, E =
glutamic acid, N = aasparagine, K = lysine, T = threonine, G = glycine,
V = valine).
Many beta-lactamases with divergent substrate specificity have been known in several
bacterial organisms. P. aeruginosa has been shown to produce the following beta-
lactamases: Class A extended-spectrum beta-lactamases (ESBL) (SHV, TEM, VEB, PER
and CTX-M), and Class B metallo-beta-lactamases that degrade all beta-lactams
including the carbapenems (IMP, VIM, SPM, and GIM). P. aeruginosa also acquires
plasmids encoding aminoglycoside-modifying enzymes (AMEs), as outlined by Llano-
Sotelo et al. (2002); AMEs can be attached to a phosphate, acetyl or adenyl reactive
group to the antibiotic molecule (Llano-Sotelo et al., 2002). Therefore, the binding
ability of the modified antibiotics to the target in the microbial cell is reduced. AMEs
are plasmid encoded and categorized into three main families; the aminoglycoside N-
acetyltransferases (AACs), aminoglycoside O-nucleotidyltransferases (ANTs) and the
aminoglycoside O-phosphotransferases (APHs) (Vakulenko & Mobashery, 2003).
Chromosomal mutations in the genes encoding the subunits of DNA gyrase and
topoisomerase IV are the most significant mechanisms of fluoroquinolone resistance. In
accordance to Hooper (2001), there are two common mechanisms, which lead to
fluoroquinolone resistance in P. aeruginosa (Hooper, 2001). They are structural
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modifications in target enzymes and efflux pumps. Alterations in the DNA gyrase,
topoisomerase II for fluoroquinolones occur mainly by point mutations in gyrA/gyrB
genes inside the quinolone-resistant-determinative region (QRDR) pattern that is
proposed as the enzyme active site. In a bacterial population, these changes exist in low
numbers (1/106 to 1/109). The amino acid changes in GyrA subunit of DNA gyrase
regardless of bacterial species are generally localized around the active site where the
Tyr122 is covalently linked broken DNA strand during enzyme action (Cabral et al.,
1997). Mutations in GyrB and ParE subunit are much less common than those in GyrA
and ParC and usually localized to the mid portion of the subunits in a domain involved
in interactions with their complementary subunit. The initial step in mutational
resistance is achieved by an amino acid change in the most sensitive enzyme generally
DNA gyrase in Gram-negative and topoisomerase IV in Gram-positive.
As was pointed out before, four well-known genetically diverse efflux systems have
been characterized in P. aeruginosa: MexXY–OprM, MexAB–OprM, MexCD–OprJ
and MexEF–OprN. Although every pump has preferred antibacterial drug substrates, the
fluoroquinolones are common substrates for all of them (Masuda et al., 2000a). Li et al.
(2003) found a new member of the tripartite multidrug efflux pumps, MexW (RND-type
membrane protein)-MexV (membrane fusion protein) and OprM in P. aeruginosa. It
contributes resistance to chloramphenicol, erythromycin, tetracycline, fluoroquinolones,
ethidium bromide and acriflavine (Li et al., 2003b). In P. aeruginosa the elevated-level
of fluoroquinolone resistance is because of the interaction of mutations in the genes
encoding DNA gyrase, topoisomerase IV and the efflux pump systems (Nakajima et al.,
2002; Wang et al., 2007). In vitro, and in vivo, quinolones can select for multidrug-
resistant phenotypes (Kohler et al., 1999b). The main and most frequent reasons for
their manifestation are the subsequent mutations: nfxC, nfxB and nalB resulting,
correspondingly, to the up-regulation of MexE–MexF–OprN, MexC–MexD–OprJ and
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MexA–MexB–OprM (Table 1.2). The newest fluoroquinolones mainly select for nfxB P.
aeruginosa mutants, whereas older quinolones choose nfxC or nalB mutants (Kohler et
al., 1999b). A phenomenon of antibiotic resistance emerges in P. aeruginosa and
exhibits all recognized mediated mechanisms of resistance that destroy the activity of
antimicrobial agents. Non-enzymatic mediated mechanisms use the efflux pumps,
which actively pump the antimicrobial agents out of the cell. In addition, the decreased
outer membrane permeability of the cell prevents the antimicrobial agent from getting
into the cell (Strateva & Yordanov, 2009; Poole, 2011).
1.7.1 Enzymatic mediated mechanisms of resistance in P. aeruginosa
β-Lactamase expression is the most common mechanisms of resistance to β-lactam
antibiotics. β-lactamase are able to hydrolyze the four members of the β-lactam
antibiotic family including carbapenems, penicillins, cephalosporins and monobactams
(Fisher et al., 2005; Henrichfreise et al., 2007). The main cause of acquired resistance to
-lactam antibiotics in P. aeruginosa is the β-lactamase expression (Strateva &
Yordanov, 2009). In a classification recognized as the Ambler scheme, -lactamases
can be classified depending on the amino acid and nucleotide sequences into 4 major
classes: A through D (Ambler, 1980; Paterson & Bonomo, 2005). P. aeruginosa clinical
isolates express all 4 Ambler classes (Rice, 2006), correlating with the functional
classification defined by enzyme substrate and inhibitor profiles (Poole, 2004b). Classes
A, C and D act via a serine-based mechanism, while class B or metallo--lactamases
(MBLs) require zinc for their action. All of these molecular classes of -lactamases
were discovered in P. aeruginosa, including ESBLs of classes A, B and C (Beceiro et
al., 2004). Classes A, B and C of β-lactamase are the most common and have been
discovered worldwide (Beceiro et al., 2004; Yang et al., 1999; Bush & Mobashery,
1998). In the 1990s, class A ESBLs was discovered in the clinical isolates of P.
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aeruginosa, which involved TEM, SHV, PER, VEB, GES/IBC and BEL. These six types
have low identity at the genetic level, and yet they have similar hydrolysis profiles.
Class A ESBLs were initially reported in the second half of the 1980s and their
dissemination increased since 1995 (Bradford, 2001; Philippon et al., 2002; Ishii et al.,
1995). ESBLs are plasmid-encoded enzymes that have mutated from more common β-
lactamase enzymes. The presence of ESBL-producing organisms is associated with
higher morbidity and mortality than non-ESBL producers (Stein, 2005). Classical
ESBLs have developed from the common plasmid-encoded enzyme families cefotaxime
(CTX-M), SHV, TEM and oxacillin (OXA). The TEM 1 enzyme was originally found in
E. coli isolated from a patient named Temoniera and hence was named TEM (Medeiros,
1984). TEM 1 is unable to attack the oxyimino cephalosporin but it is able to hydrolyze
first generation cephalosporins and penicillins (Sougakoff et al., 1988a; Sirot et al.,
1987b). The first TEM variant with increased activity against extended spectrum
cephalosporins was TEM 3 which was described in 1983, and now over 100 additional
TEMs have been characterized (Bradford, 2001; Sougakoff et al., 1988a; Sirot et al.,
1987b). Numerous P. aeruginosa strains, producing TEM-24 ESBL were isolated from
a long-term-hospitalized woman, including urinary and respiratory isolates (Marchandin
et al., 2000). The diversity of TEM-24-producing organism recovered from the same
patient strongly suggests the in vivo horizontal transfer of this plasmid-mediated ESBL
from Enterobacteriaceae to P. aeruginosa.
The SHV 1 (sulphydryl variable) is the second most common plasmid mediated β-
lactamase found in E. coli and K. pneumoniae (Tzouvelekis & Bonomo, 1999). There
are fewer derivatives of SHV 1. However, a multiresistant transferable plasmid encoding
the SHV 5 β-lactamase causing unusually high resistance to aztreonam and ceftazidime
and a combination of acetylating enzymes producing resistance to all clinically
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available aminoglycosides was recognized in K. pneumoniae (Galani et al., 2002). In
clinical P. aeruginosa isolates, SHV-5 and SHV-12 genes were identified from Thailand
and Greece (Poirel et al., 2004a; Chanawong et al., 2001). PER-1 is a chromosome
encoded gene, identified and completely characterized as ESBL in P. aeruginosa and
isolated from the urine culture of a Turkish citizen in 1991 in France (Nordmann &
Naas, 1994). Currently, among healthcare-associated P. aeruginosa isolates the
dissemination of blaPER-1 is widespread in Poland, Italy, Turkey and Belgium (Kolayli et
al., 2005; Empel et al., 2007; Pagani et al., 2004; Claeys et al., 2000). PER-1 presents
the substrate profile of ESBLs and it is moderately inhibited by β-lactamase inhibitors
and imipenem (Weldhagen et al., 2003). The VEB enzymes are another type of
molecular class A ESBLs. VEB-1 β-lactamase was isolated in 1998 in France (Naas et
al., 1999). In Thailand, Girlich et al. (2002) reported the prevalence of blaVEB-like genes
in (93%) ceftazidime-resistant P. aeruginosa clinical isolates (Girlich et al., 2002), then
identified a new blaVEB-2 gene. The only difference between VEB-1 and VEB-2 is a
single amino acid outside the active site of the enzyme. Recently, the high
dissemination (56.8%) of VEB-1 ESBL was reported from Bulgaria among ceftazidime-
resistant healthcare-associated P. aeruginosa isolates (Strateva et al., 2007). The VEB
enzymes substrate profile was very similar with that of PER-1 (Weldhagen et al., 2003).
An ESBL strain is acquired due to contact with a colonized health care worker or
contaminated fomites. Hereafter, the ESBL producing strains emerge due to the
selective effect of antibiotic use (Lautenbach et al., 2001).
Removal of selective pressure by drug class restriction leads to the disappearance of
ESBL producing strains (Urban et al., 2000). The seriously ill patients with prolonged
hospital stays, in whom invasive medical devices are present, are considered important
factors leading to acquisition and infection with ESBL producing organisms (Paterson
& Bonomo, 2005; de champs et al., 1989; Wiener et al., 1999). Heavy antibiotic use is
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also a risk factor for acquisition of an ESBL producing organism (Peña et al., 1998).
The emergence of ESBLs has been shown to be associated with over use of
aminoglycosides, quinolones and third generation cephalosporins ceftazidime (Lee et
al., 2003; Rice et al., 1996; De champs et al., 1991). Patient to patient transmission has
also been described (Paterson & Bonomo, 2005). However, in a particular unit of a
hospital, the same ESBLs may be mediated by different plasmids and many different
ESBLs may be found in the same unit at a same time (Bradford et al., 1994). Usually
the epicenters of ESBL production are the intensive care units. From hospital to hospital
the transfer of genotypically related ESBLs may occur (Monnet et al., 1997), from city
to city (Yuan et al., 1998), country to country (Gori et al., 1996) and even
intercontinental transfer has been described (Shannon et al., 1990). Community
acquired infections with ESBLs have also been found (Rodríguez-Baño et al., 2004).
Genes for class A enzymes TEM and SHV can be found in the chromosomal DNA of
their host bacteria, or on mobile genetic elements called plasmids, which bacteria share
with one another. This enhances the spread of resistance among different types of
bacteria in both the hospital and general environment. The original or “wild type” TEM
and SHV enzymes were highly suited to hydrolyzing penicillins, with active sites that
accommodate the penicillins like a hand in a glove. In contrast to the penicillins, highly
active third generation cephalosporins possessed bulky side chains that precluded entry
into the TEM active site. The widespread use of these “extended-spectrum”
cephalosporins in the 1980s was associated with the appearance of the so-called
“extended-spectrum beta-lactamases” (ESBLs) (Kliebe et al., 1985; Podbielski et al.,
1991; Sirot et al., 1987a; Sougakoff et al., 1988b). Class A ESBLs hydrolyze aztreonam
and oxyimino-cephalosporins, but not 7- -substituted β-lactams, and are generally
susceptible to β-lactamase inhibitors such as sulbactam, clavulanate and tazobactam
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(Shahid et al., 2009). Many groups of β-lactamases have hydrolytic proﬁles similar to
those of the SHV and TEM mutants but have different evolutionary histories. These non-
TEM and non-SHV plasmid mediated class A ESBLs have been sub-divided into
ceftazidimases (PER, VEB, TLA-1, and GES/IBC types) and cefotaximases (CTX-M,
SFO-1, and BES-1 type) (Livermore, 2008; Bonnet, 2004). According to recent reports,
CTX-M β-lactamases are the most widespread ESBL enzymes worldwide (Bradford,
2001; Gniadkowski, 2001). Nearly 113 CTX-M variants have been identiﬁed and
designated from CTX-M-1 to CTX-M-113 (http://www.laheyclinic.
org/studies/webt.htm). CTX-M-producing isolates are now endemic in South America,
most European countries and Asia. Recently CTX-M enzymes have been detected in a
number of focal outbreaks from different parts of the world, e.g., in India (CTX-M-15)
(Karim et al., 2001), Japan (Toho-2) (Ma et al., 1998) and UK (Naas & Nordmann,
1999) suggesting their wide dispersal.
ESBL-producing isolates are usually selected in hospitals. They may become visible in
hospitals due to drug selection, which may lead to a novel type of the enzyme. When
selected, the ESBL producers may spread in the hospitals in a number of ways,
including clonal dissemination of the producer isolates or horizontal transmission of the
ESBL gene-carrying plasmid among non-related isolates (Poirel et al., 2004b; Neonakis
et al., 2003). Carbapenem-hydrolysing enzymes are a further group of ESBLs occurring
in P. aeruginosa and known as MBLs or carbapenemases because of the presence of
Zn2+ in their active centre (Nordmann & Guibert, 1998).
MBLs or carbapenemases enzymes, mostly classiﬁed as Ambler class B metallo-β-
lactamases (MBLs), are zinc dependent and have a very wide substrate proﬁle, such as
carbapenems and expanded-spectrum cephalosporins. The three subclasses of clinically
relevant mobile MBLs that have been identiﬁed thus far in P. aeruginosa are; VIM, IMP
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and SPM-1. A new fourth subclass of Ambler class B enzyme, GIM-1, was lately
detected in isolates that originated from Germany (Castanheira et al., 2004). Most
recent resistances have emerged in Gram-negative bacteria (e.g., NDM-1) (Kumarasamy
et al., 2010). In P. aeruginosa, acquired carbapenemases is an emergent cause of
resistance and there has been an increase in the reports on carbapenemases over the last
decade (Nordmann & Poirel, 2002).
Carbapenemase production establishes resistance to all β-lactams including the
carbapenems (meropenem and imipenem). The hydrolytic features of MBLs do not
affect the monobactam aztreonam (Bush & Mobashery, 1998). Metallo-betalactamase
(MBLs) production is a significant problem especially in hospital isolates of P.
aeruginosa. MBLs are spreading throughout various parts of the world. In 1988, it was
found that the IMP type MBL emerged from a P. aeruginosa strain in Japan (Watanabe
et al., 1991). However, other genes such as SPM, VIM, and GIM type MBLs were
recognized worldwide (Navaneeth et al., 2002; Gupta et al., 2006). Carbapenem non-
susceptible, IMP-1 producing bacteria were isolated in Europe, Korea and Singapore. In
Malaysia, only IMP-7 gens were found in P. aeruginosa (Lagatolla et al., 2004). 11% of
the Pseudomonas spp. carried blaVIM among imipenem-nonsusceptible isolates reported
in Korea (Lee et al., 2004). These blaMBL genes are located on class 1 integrons residing
on mobile plasmids. The resistance cassettes carried on these MBL-containing integrons
may vary, but this machinery enables resistance to spread horizontally between species
in all cases (Rowe-Magnus & Mazel, 2002; Rice, 2002). The genes encoding IMP, VIM
in addition to GIM were found as gene cassettes in class 1 integrons, although IMP
MBL genes have also been found on class 3 integrons (Fluit & Schmitz, 1999).
However, not all MBL genes are necessarily associated with integrons or transposons.
The genetic context of blaSPM-1 is noticed in mobile genomic pathogenicity islet and is
found on a plasmid of 180 kb (Shibata et al., 2003).
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Poirel & Nordmann (2002) reported that the class B carbapenem hydrolyzing enzymes
activity is not suppressed by tazobactam and clavulanic acid, however it is inhibited by
bivalent ionic chelators (Poirel & Nordmann, 2002). Based on Ambler and the first
functional group according to Bush, an inducible chromosome-encoded AmpC β-
lactamase (cephalosporinase) that belongs to molecular class C is produced by P.
aeruginosa (Bush et al., 1995), P. aeruginosa Wild-type strains produce AmpC in low
quantities (low expression level ). AmpC is a common chromosomally encoded enzyme
found in many Gram-negative bacteria (Campbell et al., 1997; Colom et al., 1995;
Hanson & Sanders, 1999). It is inducible by a number of β-lactam antibiotics (e.g.,
narrow-spectrum cephalosporins and benzyl penicillin) and thus confers intrinsic
resistance (Livermore & Brown, 2001), but is not inducible by monobactams
(aztreonam), antipseudomonal piperacillin, penicillin (Livermore, 1995) and some of
the newer cephalosporins (e.g. ceftazidime, ceftriaxone, cefotaxime) that are,
nevertheless, good substrates for the enzyme.
Resistance for these antibiotics is caused by the mutational derepression of AmpC
(Livermore & Yang, 1987; Poole, 2004b). In fact, mutational derepression of AmpC is
the most frequent mechanism of resistance to β-lactams in P. aeruginosa (Tam et al.,
2007; Drissi et al., 2008; Xavier et al., 2010), and this includes expanded-spectrum
cephalosporins (e.g., ceftazidime) and penicillins (e.g., ticarcillin) (Dubois et al., 2008;
Queenan et al., 2010). While carbapenems (e.g., imipenem) are excellent inducers of
AmpC, their rapid bactericidal activity and stability to hydrolysis renders them effective
against AmpC overproduction P. aeruginosa (Jones, 1998), while derepressed AmpC
emerges to confer to carbapenem resistance in association with other mechanisms of
resistance (e.g. loss of porin protein D). Lately, the production of AmpC variants with
improved activity against oxyiminocephalosporins (e.g., ceftazidime), carbapenems
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(including imipenem), and cefepime have been reported in clinical isolates of P.
aeruginosa (Rodríguez-Martínez et al., 2009). These, also, emerge to confer
carbapenem resistance in association with loss of OprD (Rodriguez-Martinez et al.,
2009).
1.7.2 Non-enzymatic mediated mechanisms of resistance in P. aeruginosa
There are two types of non-enzymatic mediated mechanisms of resistance in P.
aeruginosa and they are the efflux pump expression and outer membrane protein.
Modification bacterial efflux systems are capable of extruding antibiotics and to date,
five families of bacterial drug efflux pumps have been identified. They are the ATP-
binding cassette (ABC) family, the major facilitator (MF) family, the small multidrug
resistance (SMR) family, the resistance nodulation-division (RND) family, and the
multidrug and toxic compound extrusion (MATE) family. The main clinically relevant
efflux systems belong to the RND efflux systems because of their abundance and
contribution to antibiotic resistance (Poole, 2004a). These efflux pumps usually work as
a tripartite system that consist of the cytoplasmic membrane protein that roles to efflux
antibiotics through the cytoplasmic membrane, an outer membrane channel protein that
supplies the means of access of drugs to the outer part of the cell and a linker protein
that joins the two pumps to a membrane fusion protein (MFP) (Livermore, 2002).
Together these three proteins are capable of efficiently pumping a range of ions, dyes
and antibiotics depending on the type of RND pump combined with the system. There
are 12 RND-type efflux systems found in P. aeruginosa, however, only four genetically
different three-part efflux systems confer resistance to antipseudomonal agents
(Livermore, 2001b; Livermore, 2002): MexX-MexY, MexA-MexB-OprM, MexE-
MexF-OprN and MexC-MexD-OprJ. The first component is a protein situated in the
cytoplasmic membrane (MexY, MexB, MexF and MexD) that functions as a pump and
is energy dependent with broad substrate specificity. The second component is a gated
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outer membrane protein (OprM, OprM, OprN and OprJ). The third protein (MexX,
MexA, MexE and MexC) is positioned in the periplasmic space and links the other two.
Efflux pump substrate specificities are summarized in Table 1.2 (Sanchez et al., 1997;
Mokhonov et al., 2004; Lister et al., 2009). MexXY-OprM and MexAB-OprM efflux
systems contribute together in acquired and natural antibacterial-resistance mechanisms
of P. aeruginosa, whereas MexEF-OprN and MexCD-OprJ only act in acquired
resistance (Llanes et al., 2004; Poole et al., 1996a; Kohler et al., 1999a).
In P. aeruginosa, the MexAB-OprM system was the ﬁrst pump detected (Li et al., 1995).
The MexAB-OprM system has the widest substrate specificity for antimicrobial agents,
which include tetracyclines, macrolides, quinolones, chloramphenicol and β-lactams
such as, ceftazidime, cefepime, piperacillin, and aztreonam (Li et al.,1995; Li et al.,
1994; Kohler et al., 1996; Li et al., 1998b). Cao et al. (2004) reported that in P.
aeruginosa the overexpression MexA–MexB–OprM might decrease susceptibility to
meropenem. There is however no activity on the extra imipenem and carbapenems-
panipenem (compared to P. aeruginosa wild-strain). This is because the diverse
molecular structure of carbapenems-meropenem has a hydrophobic side-chain at the
second location, which makes it a substrate for this efflux system. At the same time,
panipenem and imipenem are not substrates as their side-chains are hydrophilic and
charged (Cao et al., 2004b). Besides this, the substrates include non-antibiotic
compounds such as detergents, dyes (ethidium bromide, crystal violet, acriflavine and
acridine orange), organic solvents and triclosan (Li et al., 1998a; Li & Poole, 1999).
The MexR repressor negatively controls the overproduction of the MexAB-OprM
system. Mutational inactivation of nalC regulatory gene increases the expression of the
PA3719 protein, which then increases MexAB-OprM expression. nalC is the second
regulatory gene and the mutational inactivation of this regulatory gene leads to increase
expression of the PA3719 protein, which then increases the MexAB-OprM
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overproduction. nalD is the third regulatory gene of the mexAB-OprM operon, and
mutations in this gene have been noted in clinical isolates that up regulate MexAB-
OprM (Hancock & Brinkman, 2002). The MexCD-OprJ system is not expressed
constitutively. However, MexCD-OprJ overproduce as have mutations in the nfxB gene,
which encodes a transcriptional repressor (Poole et al., 1996b). This efflux system
mostly exports the antipseudomonal β-lactams (cefepime, piperacillin and meropenem,
but not ceftazidime, aztreonam or imipenem), fluoroquinolones, tetracycline,
chloramphenicol and macrolides (Li et al., 2000a). MexEF-OprN is the third efflux
system, which can confer resistance to quinolones, chloramphenicol and trimethoprim
(Kohler et al., 1999c). MexEF-OprN is up regulated by nfxC P. aeruginosa mutants. In
addition, nfxC mutations cause cross-resistance to imipenem due to have down-
regulation of OprD outer membrane proteins. Conversely, the MexEF-OprN is subject
to regulation by the MexT protein, which belongs to the LysR family of transcriptional
activators (Kohler et al.,1999c; Li et al., 2000b). Masuda et al. (2000) have reported
that MexXY-OprM overexpress export fluoroquinolones, aminoglycosides,
erythromycin and tetracycline from bacterial cells (Masuda et al.,2000a). This is known
as ‘intrinsic resistance’ of P. aeruginosa to antipseudomonal agents (Mao et al., 2001).
Like MexAB–OprM, MexXY proteins are constitutively overexpressed in stains
containing mutations in the mexZ repressor gene that is located close and transcribed
divergently from the mexXY operon (Hocquet et al., 2007).
The efflux pumps in P. aeruginosa are different from each other in various ways, which
include the substrate antibiotics they extrude, and regulation of their operons. However,
just the mexXY efflux system has been detected to supply both impermeability and
adaptive resistance to aminoglycoside antibiotics in these bacteria (Hocquet et al., 2003;
Sobel et al., 2003; Vogne et al., 2004). A dominant resistance mechanism in P.
aeruginosa is the overexpression of efflux systems with wide substrate profiles. The
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effect of the overexpression of efflux systems one the resistance to antipseudmonal
antibiotics (aminoglycosides, -lactams, fluoroquinolones and polymyxin B) are
summarized in Table 1.3 (Livermore, 2002). In P. aeruginosa, the outer membrane
works as a protecting permeability barrier, which slows down the diffusion of
antibiotics and other toxic compounds into the cell. On the other hand, many substrates
essential for the growth of the cell must pass through this permeability barrier and in P.
aeruginosa this is achieved by the existence of water-filled protein channels identified
as porins located in the outer membrane. There are three large families of porins in P.
aeruginosa. They are: the OprM family of efflux porins, the OprD family of specific
porins and the TonB family of gated porins (Hancock & Brinkman, 2002). These porin
proteins transport nutrients such as amino acids, sugars and phosphate (Hancock et al.,
1990). These porin channels also provide the route for hydrophilic antibiotics such as
aminoglycosides, β-lactams, tetracyclines and some fluoroquinolones (Nikaido, 1989;
Yoshimura & Nikaido, 1985). The OprD channel’s choice for carbapenems is related
to the chemical similarity between carbapenems and basic amino acids, permitting
binding of the carbapenems to the external loop positions 2 and 3. Therefore, mutations
in these positions confer resistance to the carbapenems (Ochs et al., 2000). The external
loop positions 5, 7 and 8 are considered to constrict the channel entrance (Huang et al.,
1995). In addition, amino acid changes or deletions in these regions have been found to
expand the channel, conferring a hyper-susceptible phenotype (Epp et al., 2001).
Even though alterations in the carbapenem-binding regions of OprD will possibly
confer a carbapenem resistant phenotype, the main mechanism of carbapenem
resistance in P. aeruginosa clinical isolates is the down-regulation of OprD (Pai et al.,
2001; Livermore, 2001b). Usually, the meropenem MIC is elevated to 2-4 mg/L and
imipenem MIC to 8-32 mg/L in isolates characterized by down-regulation of OprD
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(Livermore, 2001b). The rate of resistance emerging during imipenem therapy in P.
aeruginosa was 17% (Calandra et al., 1986). However, another study found a resistance
frequency of 44%, which was considered the highest of the antipseudomonal agents
(Carmeli et al., 1999a). Some investigators reported that the mechanism by which OprD
is decreased is due to the mutation of the structural gene OprD or the putative
promoter region, which is responsible for the loss of OprD (Yoneyama & Nakae,
1993; Pirnay et al., 2002; Masuda et al., 1995). The mutations associated with OprD
and its promoter, down-regulation of OprD in mutant P. aeruginosa is coupled with
the up-regulation of MexEF-OprN. These mutants demonstrate up-regulation of the
MexEF-oprN during the action of a transcriptional regulator MexT. While a consensus
binding region has not been recognized upstream of OprD , expression of cloned MexT
from a plasmid has been found to repress the expression of OprD which was adequate
to considerably increase MIC of imipenem (Masuda et al., 1995; Ochs et al., 1999).
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Table 1.2: Efflux pump substrate specificities of the efflux pump   systems in P.
aeruginosa
Pump
Periplasmic
linker
Cytoplasmic
membrane
Outer
membrane
channel Substrates
MexA MexB OprM
β-lactams except imipenem, macrolides,
tetracycline’s, chloramphenicol, novobiocin,
Quinolones,  lincomycin
MexC MexD OprJ
meropenem, macrolides, novobiocin,
Quinolones, lincomycin, tetracyclines
,chloramphenicol, penicillins except
sulbenicillin and carbenicillin, cefepime,
cefpirome
MexE MexF OprN Fluoroquinolones, carbapenems
MexX MexY OprM
Quinolones, cefepime, meropenem, cefpirome.
aminoglycosides, macrolides, lincomycin,
chloramphenicol, tetracycline’s  and, Penicillins
except sulbenicillin and carbenicillin
Table 1.3: Effect of the overexpression of efflux pumps on the resistance to antimicrobial
agents
Impact on resistance to antipseudomonal with antimicrobial
agents activityMutation
site
Overexpression
of:
PBAglMEMIMPFEPCPO
CAZ
ATM
PIP
AZL
CAR
TICFq
–r/Rr–r/Rr/Rr/Rr/Rr/RmexZMexX–MexY–OprM
––r–r/Rr/Rr/RRr/R
mexR;
PA3721
and
PA3719;
PA3574
MexA–MexB–
OprM
––r–Rr/Rr/Rr/Rr/RnfxBMexC–MexD–OprJ
––rrr/Rr/Rr/Rr/Rr/RmexTMexE–MexF–OprN
Aztreonam (ATM,); aminoglycosides(Agl); fluoroquinolones(Fq); azlocillin(AZL); carbenicillin(CAR);
ceftazidime(CAZ);  cefpirome(CPO); cefepime(FEP); imipenem(IMP); meropenem(MEM); ticarcillin(TIC);
piperacillin (PIP); polymyxin B(PB); resistance(R) and reduced susceptibility(r).
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1.8 Objectives
This study contributes to the understanding of antibiotic susceptibility and resistance,
characterization of the causes of resistance and mechanisms of resistance to assist in the
management of infections caused by P. aeruginosa.
A number of studies have been performed to determine the effectiveness of several
antibiotics to these bacteria (Livermore et al., 2001, Nadeem Sajjad Raja, 2007,
Olayinka et al., 2004, Wroblewska et al., 2006).
There are several studies (Islam et al., 2004, Dumas et al., 2006, Strateva et al., 2007,
Tam et al., 2009) that evaluate the chromosomally encoded resistance mechanisms
among P. aeruginosa clinical isolates. However, to date (2009), this is the first study to
investigate the contribution of different mechanisms of multidrug resistance among the
Malaysian clinical P. aeruginosa isolates.
Thus, the purpose of this study was to analyze the expression of multidrug efflux pumps
in addition to its relationship with further resistance mechanisms, such as porin down-
regulation and β -lactamase production, between P. aeruginosa clinical isolates.
Furthermore this study aimed to elucidate whether production of metalo-β-lactamase
(MBL) contribute to imipenem resistance in the clinical isolates of P. aeruginosa.
The specific objectives of this study are:
1. To identify and characterize P. aeruginosa clinical isolates from the University
of Malaya Medical Center, Kuala Lumpur, Malaysia.
2. To determine the antibiotic resistance profile for each isolate.
3. To determine the drug resistance genes in these isolates according to the
mechanisms of antibiotic resistance among the multidrug resistant isolates.
4. To elucidate whether the production of metallo-β-lactamase (MBL) contributes
to imipenem and meropenem resistance in clinical isolates of P. aeruginosa.
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Chapter 2
Materials and Methods
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2.1 Bacterial isolates
Eighty-eight P. aeruginosa were collected randomly from April 2009 to March 2010
from the University of Malaya Medical Center, Kuala Lumpur, Malaysia, from various
samples. The clinical specimens of P. aeruginosa isolates were isolated from urine,
wound, sputum, blood and indwelling medical devices. Specimens were collected from
different hospital wards such as surgery, general medicine, orthopedics, paediatric,
neurosurgery, intensive care units, ENT and gynaecology wards. The control strain used
in this study was P. aeruginosa ATCC 27853.
2.1.1 Cultivation of clinical specimens
10 mL of blood from a venopuncture was collected into a Bactec Plus Aerobic/F (gray
cap) bottle and incubated in a BACTEC 9000 Series blood culture instrument (Becton
Dickinson, USA). The positive sample was then subcultured onto blood agar. Sputum
was considered acceptable for the culture if it contained <25 epithelial cells per low-
power field and >25 polymorphonuclear leukocytes. Sputum was then cultured on
chocolate agar, blood agar and macconkey agar. In addition, body fluids and wound
samples were cultured on chocolate agar, blood agar and MacConkey agar and then
incubated in a 5% CO2 incubator at 37°C for 24 hours. In dwelling medical devices and
urine samples were cultured on MacConkey agar and blood agar then incubated at 37°C
in an incubator for 24 hours.
2.1.2 Preservation of isolates
To store the isolates for the long-term, isolates were subcultured on Nutrient agar and
incubated at 37°C for 24 hours. A single colony of pure culture was then cultured on LB
broth (Luria Bertani) and incubated overnight. The bacterial cell pellet was transferred
to the 1.5 mL plastic tubes and LB broth (Luria Bertani) in addition to 30% V/V
glycerol were added. They were then kept frozen at -80°C until used. P. aeruginosa
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isolates were then recovered from frozen stocks when needed. This was done by
subculturing on Nutrient agar and incubation for 24 hours in a 37°C incubator.
2.1.3 Ethical consideration
The protocol for this study (Reference Number: 902.5) and use of isolates has been
approved by the Medical Ethics Committee of the University of Malaya Medical
Centre, Kuala Lumpur, Malaysia (Appendix I).
2.2 Conventional methods of identification and characterization of P. aeruginosa
P. aeruginosa colonies were identified based on morphology, Gram staining, pyocyanin
production and a biochemical test by API20NE (bioMérieux, Marcy-l’Etoile, France).
using standard laboratory procedures (Binnerup et al., 1998).
2.2.1 Gram staining
The Gram stain was carried out on 24 hours cultures according to the Hucker method
(Binnerup et al., 1998). Three to four colonies of pure P. aeruginosa culture were
smeared thinly on to a glass slide and air-dried, then it was fixed with a gentle flame
heat or 95% methanol was added for 2 minutes. The primary stain (Crystal violet) was
added and allowed to stand for 1 minute. Excess stain was washed off with a gentle
stream of tap water. The Gram’s iodine was added and allowed to stand for 30 seconds
before being rinsed off. This was decolorized by acetone for 5 to 15 seconds, then
washed with tap water, then stained with the counter stain Safranin for 1 minute, and
washed with tap water. Finally, the slide was air dried prior to being examined under a
microscope. If the bacteria were Gram-negative, they appeared pink under the
microscope. If the cell was Gram-positive, it appeared purple under the microscope.
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2.2.2 Motility test
Motility is demonstrated macroscopically by making a straight stab of pure P.
aeruginosa colonies grow in nutrient broth. This was incubated for 24 hours at 37°C,
and then the P. aeruginosa grown in nutrient broth was placed on a slide and covered
with a clean cover slip. The motility examination was then done by a microscope
(Barrow & Feltham, 2004).
2.2.3 Oxidase test
The filter paper was saturated with oxidase reagent (bioMérieux, Marcy-l’Etoile,
France) that was placed in a petridish. A loopful of P. aeruginosa from a 24-hours-old
culture was inoculated onto filter paper. Development of a blue color at the site of
inoculation within 10 to 30 seconds indicated a positive reaction (Barrow & Feltham,
2004).
2.2.4   Biochemical tests
P. aeruginosa identification was performed using the commercially available kit, API
20NE (bioMérieux, Marcy-l’Etoile, France) according to the manufacturer’s
instructions. It consisted of 20 microtubes containing dehydrated substrates as is
illustrated in Table 2.1. The control strain used in this study was a P. aeruginosa ATCC
27853 (Figure 2.1).
The analysis of data was done by using the API20NE identification software that was
provided by the manufacturing company.
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Table 2.1: Biochemical test demonstrating the API20NE parameters and the
Characteristics of P. aeruginosa
TESTS ACTIVE INGREDIENTS Biochemical tests Characteristics
of P. aeruginosa
NO3 potassium nitrate reduction of nitrates to nitrites Positive
reduction of nitrates to nitrogen
TRP L-tryptophane indole production
(TRyptoPhane)
Negative
GLU D-glucose fermentation (GLUcose) Negative
ADH L-arginine Arginine DiHydrolase Variable
URE urea UREase Variable
ESC Esculin ferric citrate hydrolysis (β-glucosidase)
(ESCulin)
Negative
GEL Gelatin (bovine origin) hydrolysis (protease) (GELatin) Positive
PNPG 4-nitrophenyl-β-
Dgalactopyranoside
β-galactosidase (Para-Nitro
Phenyl-ßDGalactopyranosidase)
Negative
GLU D-glucose assimilation (GLUcose) Positive
ARA L-arabinose assimilation (ARAbinose) Negative
MNE D-mannose assimilation (ManNosE) Negative
MAN D-mannitol assimilation (MANnitol) Positive
NAG N-acetyl-glucosamine Assimilation (N-Acetyl-
Glucosamine)
Positive
MAL D-maltose assimilation (MALtose) Negative
GNT potassium  gluconate assimilation (potassium
GlucoNate)
Positive
CAP capric acid assimilation (CAPric acid) Positive
ADI adipic acid assimilation (ADIpic acid) Positive
MLT malic acid assimilation (MaLaTe) Positive
CIT trisodium citrate assimilation (trisodium CITrate) Positive
PAC phenylacetic acid assimilation (PhenylACetic acid) Negative
OX oxidase test cytochrome oxidase Positive
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Figure 2.1: API 20NE tests that consisted of 20 microtubes containing dehydrated
substrates.
2.3 Antibiotic susceptibility testing
The susceptibility of various antibiotics against P. aeruginosa clinical isolates was
determined using an E-test® (bioMérieux) according to the guidelines of the Clinical
and Laboratory Standards Institute (Tholen, 2006). Mueller-Hinton agar was prepared
as follows. The agar was prepared according to the manufacturer’s instructions to a pH
of 7.2-7.4. Immediately after autoclaving, the agar was allowed to cool to 45-50°C. The
freshly prepared agar was poured into plastic, flat-bottomed petri dishes on a level
surface to give a uniform depth of approximately 4 mm (this corresponded to 25-30 mL
of agar in a plate with a diameter of 100 mm). The plates were allowed to cool to room
temperature and, unless the plates were used on the same day, they were stored at 2-8°C
in a refrigerator. All plates were used within seven days of preparation. A representative
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sample of each batch of plates was examined for sterility by incubating at 37°C for 24
hours.
The E-test® was used as a quantitative antimicrobial susceptibility testing method. This
included the equal diffusion and dilution of antibiotics into the medium. It is recognized
as the epsilometer test as ‘E’ refers to the Greek sign epsilon (). A thin inert strip is a
carrier that predefines the antimicrobial gradient. There is an immediate release of the
drug when the E-test® strip is applied onto an inoculated agar plate following
incubation, as a regular inhibition ellipse is produced. The calibrated carrier strip and
the intersection of the inhibitory zone edge indicates the MIC value (Lalitha et
al.,1997). The antimicrobial agents tested in this study were piperacillin/tazobactam,
ceftazidime, aztreonam, amikacin, gentamicin, ciprofloxacin, imipenem, meropenem
and colistin.
The MIC for each antibiotic was determined on Mueller-Hinton agar. Overnight
cultures of P. aeruginosa on Mueller-Hinton broth were diluted to an initial cell density
of 107 cfu/mL with fresh Mueller-Hinton broth. Inoculums were 105 cfu to achieve a
bacterial suspension equivalent to a 0.5 McFarland turbidity standard. The 0.5
McFarland standard was prepared as follows; a 0.5 mL aliquot of 0.048 mol/L BaCl2
(1.175% w/v BaCl2. 2 H2O) was added to 99.5 mL of 0.18 mol/L H2SO4 (1% V/V) with
constant stirring to maintain a suspension. The correct density of the turbidity standard
was verified by using a spectrophotometer with a 1 cm light path and matched cuvette
to determine the absorbance. The absorbance at 600 nm was between 0.08 and 0.1 for
the 0.5 McFarland standards.
A sterile cotton swab was dipped into the adjusted suspension, optimally within 15
minutes after adjusting the turbidity of the inoculum suspension. The swab was rotated
several times and pressed firmly on the inside wall of the tube above the fluid level to
remove the excess inoculum from the swab. The dried surface of the Mueller Hinton
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agar plate was inoculated by streaking the swab over the entire sterile agar surface. This
procedure was repeated two more times, rotating the plate approximately 60° each time
to ensure an even distribution of inoculum. The rim of the agar was then swabbed as a
final step. The cover was left partly open for three to five minutes to allow any excess
surface moisture to be absorbed before applying E-test® antimicrobial strips. Two
different E-test® antimicrobial strips were placed in opposite gradient directions on a
Mueller-Hinton agar plate with sterile forceps. Printed MIC values faced upward (i.e.,
the bottom surface of the strip containing the antimicrobial gradient is in contact with
the agar). The plates were incubated in an inverted position at 37◦C for 24 hours. After
incubation, the MICs were read in the intersection point (break point) of inhibitory
eclipse and interpreted according to CLSI standards (Tholen, 2006) and were reported
as being susceptible, intermediate or resistant to the agents that were tested. P.
aeruginosa ATCC 27853 were utilized as quality control strains. The break point of
inhibition of each antibiotic were also obtained for the control strains P. aeruginosa
ATCC 27853 to ensure the method was being performed correctly and compared to the
expected point of inhibition according to CLSI (Table 2.2).
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Table 2.2: Summary of E-test® interpretative criteria of minimum inhibition
concentration (MIC) break point for P. aeruginosa according to CLSI (Tholen,
2006)
S: susceptible, I: intermediate or R: resistant.
Antibiotic Code
MIC range
µg/mL S I
P. aeruginosa
ATCC 27853
MIC µg/mL
Gentamicin GM 0.064-1024 4 5 8 1 - 4
Amikacin AK 0.016- 256 16 17 32 1 - 4
Ciprofloxacin CI 0.002- 32 1 2 4 0.25-1
Imipenem IP 0.002- 32 4 8 16 1 - 4
Meropenem MP 0.002- 32 4 8 16 0.25-1
Ceftazidime TZ 0.016- 256 8 16 32 1 - 4
Aztreonam AT 0.016- 256 8 16 32 2-8
Piperacillin*/
Tazobactam**
PTC 0.016- 256*
(4 µg/mL)**
16 32-64 128 1-8
Colistin CO 0.016- 256 2 4 8 0.5 - 4
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2.4 Gene expression of P. aeruginosa using real time PCR
2.4.1 Extraction and quantitation of RNA
TE buffer (10 mM Tris·Cl, 1 mM EDTA, pH 8.0) was prepared containing 15 mg/mL
lysozyme which was used in the lysis of the bacterial cell wall. The RNAprotect
Bacteria Reagent (Qiagen, Hilden, Germany) is a kit used to stabilize RNA before the
bacterial cells were lysed. This allows sufficient time for efficient disruption of cells
without the risk of distorting the gene expression profile. After cell lysis, the RNeasy
Mini Kit was used (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Aliquot (0.25 mL) of the suspended culture (cells pellet suspension),
equivalent to 5×108cfu/mL, was added to 0.5 mL of the RNAeasy bacteria protect
solution (Qiagen, Hilden, Germany) then mixed immediately by vortexing for 5 seconds
and incubated for 5 min at room temperature (15–25°C), then centrifuged for 10 minutes
at 8000 rpm after that supernatant was decanted by gently dabbing the inverted tube
once onto a paper towel until the residual supernatant was removed. Then 100 µL of TE
buffer containing lysozyme 15 mg/mL (Sigma Aldrich, Germany) was added and
vortexed for 10 seconds then incubated at room temperature for 5 minutes. This was
also vortexed for 10 seconds every 2 minutes during incubation. In addition, 350 µl of
RLT buffer was then added and mixed vigorously by vortex, 96% ethanol 250 µL was
added and homogenized well by pipetting. Then 700 µL lysate was transferred to the
RNeasy spin column and centrifuged for 15 seconds at 10,000 rpm. The flow through
was discarded of and the RNeasy collection tube reused and 350 µL of RW1 buffer was
added into a spin column and centrifuged for 15 seconds at 10,000 rpm. Residual DNA
was treated with DNase 1U/μL (Qiagen, Hilden, Germany). DNase I was prepared as a
stock solution by adding 10 µL of DNase I plus 70 µL of RDD buffer (Qiagen, Hilden,
Germany) then mixed gently and centrifuged. The mixture was called DNase I mix, 80
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µL of DNase I mix was added to the RNeasy spin column membrane, and incubated at
room temperature for 15 minutes, 350 µL of RW1 buffer was added to the spin column,
incubated for 5 minutes at room temperature then centrifuged for 15 seconds at 10,000
rpm. The flow-through and collection tube were discarded and the mini spin column
was transferred to another 2 mL collection tube, 500 µL of RPE buffer was then added
to the mini spin column and centrifuged for 15 seconds at 10,000 rpm. The flow-
through was discarded and the collection tube reused. Then500 µL of RPE buffer was
added to the mini spin column and centrifuged for 2 minutes at 10,000 rpm. The spin
column was placed into another collection tube and centrifuged for a minute at full
speed and the mini spin column was placed in a 1.5 mL collection tube. The RNA was
then eluted by adding 50 µL of RNase-free water directly and centrifuged for 1 minute
at 10,000 rpm. The RNA concentration was measured using NanoDrop-2000. To
exclude the possibility of any contamination of the RNA, samples with genomic DNA
real time PCR was performed. The extracted RNA was kept at −80ºC until used. The
concentration and purity of RNA was determined by measuring the absorbance at
(A260) nm and (A280) nm using Nano Drop spectrophotometer (Nano-Drop 2000
Thermo Fisher Scientific, USA) to estimate the ratio between the absorbance values at
260 and 280 nm to ensure the RNA purity. In addition, the ratio of absorbance values at
260 and 230 nm was estimated. For all samples, the ratios of A 260/280 and A 260/230
were above 2.0 in nuclease free water (Figure 2.2).
The integrity and size distribution of the total RNA was checked by 1.2% (w/v)
formaldehyde-denaturing agarose gel electrophoresis at 100 V for 50 min (Figure 2.3).
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Figure 2.2: Representative diagram of extracted RNA measured by NanoDrop ND-
2000. Note the A260/280 is 2.10.
Figure 2.3 Representative picture of 1.2% (w/v) formaldehyde-denaturing agarose
Gel electrophoresis to verify the quality of extracted RNA.
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2.4.2 cDNA synthesis
500 ng of RNA from all strains was converted to cDNA using a QuantiTect Rev.
Transcriptase Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
The following steps were taken: The reagents of reverse transcription were thawed at room
temperature, then mixed by flicking the tubes, centrifuged briefly, and stored on ice. The
RNA was thawed on ice.
The genomic DNA elimination kit was thawing on ice, then the component added as in Table
2.3. This was mixed well and incubated for 10 minutes at 40°C, then placed immediately on
ice. The reverse-transcription master mix was prepared on ice according to Table 2.4.
The RNA from step 3 (14 µL) was templated and added to each tube containing the reverse-
transcription master mix, and then mixed well. This was incubated in a thermal cycler (Master
cycler Gradient PCR, Eppendroff) under the following conditions: 15 minutes at 42°C, then 3
minutes at 95°C, ending at 4°C. The cDNA was kept at –20ºC until used.
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Table 2.3: Concentration of each reagent that was used to eliminate genomic DNA
Table 2.4: Reverse-transcription reaction components in final volume (20 µL)
Component Volume/reaction Final concentration
gDNA Wipeout Buffer, 7x 2 µL
1xRNase-free water Variable
Template RNA Variable (500 ng)
Total volume 14 µL -
Constituent Volume/reaction Final concentration
Master mix of reverse-transcription
Quantiscript RT buffer 4 µL
1xQuantiscript reverse transcriptase 1 µL
RT primer mix 1 µL
Entire genomic DNA wipe out
reaction (step 3)
14 µL (added at step 6)
Total volume 20  µL -
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2.5 Real time PCR to determine expression levels of antibiotic resistant genes
Transcriptional levels of mexB, mexY, mexCD, mexF, mexZ, oprM, ampC, PBP2, PBP3
and oprD were determined using gene-specific primers with real-time PCR (Table 2.5)
in a CFX96™ PCR detection system (BioRad, Hercules, CA). Amplifications were
carried out in triplicate PCR reactions using the iQ™ SYBR® Green supermix
(BioRad). The reagent composition of PCR mixtures is presented in Table 2.6. The
amplification conditions for real-time PCR of each gene were as shown in Table 2.7.
The amplicon for each of the melting curves was evaluated and contrasted with the
melting temperature (Tm) obtained when using the cDNA template to ensure that
specific amplification had occurred.
The transcriptional levels of the target genes were normalized using a reference gene,
rpoD. This gene is constitutively expressed in P. aeruginosa (Savli, et al., 2003) and
experiments showed a stable expression of rpoD in all isolates. Normalized expression
of each target gene was standardized against corresponding mRNA expression in the P.
aeruginosa wild strain (ATCC 27853). All published equations and available models
for all calculations of the relative expression ratio allow only for the determination of a
single transcription difference between one control and one sample. Therefore, the
relative gene expression results are presented as ratios between the target gene (target)
and the reference gene (rpoD), which were obtained based on the following equation:
Ratio = (Etarget gene)ct target (ATCC 27853-sample) /(ErpoD)ct rpoD (ATCC 27853-sample) (Pfaffl et al.,
2002), where E is the real-time PCR efficiency for a given gene,  unknown sample
versus a control (ct ATCC 27853-sample) and Ct the crossing point of the ampliﬁcation
curve with the threshold. Transcription data was analyzed using Bio-Rad CFX manager
software.
According to previous studies (Dumas et al., 2006; Savli et al., 2003; Li & Nikaido,
2009; Tomas et al., 2010; Yoneda et al., 2005), the efflux system genes mexY and mexB
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were considered up regulated when the transcription levels of MexY and MexB were,
respectively, at least 4 and 2 fold higher than the reference strain P. aeruginosa wild-
type (ATCC 27853). Overexpression of ampC and down-regulation of oprD was
considered significant when their transcriptional levels were respectively, ≥ 10 and ≤
70% -fold, compared to the reference strain wild type. The data were subjected to
statistical analysis using SPSS version 11.5 (SPSS Inc., Chicago, US). A chi-square was
done to show the mRNA expression in comparison to antibiotics resistance. A p-value
of 0.05 was considered indicative of a statistically significant difference. Fisher’s
exact test is to be used if less than 50% of the cells are less than 5.
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Table 2.5: Primers used in real-time PCR
Table 2.6: Reagents used  in a real-time PCR master mix for the MexB, MexY,
mexCD, mexEF, mexZ, oprM, ampC, PBP2, PBP3 and oprD genes
(final volume 25 µL)
Genes 5´- sequence- 3´ Reference
mexB FR
5´- GTGTTCGGCTCGCAGTACTC - 3´ (Dumas, et al.,2006)
5´- AACCGTCGGGATTGACCTTG - 3´
mexY FR
5´- CCGCTACAACGGCTATCCCT - 3´ (Dumas, et al.,2006)
5´- AGCGGGATCGACCAGCTTTC - 3´
mexZ FR
5´- AGGTCTGCCTGGCGATGTGC- 3´ (Yoneda et al., 2005)
5´- AGCGTTGCCCCTGCTTCTCG – 3´
oprD FR
5´-CGACCTGCTGCTCCGCAACTA - 3´ (Yoneda, et al., 2005)
5´- TTGCATCTCGCCCCACTTCAG- 3´
ampC FR
5´- AGATTCCCCTGCCTGTGC- 3´ (Dumas, et al., 2006)
5´-GGCGGTGAAGGTCTTGCT- 3´
PBP2 FR
5´ -GCCCAACTACGACCACAAG - 3´ (Yoneda, et al., 2005)
5´ -CGCGAGGTCGTAGAA ATA G - 3´
PBP3 FR
5´ -TGATCAAGTCGAGCAACGTC - 3´ (Yoneda, et al., 2005)
5´ -TGCATGACCGAGTAGATGGA - 3´
rpoD FR
5´-GGGCGAAGAAGGAAATGGTC- 3´ (Savli, et al., 2003)
5´ -CAGGTGGCGTAGGTGGAGAA- 3´
mexCD F
R
5´ -GGAGTTCGGCCAGGTAGTGCTG- 3´ (El Amin et al., 2005)
5´ -ACTGCATGTCCTCGGGGAAGAA- 3´
mexEF F
R
5´ -CGCCTGGTCACCGAGGAAGAGT- 3´ (Giske et al., 2005)
5´ -TAGTCCATGGCTTGCGGGAAGC- 3´
oprM FR
5´ -GATCCCCGACTACCAGCGCCCCG- 3´ (Dumas, et al., 2006)
5´ -ATGCGGTACTGCGCCCGGAAGGC- 3´
Reagent Volume(µl):1sample Final concentration
iQ™ SYBR®Green supermix 12.5 µL 1X
Forward primer (10 pM) 1.0 µL 1 pM
Reverse primer (10 pM) 1.0 µL 1 pM
Total cDNA (1:4) 2.0 µL 125 ng
RNase-free water 8.5 µL -
Total volume 25 µL
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Table 2.7: qRT-PCR conditions individual resistance genes
Each step of qRT-
PCR
qRT-PCR  condition  (°C, minutes, seconds)
mexB mexY mexCD mexEF mexZ oprM ampC PBP2 PBP3 oprD rpoD
Predenaturing 95
ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC
10min 10min 10min 10min 10min 10min 10min 10min 10min 10min 10min
35 cycles of
Denaturing 95
ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC 95ºC
20 sec 20 sec 20 sec 20 sec 20 sec 20 sec 20 sec 20 sec 20 sec 20 sec 20 sec
Annealing 58
ºC 59ºC 63.5ºC 60ºC 57 ºC 63ºC 56ºC 64ºC 62ºC 61ºC 55ºC
30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec
Extension 72
ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC
30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec 30 sec
Plate read
Final Extension 72ºC 72
ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC 72ºC
5 min 5 min 5 min 5 min 5 min 5 min 5 min 5 min 5 min 5min 5 min
Melting curve  65ºC  to 95ºC, increment  5ºC for  0:05 +  Plate read
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2.6 Gene identification of metallo-β-lactamase production in P. aeruginosa using
polymerase chain reaction (PCR)
2.6.1 DNA extraction and quantitation
P. aeruginosa clinical isolates were subcultured on nutrient agar for 24 hours at 37ºC. A
single colony of pure culture was cultured on LB (Luria Bertani) broth at 37ºC for 18
hours and the cells were diluted in fresh LB broth (1:100). They were then grown to
logarithmic phase (0.5 at OD600) and the cells pellet was collected by centrifugation at
4000 rpm for 10 minutes at 4ºC. The supernatant was removed and the cells pellet was
resuspended.  The DNA was then extracted using a DNeasy blood and tissue mini kit
(Qiagen) according to the manufacturer’s instructions using the following steps: The
supernatant was removed and the cell pellet resuspended. ATL buffer (180 µL) was
added to the cell pellet. Then, 20 µL proteinase K was added and mixed well, then
incubated at 56°C for 1 hour. RNase A 4 µL (100 mg/mL) was added and mixed by
vortex then incubated for 2 minutes at room temperature to digest genomic DNA. AL
buffer (200 µL) was added and mixed thoroughly by vortex. Ethanol (200 µL /96%)
was then added and mixed again thoroughly by vortex. The mixture from step 5 was
transferred into the mini spin column tube then centrifuged at 8000 rpm for 1 minute.
The flow-through and collection tube were discarded. The mini spin column was placed
in another collection tube. Then 500 µL AW1 buffer was added then centrifuged for 1
minute at 8000 rpm. The flow-through and collection tube were discarded. The mini
spin column was placed in another collection tube. Then 500 µL AW2 buffer was added
then centrifuged for 3 minutes at 14,000 rpm to dry the membrane of the mini spin
column. The flow-through and collection tube were discarded. The mini spin column
was placed in a clean 1.8 mL tube and centrifuged at 14,000 rpm for 1 minute to
eliminate residual ethanol. The mini spin column was placed in a clean 1.8 mL tube.
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The 100 µL AE buffer was added directly and incubated at room temperature for 5
minutes and centrifugation at 8000 rpm was done after that for 1 minutes to elute for
DNA. The DNA was stocked up at -20°C until used.
The concentration and purity of DNA was determined by measuring the absorbance at
(A260) nm and (A280) nm using a Nano drop-2000 spectrophotometer to estimate the
ratio between the absorbance values at 260 and 280 nm to ensure DNA purity. In
addition, the ratios between the absorbance values were estimated at 260 nm and 230
nm. The ratios for all samples of A 260/280 and A 260/230 were above 2.0 in nuclease
free water.
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2.6.2 PCR amplification of the (blaIMP, blaVIM, blaGIM, blaSIM, blaSPM and blaNDM)genes
Sixty-five P. aeruginosa isolates that were resistant to imipenem and meropenem were
tested for MBL production according to the Pitout et al. method (Pitout et al., 2005).
The genes encoded for the following metallo-β-Lactamase class B (blaIMP, blaVIM,
blaGIM, blaSIM, blaSPM and blaNDM) were determined from genomic DNA using gene-
specific primers for the metallo β-Lactamase genes by PCR amplification assay (Table
2.8).
The amplification was carried out using a Master cycler Gradient PCR (Eppendroff) and
top taq™ master mix 250 unit kit (Qiagen). This was used for genes identification
(blaIMP, blaVIM, blaGIM, blaSIM, blaSPM and blaNDM) and the concentration of each reagent
used (Table 2.9) in a final volume of 25 µL. The PCR conditions included the primary
incubation at 37°C for 10 minutes and the first step denaturation for 5 minutes at 94°C.
This was followed by 30 cycles of DNA denaturation for 1 minute at 94°C, annealing
temperature for 1 minute at 54°C, and an extension for 1.5 minutes at 72°C. Finally, the
PCR products were analyzed (1/10 volume) by electrophoresis with 2.0% (w/v) agarose
gels in a TAE buffer using sybr green dye for 50 minutes at 100 V. The PCR product
was visualized with UV light in a gel doc XR system (BioRad).
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Table 2.8: The oligonucleotide PCR primers used for identification of
Metallo-β-Lactamase Genes
*Amplicon size in base pair
Table 2.9: PCR mixture and concentration of each reagent used for gene
identification of (blaIMP, blaVIM, blaGIM, blaSIM, blaSPM and blaNDM) in afinal volume 25 µL
Genes 5´- sequence- 3´ Reference bp*
blaIMP FR
5-GAA GGY GTT TAT GTT CAT AC-3 (Pitout, et al.,2005) 587
5-GTA MGT TTC AAG AGT GAT GC-3
blaVIM FR
5-GTT TGG TCG CAT ATC GCA AC-3 (Pitout, et al.,2005) 382
5-AAT GCG CAG CAC CAG GAT AG-3
blaSIM FR
5-TACAAGGGATTCGGCATCG-3 (Poirel et al.,2011) 570
5-TAATGGCCTGTTCCCATGTG-3
blaSPM FR
5-AAAATCTGGGTACGCAAACG-3 (Poirel, et al.,2011) 271
5-ACATTATCCGCTGGAACAGG-3
blaGIM FR
5-TCGACACACCTTGGTCTGAA-3 (Poirel, et al.,2011) 477
5-AACTTCCAACTTTGCCATGC-3
blaNDM FR
5-GGTTTGGCGATCTGGTTTTC (Poirel, et al.,2011) 621
CGGAATGGCTCATCACGATC
Reagent Volume(µL):1sample Final concentration
top taq™  master mix 12.5 µL 1X
Total DNA 2.0 µL 100-500 ng
Forward primer (10 pM) 1.0 µL 1 pM
Reverse primer (10 pM) 1.0 µL 1 pM
RNase-free water 8.5 µL -
Total volume 25 µL
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2.6.3 PCR amplification of the beta-lactamases (blaSHV, blaTEM, blaCTX-M, blaVEBand blaPER)
Sixty-five isolates of P. aeruginosa, which showed resistance to meropenem and
imipenem, were evaluated for the ESBL production genes. The genes encoding for the
beta-lactamases (blaSHV, blaTEM, blaCTX-M, blaVEB and blaPER) were identified using the
conventional PCR amplification assay from genomic DNA using gene-specific primers
(Table 2.10). A top taq™ master mix 250 unit kit (Qiagen) was used in a ﬁnal volume
reaction of 50 µL as is illustrated in Table 2.11.
PCR ampliﬁcation conditions included the first step of denaturation for 15 minutes at
95°C. This was followed by 30 cycles of denaturation for 30 seconds at 94°C, annealing
temperature for 30 seconds at 50°C for blaTEM, at 52°C for blaVEB, at 54°C for blaPER,
56°C for blaSHV and 58°C for blaCTX-M primers. This was followed by extension
temperature for 2 minutes at 72°C and a ﬁnal step extension for 10 minutes at 72°C.
Finally, the cycles was hold at 4°C. Subsequently the PCR products (1/10 volume) were
analyzed by electrophoresis with 2.0% (w/v) agarose gels in TAE buffer using sybr
green dye for 50 minutes at 100 V and visualized with UV light using a gel doc XR
system (BioRad).
The whole genome amplified DNA was obtained from the Klebsiella pneumoniae strains. Both
strains possessing the (blaSHV, blaTEM and blaCTX-M ) gene were kindly provided by Dr.
Hans-Jürg Monstein (Monstein et al., 2007), (Clinical Microbiology, Molecular Biology
Laboratory, University Hospital, Linköping, Sweden) and used as positive control
strains.
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Table 2.10: Primers used in PCR ampliﬁcation for identification of the (blaSHV, blaTEM,blaCTX-M, blaVEB and blaPER) genes respectively
*Amplicon size in base pair
Table 2.11: PCR mixture and concentration of each reagent used for gene
identification of (blaIMP, blaVIM, blaGIM, blaSIM, blaSPM and blaNDM) in afinal volume 25 µL
Genes 5´- sequence- 3´ bp* reference
blaSHV FR
5´- ATGCGTTATATTCGCCTGTG - 3´
747
(Paterson et
al.,2003)5´- TGCTTTGTTATTCGGGCCAA - 3´
blaTEM FR
5´- TCGCCGCATACACTATTCTCAGAATGA - 3´
445
(Monstein, et
al.,2007)5´- ACGCTCACCGGCTCCAGATTTAT - 3´
blaCTX-M FR
5´- ATGTGCAGYACCAGTAARGTKATGGC - 3´
593
(Boyd et al.,2004)
5´TGGGTRAARTARGTSACCAGAAYCAGCGG-3´
blaVEB FR
5´- CGACTTCCATTTCCCGATGC- 3´
643
(Naas et al.,2000)
5´- GGACTCTGCAACAAATACGC- 3´
blaPER FR
5´- AATTTGGGCTTAGGGCAGAA- 3´
925
(Claeys et
al.,2000)5´- ATGAATGTCATTATAAAAGC- 3´
Component Volume(µL):1sample Final concentration
top taq™  master mix 20 µL 1X
Forward primer (10 pM) 1.0 µL every gene 1 pM
Reverse primer (10 pM) 1.0 µL  every gene 1 pM
Total DNA 4.0 µL 100-500 ng
RNase-free water 20 µL -
Total volume 50 µL
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Chapter 3
Results
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3.1 Characterization of clinical bacterial isolates
Eighty-eight P. aeruginosa isolates were collected from various clinical samples from
different wards at the University of Malaya Medical Center, Kuala Lumpur, Malaysia.
These samples were sourced from April 2009 to March 2010. Preliminary identification
tests were performed for all isolates using a variety of techniques, which included
morphological characteristics, Gram staining, pyocyanin production and a biochemical
test, by API20NE. The clinical specimens of P. aeruginosa isolates were isolated from
urine (53.4%), wound (21.6 %), sputum (5.7%), blood (5.7%) and indwelling medical
devices (13.6 %) as shown in Table 3.1a. Samples were collected from patients
hospitalized in the surgical (31), medical (20), orthopedic (13), paediatric (7),
neurosurgery (7), intensive care unit (ICU) (5), otorhinolaryngology (ENT) (3) and
gynaecology wards (2). Of these isolates, 47 were from urine, 19 from wounds, 12 from
in dwelling medical devices, 5 from blood, and 5 from sputum (Table 3.1b).
The morphology of the identified colonies was smooth and large with an elevated center
giving it the appearance of a fried egg. Colonies were pigmented blue green due to
pyocyanin pigment on the Nutrient agar culture at 37ºC  as illustrated in Figure 3.1a.
When the colonies were cultured on MacConkey agar, they appeared as non-lactose
fermenters, with smooth, large, elevated and occasionally mucoid colonies as shown in
Figure 3.1b. All strains were identified as being Gram negative, rod or coccobacilli
shape, and non-spore forming (Figure 3.1c). Further identification was performed using
the commercially available identification kit, API 20NE (bioMérieux) according to the
manufacturer’s instructions. It consisted of 21 microtubes containing enzymatic and
carbon compound assimilation tests and all of the isolates were identified as P.
aeruginosa as shown in Appendix III.
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Table 3.1a: the distribution of P. aeruginosa from various clinical specimens
Table 3.1b: Distribution of specimen based on ward
Source/Site No of isolates %
Urine 47 53.4
Wound 19 21.6
Sputum 5 5.7
Blood 5 5.7
In dwelling medical devices 12 13.6
Total 88 100
Wards
Specimen type
Urine Wound In dwellingmedical devices Sputum Blood Total
Surgery 20 5 3 2 1 31
Medicine 12 2 2 2 2 20
Orthopedic 3 8 1 0 1 13
Paediatric 3 1 2 0 1 7
Neurosurgery 4 1 1 1 0 7
ICU 2 1 2 0 0 5
ENT 1 1 1 0 0 3
Gynaecology 2 0 0 0 0 2
Total 47 19 12 5 5 88
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Figure 3.1a: Pyocyanin pigment formation on nutrient agar.
Figure 3.1b: Non-lactose-fermenting colonies on Mac-Conkey agar.
Figure 3.1c: Gram stain shows that bacteria are Gram–negative coccobacilli or rod
shape.
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3.2 Antibiotic susceptibility test
The susceptibilities of various antibiotics against the P. aeruginosa clinical isolates
were determined using E-test® as a quantitative antimicrobial susceptibility testing
method. The susceptibility patterns of amikacin and gentamicin drugs for all 88 P.
aeruginosa clinical isolates are shown in Figure 3.2a. Eighty-three isolates were
resistant to gentamicin, 3 isolates were intermediate and only 2 isolates were sensitive to
the gentamicin. Fifty-eight of the isolates were resistant to amikacin, 10 isolates were
intermediate and 20 isolates were susceptible to amikacin.
The results of susceptibility testing of P. aeruginosa clinical isolates to ceftazidime,
piperacillin/tazobactam and aztreonam are shown in Figure 3.2b. Eighty-one isolates
were non-susceptible for ceftazidime, 5 isolates were intermediate, while 2 of the
isolates were sensitive to ceftazidime. Interestingly, 51 of the isolates were resistant to
piperacillin/tazobactam, while 6 of the isolates were intermediate for
piperacillin/tazobactam, and 31 were susceptible for piperacillin/tazobactam. Although
49 P. aeruginosa clinical isolates were resistant to aztreonam, 27 of the isolates showed
intermediate resistance, while 12 of the isolates demonstrated susceptibility to
aztreonam.
The susceptibility testing of P. aeruginosa clinical isolates for carbapenems showed that
69 of the isolates were resistant to meropenem, while only 19 of the isolates were
sensitive to meropenem. Sixty-five isolates were resistant to imipenem, while 23 of the
isolates showed susceptibility to imipenem (Figure 3.2c).
Figure 3.2d shows the susceptibility of the isolates for ciprofloxacin tested by E-test®.
Most of the isolates were resistant to ciprofloxacin (81), however, the intermediate
resistance was only recorded for 2 isolates, while 5 isolates were sensitive to
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ciprofloxacin. Most of P. aeruginosa clinical isolates have a high-level of susceptibility
for colistin (82), while only 6 isolates were resistance to colistin (Figure 3.2d).
The activities and MIC values of the tested antipseudomonal agents towards the
collection of P. aeruginosa clinical isolates are shown in Table 3.2a and Appendix III
according to CLSI breakpoints (Tholen, 2006). The overall antibiotic resistance of
clinical isolates is summarized in Figure 3.2e, which also illustrates the increased
resistance level for gentamicin (94.0%), followed by ciprofloxacin and ceftazidime
(92.0%), meropenem (78.0%), imipenem (74.0%), amikacin (66.0%),
piperacillin/tazobactam (58.0%), aztreonam (56.0%) and colistin (7.0 %).
In the present study, the highest resistant rate of P. aeruginosa infections were observed
in the surgical department for all antibiotics except colistin which showed the least
amount of resistance followed by the medical and orthopedic departments (Table 3.2b).
The MICs of different antibiotics against P. aeruginosa based on the site of the
specimen appeared highly resistant with urine and wound specimens being most
resistant to the antibiotics except for colistin (Table 3.2c).
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Figure 3.2 a: The susceptibility pattern of amikacin and gentamicin drugs
against P. aeruginosa clinical isolates (n= 88).
Figure 3.2b: The susceptibility patterns of aztreonam, ceftazidime and piperacillin/tazobactam
drugs against P. aeruginosa clinical isolates (n= 88).
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Figure 3.2c: The susceptibility distribution of imipenem and meropenem drugs
against P. aeruginosa clinical isolates (n= 88).
Figure 3.2d: The susceptibility distribution of ciprofloxacin and colistin drugs
against P. aeruginosa clinical isolates (n= 88).
76
Figure 3.2e: Percentage of antibiotic resistance among of P. aeruginosa clinical
isolates in comparison to P. aeruginosa ATCC 27583 (n=88).
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Table 3.2a: Activities of antipseudomonal agents toward P. aeruginosa clinical isolate
(n=88)
MIC: minimum of inhibition concentration, a percentage of isolates susceptible (S), intermediate (I), or resistant (R)
according to CLSI breakpoints (Tholen, 2006).
Antibiotics
MIC50
( g/mL)
MIC90
( g/mL)
MIC range
( g/mL)
% (S)
(according to
CLSI)a
%  (I)
(according to
CLSI)a
% ( R)
(according to
CLSI)a
Gentamici
n
2 64 0.06 – 64 2 4 94
Ceftazidim
e
4 32 0.25– 128 2 6 92
Ciprofloxa
cin
0.25 32 0.03– 32 6 2 92
Imipenem 2 32 0.12 – 64 26 0 74
Amikacin 4 8 0.12 – 128 23 11 66
Piperacilli
n/
Tazobacta
m
8 128 1 – 128 35 7 58
Aztreonam 8 32 0.25– 128 14 30 56
Colistin 0.5 1 0.03 – 8 93 0 7
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Table 3.2b: Antibiotic resistance of P. aeruginosa based on ward
Antibiotics Surgery
( n= 31)
Medicine
( n=  20)
Orthopedic
( n= 13 )
Paediatric
( n= 7 )
Neurosurgery
( n= 7)
ICU
( n= 5 )
ENT
( n= 3)
Gynaecology
( n= 2 )
Imipenem 77% 70% 69% 71% 71% 100% 33% 100%
Meropenem 84% 75% 69% 71% 85% 100% 33% 100%
Ceftazidime 100% 90% 92% 86% 100% 100% 66% 100%
Piperacillin/
Tazobactam
61% 65% 54% 100% 14% 60% 0% 50%
Aztreonam 68% 45% 54% 29% 57% 100% 0% 50%
Amikacin 45% 45% 76% 86% 14% 40% 33% 50%
Gentamicin 100% 90% 100% 86% 100% 60% 100% 100%
Ciprofloxacin 97% 90% 92% 86% 100% 60% 67% 100%
Colistin 3% 0% 8% 14% 0% 0% 0% 0%
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Table 3.2c: Antibiotic susceptibility pattern of P. aeruginosa isolates based on site of specimen
* In dwelling medical devices, S (susceptible), I (intermediate) and R (resistant)
Source Imipenem Meropenem Ceftazidime Amikacin Aztreonam
Piperacillin
/tazobactam Ciprofloxacin Gentamicin Colistin
S I R S I R S I R S I R S I R S I R S I R S I R S I R
Urine 13 0 34 10 0 37 1 0 46 10 17 20 3 12 32 19 3 25 0 0 47 1 0 46 45 1 1
Wound 6 0 13 5 0 14 0 1 18 5 4 11 5 8 8 6 1 12 1 2 16 0 1 18 16 3 0
Sputum 0 0 5 0 0 5 1 0 4 2 0 3 1 0 4 1 1 3 1 0 4 0 1 4 5 0 0
Blood 2 0 3 2 0 3 0 0 5 0 0 5 0 4 1 1 0 4 0 0 5 0 0 5 5 0 0
In dwelling* 2 0 10 2 0 10 2 0 10 3 3 6 3 3 6 4 1 7 1 3 8 1 1 10 10 0 2
Total 23 0 65 19 0 69 4 1 83 20 24 45 12 27 51 31 6 51 3 5 80 2 3 83 81 4 3
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3.3 Molecular analysis of antibiotic patterns and gene regulation results
The current study aimed to determine the gene expression profiles of the Malaysian
isolates of P. aeruginosa using real time PCR to evaluate the resistance mechanisms
responsible for antibiotic resistances among the P. aeruginosa clinical isolates. The
gene expression levels of ampC cephalosporinase, the multidrug efflux pumps, the
OprD outer membrane porin and two penicillin binding proteins (PBP2, PBP3) were
investigated and the antibiotic susceptibility patterns of these isolates were determined
in association with the mRNA gene expression in comparison to P. aeruginosa ATCC
27583.
3.3.1 Aminoglycosides
Twenty isolates were susceptible to amikacin according to the CLSI breakpoints (Table
3.3.a). Among these isolates, the mexB gene was upregulated in 15 isolates, 14 isolates
for both mexZ and ampC, 12 isolate showed upr-egulated mexY and mexEF and only 10
isolates showed mexCD gene up-regulation. Also, the up-regulation of oprM, PBP2,
PBP3 and oprD was noted in 8, 6, 4 and 2 of the isolates, respectively. In contrast,
among these isolates, down-regulation was found in 5 isolates with the (mexB), in 6
isolates (both mexZ and ampC) and in 8 isolates (both mexY and mexEF). For the oprD
, PBP3, PBP2 and oprM genes, down-regulation was noted in the 18, 16, 14 and 12 of
the susceptible isolates, respectively, in comparison to P. aeruginosa ATCC 27583.
Ten isolates had intermediate susceptibility to amikacin based on the CLSI breakpoints
(Table 3.3.a). Amongst these, the up-regulation of mexEF, ampC, mexY, mexB, mexCD
and mexZ genes was noted in 9, 8, 8, 7, 5 and 4 isolates, respectively. However, in
these ten isolates, oprD, PBP2 and PBP3 were down-regulated, while in nine of isolates
only oprM was down-regulated. A total of 58 isolates were found to be resistant to
amikacin. The mexY gene was upregulated in 52 isolates. For the others, mexB, mexZ,
mexEF, ampC and mexCD up-regulation was noted in 42, 39, 39, 35 and 27 of isolates
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respectively. Down-regulation was noted for oprD in 57 of the isolates. Also, PBP3,
PBP2 and oprM gene expression was down-regulated in 48, 46 and 36 of these isolates
respectively (Table 3.3.a).
For gentamicin, only 2 isolates were susceptible (Table 3.3.a), among these isolates, up-
regulation was noted only with 1 isolate for the ampC, mexEF, PBP2 and PBP3 genes.
However, among these two isolates down-regulation was noted for mexB, mexZ, mexY,
mexCD, oprD, PBP2 and oprM but not for ampC, mexEF, and PBP3 which was seen
only in one isolate (Table 3.3.a). With the 3 isolates that had intermediate resistance to
gentamicin, up-regulation of mexB, mexZ and mexEF was found in 2 of these isolates
and in 1 isolate for ampC, mexY and mexCD. In all of the 3 isolates the oprD, PBP2 and
oprM genes, were down-regulated while in 2 isolates ampC, mexY, mexCD and PBP3
were also found down-regulated.
Eighty-three of the isolates were found to be resistant to gentamicin, of which 71 had
up-regulation of mexY gene, followed by 62 for mexB, 57 for mexEF gene and 55 for
both mexZ and ampC. Down-regulation was noted in 80 isolates for oprD , while, for
genes PBP3, PBP2 and oprM, 71, 64 and 52 were down-regulated in these isolates as
compared to P. aeruginosa ATCC 27853 (Table 3.3.a).
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Table 3.3.a: Distribution of mRNA gene expression of aminoglycoside resistant isolates in comparison to P. aeruginosa ATCC 27583 (n=88)
S (susceptible), I (intermediate) and R (resistant), T (Total), = up-regulation and = down-regulation.
Antibiotics mexB mexZ mexY ampC mexCD mexEF oprD PBP2 PBP3 OprM
T T T T T T T T T T
Amikacin S 15 5 20 14 6 20 12 8 20 14 6 20 10 10 20 12 8 20 2 18 20 6 14 20 4 16 20 8 12 20
I 7 3 10 4 6 10 8 2 10 8 2 10 5 5 10 9 1 10 0 10 10 2 8 10 0 10 10 1 9 10
R 42 16 58 39 19 58 52 6 58 35 23 58 27 31 58 39 19 58 1 57 58 12 46 58 10 48 58 22 36 58
T 64 24 88 57 31 88 72 16 88 57 31 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
Gentamicin S 0 2 2 0 2 2 0 2 2 1 1 2 0 2 2 1 1 2 0 2 2 1 1 2 1 1 2 0 2 2
I 2 1 3 2 1 3 1 2 3 1 2 3 1 2 3 2 1 3 0 3 3 0 3 3 1 2 3 0 3 3
R 62 21 83 55 28 83 71 12 83 55 28 83 41 42 83 57 26 83 3 80 83 19 64 83 12 71 83 31 52 83
T 64 24 88 57 31 88 72 16 88 57 31 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
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3.3.2 β-lactamase drugs
Two isolates were found to be susceptible to ceftazidime, and these isolated
demonstrated up-regulation of mexZ, mexY, ampC, mexCD and mexEF gene expression.
Also these 2 isolates showed down-regulation of oprM expression. However, one of the
isolates had down-regulation for oprD, PBP2 and PBP3 expression as shown in Table
3.3b. Five of the isolates showed intermediate susceptibility for ceftazidime and 4 of
them showed up-regulation of mexY, mexEF and ampC, although oprD was down-
regulated in all as shown in Table 3.3b.
Eighty-one of the isolates were found to be resistant to ceftazidime. Sixty-six of these
isolates showed up-regulation of mexY, 60 of mexB and 54 of mexEF. On the other
hand, 79, 69, 63 and 52 of these isolates demonstrated down-regulation for oprD, PBP3,
PBP2 and oprM gene expression respectively (Table 3.3b).
Thirty-one of the isolates were found to be susceptible to piperacillin/tazobactam. Up-
regulation of (mexY, mexEF, mexB and mexZ) gene expression was noted in 25, 23, 22
and 18 of these isolates, respectively. In addition, 15 isolates showed up-regulation of
both mexCD and ampC gene expression. On the contrary, all of the 31 isolates
demonstrated down-regulation of oprD followed by 28, 26 and 20 for PBP3, PBP2 and
oprM gene, respectively (Table 3.3b).
Six of the isolates had intermediate susceptibility for piperacillin/tazobactam and 5 of
these isolates had up-regulation of mexB, mexZ and mexEF expression while for ampC
and mexCD, up-regulation was noted in only 4 isolates. However, down-regulation was
noted with all of these 6 isolates for oprD and in 4, 3, 3 of these isolates for PBP2,
PBP3 and oprM gene, respectively, as shown in Table 3.3b.
Fifty-one of the isolates were resistant to piperacillin/tazobactam, while 44, 38, 37 and
32 of these isolates showed up-regulation of mexY, ampC, mexB and mexEF expression
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respectively. However, down-regulation of oprD PBP3, PBP2 and oprM gene
expression was noted in 48, 43, 38 and 34 of these isolates, respectively (Table 3.3b).
Twelve of the isolates were sensitive to aztreonam. Up-regulation of expression was
noted with 11 of these isolates for mexY, in 8 isolates for both mexEF and mexB and 7
isolates for both mexZ and ampC. On the other hand, down-regulation of expression was
noted with all of these 12 isolates for oprD, also in 10, 9 and 8 of these isolates for
PBP3, PBP2 and oprM, respectively (Table 3.3b).
Twenty-seven of the isolates demonstrated an intermediate susceptibility for aztreonam.
Twenty-four of these isolates showed up-regulation of mexY, followed by 20 of these
isolates of both mexB and mexEF. However, down-regulation was noted in 25 of these
isolates for oprD and in 22 of these isolates for both PBP2 and PBP3 (Table 3.3b).
Forty-nine of the isolates were found to be resistant to aztreonam. Up-regulation was
noted in 37, 36, 33 and 32 of these isolates for mexY, mexB, mexZ and mexEF
respectively. Whereas, down-regulation was noted in 48, 42 and 37 of these isolates for
oprD, PBP3 and PBP2 respectively (Table 3.3b).
For carbapenem drugs, 19 isolates were found to be sensitive for meropenem and 17 of
these isolates had up-regulated for mexY as well as up-regulated both mexB and mexZ
that was found in 15 of the isolates. Sixteen of these isolates showed down-regulated
oprD expression as illustrated in Table 3.3c.
Sixty-nine of the isolates showed resistance to meropenem. Up-regulation was noted in
55, 49, 48 and 45 of these isolates for mexY, mexB, mexEF and ampC, in that order.
Conversely, all of the 69 isolates had down-regulated oprD, except for PBP3 and PBP2,
which were found to be down-regulated in 62 and 55 correspondingly (Table 3.3c).
In regards to carbapenem drugs, 23 of the isolates showed susceptibility for imipenem
and 20 of these isolates had up-regulation mexY expression followed by 18 isolates that
showed up-regulated both mexB and mexZ expression. On the other hand, down-
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regulation was noted in 20, 16 and 15 of these isolates for oprD, PBP2 and PBP3
expression, respectively (Table 3.3c).
Sixty-five of the isolates were found to be resistant to imipenem. Up-regulation was
noted in 52, 46, 44, and 43 of these isolates for mexY, mexB, mexEF and ampC
respectively. However, down-regulation was observed in all 65 of the isolates for oprD
as well as in 59, 52 and 43 for PBP3, PBP2 and oprM respectively, as illustrated in
Table 3.3c.
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Table 3.3b: Distribution of mRNA gene expression of β-lactamase resistant isolates in comparison to P. aeruginosa ATCC 27583 (n=88)
S (susceptible), I (intermediate) and R (resistant), T (Total), = up-regulation = down-regulation
Antibiotics mexB mexZ mexY ampC mexCD mexEF oprD PBP2 PBP3 oprM
T T T T T T T T T T
Ceftazidime S 1 1 2 2 0 2 2 0 2 2 0 2 2 0 2 2 0 2 1 1 2 1 1 2 1 1 2 0 2 2
I 3 2 5 2 3 5 4 1 5 4 1 5 1 4 5 4 1 5 0 5 5 1 4 5 1 4 5 2 3 5
R 60 21 81 53 28 81 66 15 81 51 30 81 39 42 81 54 27 81 2 79 81 18 63 81 12 69 81 29 52 81
T 64 24 88 57 31 88 72 16 88 57 31 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
Piperacillin/
Tazobactam
S 22 9 31 18 13 31 25 6 31 15 16 31 15 16 31 23 8 31 0 31 31 5 26 31 3 28 31 11 20 31
I 5 1 6 5 1 6 3 3 6 4 2 6 2 4 6 5 1 6 0 6 6 2 4 6 3 3 6 3 3 6
R 37 14 51 34 17 51 44 7 51 38 13 51 25 26 51 32 19 51 3 48 51 13 38 51 8 43 51 17 34 51
T 64 24 88 57 31 88 72 16 88 57 31 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
Aztreonam S 8 4 12 7 5 12 11 1 12 7 5 12 6 6 12 8 4 12 0 12 12 3 9 12 2 10 12 4 8 12
I 20 7 27 17 10 27 24 3 27 19 8 27 9 18 27 20 7 27 2 25 27 5 22 27 5 22 27 10 17 27
R 36 13 49 33 16 49 37 12 49 31 18 49 27 22 49 32 17 49 1 48 49 12 37 49 7 42 49 17 32 49
T 64 24 88 57 31 88 72 16 88 57 31 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
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Table 3.3c: Distribution of mRNA gene expression of carbapenem resistant isolates
in comparison to P. aeruginosa ATCC 27583 (n=88)
S (susceptible), I (intermediate) and R (resistant), T (Total), = up-regulation =
down-regulation.
3.3.3 Fluoroquinolones
Five of the isolates were susceptible to ciprofloxacin. Up-regulation was noted in 4 of
these isolates for mexEF and in 3 of them for mexZ, ampC and mexCD genes. However,
down-regulation was evident in all of these five isolates for oprD as well as in 4, 3,
and 3 of these isolates for oprM, PBP2 and PBP3, respectively (Table 3.3d).
Two of the isolates were intermediately susceptible to ciprofloxacin. Up-regulation was
noted in two isolates for mexY and mexCD and only in one isolate for mexB and mexEF.
On the other hand, both these isolates had down-regulation oprD, PBP2, PBP3 and
oprM expression (Table 3.3d).
Antibiotics mexB mexZ mexY ampC mexCD mexEF oprD PBP2 PBP3 oprM
T T T T T T T T T T
Meropenem
S 15 4 19 15 4 19 17 2 19 7 12 19 4 15 19 12 7 19 3 16 19 6 13 19 7 12 19 8 11 19
R 49 20 69 42 27 69 55 14 69 45 24 69 38 31 69 48 21 69 0 69 69 14 55 69 7 62 69 23 46 69
T 69 24 88 57 31 88 72 16 88 52 26 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
Imipenem
S 18 5 23 18 5 23 20 3 23 14 9 23 7 16 23 16 7 23 3 20 23 7 16 23 8 15 23 10 13 23
R 46 19 65 39 26 65 52 13 65 43 22 65 35 30 65 44 21 65 0 65 65 13 52 65 6 59 65 22 43 65
T 64 24 88 57 31 88 62 16 88 57 31 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
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Eighty-one of the isolates were resistant to ciprofloxacin. Up-regulation was evident in
68, 61 and 55 of these isolates for mexY, mexB and mexEF, respectively, as well as in 53
of these isolates for both mexZ and ampC. However, down-regulation was noted in 78,
69 and 63 of these isolates for oprD, PBP3 and PBP2 in that order (Table 3.3d).
3.3.4 Polymyxin E (Colistin)
Eighty-two of the isolates were found to be susceptible to colistin. Up-regulation was
noted in 68, 60 and 55 of these isolates for mexY, mexB and mexEF, respectively,
whereas, down-regulation was observed in 79, 71 and 65 of these isolates for oprD,
PBP3 and PBP2, respectively (Table 3.3d).
Six of the isolates were resistant to colistin and all of these isolates had up-regulation
for mexB, mexY, ampC and mexEF gene expression. However, down-regulation
observed in all of these isolates for oprD and oprM genes (Table 3.3d).
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Table 3.3d: Distribution of mRNA gene expression in ciprofloxacin and colistin resistant isolates in comparison to P. aeruginosa ATCC 27583
(n=88)
S (susceptible), I (intermediate) and R (resistant), T (Total), = up-regulation = down-regulation.
Antibiotics mexB mexZ mexY ampC mexCD mexEF oprD PBP2 PBP3 oprM
T T T T T T T T T T
Cip
rof
lox
aci
n
S 2 3 5 3 2 5 2 3 5 3 2 5 3 2 5 4 1 5 0 5 5 2 3 5 2 3 5 1 4 5
I 1 1 2 1 1 2 2 0 2 1 1 2 0 2 2 1 1 2 0 2 2 0 2 2 0 2 2 0 2 2
R 61 20 81 53 28 81 68 13 81 53 28 81 39 42 81 55 26 81 3 78 81 18 63 81 12 69 81 30 51 81
T 64 24 88 57 31 88 72 16 88 57 31 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
Co
list
in
S 60 22 82 52 30 82 68 14 82 54 28 82 40 42 82 55 27 82 3 79 82 17 65 82 11 71 82 30 52 82
I 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
R 6 0 6 6 0 6 6 0 6 6 0 6 2 4 6 6 0 6 0 6 6 3 3 6 3 3 6 0 6 6
T 64 24 88 57 31 88 72 16 88 57 31 88 42 46 88 60 28 88 3 85 88 20 68 88 14 74 88 31 57 88
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3.3.5 Overall gene expression analysis of chromosomal resistance genes
The gene expression analysis of 88 P. aeruginosa isolates showed overexpression of
efflux pump genes for mexY (82.0%, from 2.0 to 1731.0 fold), mexB (73.0%, from 2.0
to 50.0 fold), mexEF (68.0%, from 2.9 to 371), mexZ (66.0%) and mexCD (48.0%, from
2.0 to 522), while for ampC overexpression it was 65.0% (from 10.4 to 1806.0 fold).
Down-regulation were noted for oprD (97.0%, from 0.2 to 0.7 fold), PBP2 (77.0%,
from 0.1 to 0.7 fold), PBP3 (84.0%, from 0.01 to 0.7 fold) and oprM (65%, from 0.2 to
0.7) as compared to expression of the respective genes in P. aeruginosa ATCC 27853
(Figure 3.3 and Appendix III).
Among the resistant isolates overexpressing mexB, the lowest mRNA expression was
noted for isolates resistant to colistin (67%), whereas the highest mRNA expression was
noted for isolates resistant to ciprofloxacin (78%). In relation to isolates that were
resistant to meropenem, imipenem, gentamicin, ceftazidime, amikacin, aztreonam and
piperacillin/tazobactam, the range of mexB mRNA expression ranged from 71% to 77%
(Table 3.3e).
When mexY gene overexpression was examined, the lowest and highest mRNA
expression were seen for isolates resistant to colistin (67%) and amikacin (90%) , whilst
the mRNA expression of this gene for isolates resistant to gentamicin, ciprofloxacin,
ceftazidime, aztreonam and piperacillin/tazobactam ranged from 76% to 86% as
depicted in Table 3.3e.
For the overexpression of mexCD, the lowest mRNA expression was seen with isolates
resistant to gentamicin and piperacillin/tazobactam (49%). However, the highest
overexpression was seen with isolates resistant to meropenem and aztreonam (55%). In
relation to isolates resistant to other antibiotics, mexCD mRNA expression (up-
regulation) ranged from 47% to 54% (Table 3.3e).
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For the overexpression of mexEF, the lowest mRNA expression was observed with
isolates resistant to piperacillin/tazobactam (63%), and the highest mRNA expression
was noted with isolates resistant to colistin (100 %). In relation to the isolates that were
resistant to other antibiotics, mRNA expression of these isolates for mexEF gene up-
regulation ranged from 65% to 70% (Table 3.3e).
For the overexpression of ampC gene, the lowest mRNA expression was seen with
isolates resistant to colistin (50%) and the highest mRNA expression was noted with
isolates resistant to piperacillin/tazobactam (75%). In relation to the resistant isolates to
other antibiotics, mRNA expression of these isolates for ampC gene up-regulation
ranged from 60% to 66.0% (Table 3.3e).
The oprD, mRNA expression of isolates resistant to meropenem, imipenem and colistin
demonstrated 100% down-regulation and in relation to the resistant isolates to other
antibiotics, mRNA expression of these isolates for OprD gene down-regulation ranged
from 94% to 98% (Table 3.3d).
For oprM, the isolates resistant to amikacin were noted to have the lowest mRNA
expression (62%), while the highest mRNA expression was seen with isolates resistant
to colistin that showed 100% down-regulation for oprM gene. In relation to isolates
resistant to other antibiotics, mRNA expression of these isolates for oprM shows that
down-regulation ranged from 63% to 67% (Table 3.3e).
For PBP2 gene, isolates resistant to colistin had the lowest mRNA expression (50%),
while the highest mRNA expression value was 80% for isolates resistant to meropenem
and imipenem. On the other hand, for the PBP3 gene, the mRNA expression was down-
regulated and showed the lowest and highest mRNA expression for isolates resistant to
colistin (50%) and imipenem (91%) respectively. However, in relation to the resistant
isolates to other antibiotics investigated, these isolates showed low mRNA expression
for PBP2 and PBP3 which varied from 75% to 86% (Table 3.3e).
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With regard to the significance of the above results, the overexpression patterns of mexY
were significantly different in isolates resistant to amikacin (90%), gentamicin (86%)
and ciprofloxacin (84%) as compared to other antibiotics (p < 0.05). On the other hand,
for ampC, mRNA expression in P. aeruginosa isolates demonstrated high significant
differences towards piperacillin/tazobactam antibiotics as compared to other antibiotics
(p < 0.05).
All P. aeruginosa clinical isolates that were resistant to imipenem and meropenem
showed significantly decreased oprD expression (p = 0.016). The down-regulation of
mRNA expression of PBP3 was observed in isolates resistant to meropenem (90%) and
imipenem (91%) (p = 0.04). Likewise, the down-regulation of penicillin binding
protein (PBP3) demonstrated high significant in isolates that were resistance to
piperacillin/tazobactam (84%) (p = 0.047) as compared to P. aeruginosa ATCC 27853
(Table 3.3e and Table 3.3f).
Of 88 isolates, 85 had 100% down-regulation of oprD gene. These 85 isolates were
further analyzed and the results are shown in Table 3.3g. The analysis of the efflux
pump overexpression gene (mex+) showed the lowest mRNA expression in isolates that
were resistant to colistin (50%) and the highest mRNA expression was seen in isolates
resistant to meropenem (65%). On the other hand, in relation to isolates resistant to
other antibiotics, mRNA expression of these isolates for mex+ were up-regulated (range
from 52% to 55%) (Table 3.3g). In those isolates, ampC showed the lowest and highest
mRNA expressions in isolates that were resistant to colistin (50%) and
piperacillin/tazobactam (69%), respectively. In addition, the mRNA expression in these
isolates for PBP genes demonstrated down-regulation in isolates resistant to imipenem
(75%) and colistin (50%) showing the lowest mRNA expression. Furthermore, the
oprM mRNA expression level in these isolates was down-regulated in isolates that were
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resistant to meropenem and imipenem (67%) and the highest mRNA expression was
seen in isolates resistant to colistin (Table 3.3g).
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Figure 3.3: The percentage change of gene expression levels of P. aeruginosa
clinical isolate in comparison to P. aeruginosa ATCC 27583 (n=88).
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Table 3.3e: Percentage of mRNA transcription levels of gene expression of multidrug resistant isolates in comparison to P. aeruginosa
ATCC 27583 (n=88)
Resistance  of
Antibiotics
mRNA expression for:
Efflux pump β-Lactamase Out membrane protein
Penicillin binding
Protein
mexB+ mexZ+ mexY+ mexCD + mexEF+ ampC+ oprD - oprM- PBP2- PBP3-
Gentamicin 77.0 68.0 86.0
*
49.0 69.0 66.0 97.0 63.0 77.0 86.0
Ceftazidime 77.0 67.0 82.0 48.0 67.0 63.0 98.0
*
64.0 78.0 85.0
Ciprofloxacin 78.0 67.0 84.0
*
48.0 68.0 65.0 96.0 63.0 78.0 85.0
Meropenem 71.0 61.0 80.0 55.0* 70.0 65.0 100
*
67.0 80.0* 90.0*
Imipenem 74.0 62.0 80.0 54.0* 68.0 66.0 100
*
66.0 80.0 91.0
*
Amikacin 72.0 67.0 90.0
*
47.0 67.0 60.0 98.0 62.0 79.0 83.0
Piperacillin/
Tazobactam
77.0 69.0 86.0 49.0 63.0 75.0
* 94.0 67.0 75.0 84.0
*
Aztreonam 74.0 67.0 76.0 55.0 65.0 63.0 98.0 65.0 76.0 86.0
Colistin 67.0 83.0 67.0 50.0 100 50.0 100 100 50.0 50.0
All values are in percentage (%)
*Significantly different from other groups (p <.05).
The abbreviations mexB+, mexY+ , mexCD +, mexEF+ and ampC+ designate mexAB-OprM, mexXY, mexCD, mexEF and ampC overexpression, respectively.
oprD-: oprD porin down-regulation, oprM- : oprM out membrane protein down regulation.
PBP2- and PBP3- penicillin binding protein down-regulation.
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Table 3.1f Associations of susceptibility patterns of different antibiotics toward P.
aeruginosa clinical isolates with different gene expressions
* Fisher’s exact test is to be used if less than 50% of the cells are less than 5.
a S. pattern: susceptibility patterns of antibiotics.
Up: up- regulation, down -regulation
S: susceptible or R: resistant
Antibiotics GENE S. patterns
a
UP DOWN chi-
square
p-value
Gentamicin mexY
S 5 1 4 14.5 0.001
R 83 71 12
Ceftazidime oprD
S 7 1 6 13.5 0.001
R 81 2 79
Ciprofloxacin mexY
S 7 4 3 6.5 0.037
R 81 68 13
Imipenem
oprD S 23 3 20 8.7 0.016*
R 65 0 65
PBP3 S 23 7 16 4.8 0.04
*
R 65 7 58
Amikacin
mexY S 30 20 10 8.8 0.012
R 58 52 6
Piperacillin/
Tazobactam
ampC
S 37 19 18 5.7 0.05
R 51 38 13
PBP3 S 37 6 31 6.1 0.047R 51 8 43
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Table 3.3g: Percentage expression level of resistance genes according to the mechanism of resistance and its association to OprD down-
regulation according to mechanism of resistant in comparison to P. aeruginosa ATCC 27583 (n=85)
All values are in percentage (%)
The abbreviations Mex+ and ampC+ designate mexAB-OprM, mexXY-oprM, mexCD, mexEF and ampC overexpression, respectively.
PBP- :  penicillin binding protein (PBP2 and PBP3) down-regulation, OprM- : oprM out membrane protein down regulation.
Resistance  of Antimicrobial
mRNA expression for:
Efflux pump β-Lactamase Penicillin binding  Protein Out membrane  Protein
mex+ ampC+ PBP- oprM-
Gentamicin 54.0 63.0 70.0 64.0
Ceftazidime 53.0 61.0 70.0 66.0
Ciprofloxacin 53.0 62.0 70.0 64.0
Meropenem 65.0 65.0 74 67.0
Imipenem 53.0 66.0 75.0 67.0
Amikacin 53.0 59.0 72.0 63.0
Piperacillin/Tazobactam 52.0 69.0 67.0 69.0
Aztreonam 55.0 61.0 71.0 67.0
Colistin 50.0 50.0 50.0 100
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3.4 PCR amplification of beta-lactamases genes
Sixty-five of the clinical P. aeruginosa isolates that were resistant to imipenem and
meropenem were evaluated for presence of six different metallo-beta-lactamase (MBL)
genes (blaIMP, blaVIM, blaGIM, blaSIM, blaSPM and blaNDM). In addition, these isolates were
tested for presence of extended spectrum beta-lactamase (ESBL) production genes
(blaVEB, blaTEM, blaCTX-M, blaSHV and blaPER) using PCR (Table 3.4a). Of these isolates,
35 were from urine, 13 from wounds, 10 from indwelling medical devices, 4 from
sputum and 3 from blood (Table 3.4b). Samples were collected from patients
hospitalized in the surgical ward (n = 23), medical ward (n = 15), orthopedic ward (n =
9), paediatric ward (n = 5), neurosurgery ward (n = 5), intensive care unit (n = 5),
gynaecology ward (n = 2) and otorhinolaryngology ward (n = 1) as shown in Table
3.4c.
Thirty-three out of 65 of the imipenem and meropenem resistant P. aeruginosa isolates
used in the study tested were positive for ESBL genes. Out of 33 ESBL, genes were
amplified in 25 isolates for blaVEB, in 5 isolates for blaTEM and in 3 isolates for blaCTX-M.
No blaSHV and blaPER genes were detected for imipenem and meropenem resistant
isolated in this study as illustrated in Table 3.4a and gel picture (Figure 3.4). All ESBL
positive isolates were multi-resistant to ceftazidime, piperacillin/tazobactam, aztreonam,
gentamicin and ciprofloxacin. However, when colistin was tested, all ESBL positive
isolates in this study were susceptible to this antibiotic (Table 3.4d). Twenty-three of the
35 isolates from urine specimens tested positive for blaVEB, blaTEM and blaCTX-M genes
and only 10 isolates from other clinical samples tested positive for the same genes
(Table 3.4b). As shown in Table 3.4c, 16 of the 23 isolates from surgical wards, 5 of the
15 isolates from the medical wards and 5 of the 9 isolates from orthopedic wards tested
positive for all above genes. Only seven isolates from other wards tested positive for the
above genes.
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Among the 65 isolates of P. aeruginosa resistant to imipenem and meropenem, 41
isolates were MBL producers. Out of 41, MBL, genes were amplified in 20 isolates for
blaIMP, in 14 isolates for blaVIM, in 4 isolates for blaGIM, in 2 isolates for blaNDM and only
in one isolate for blaSIM as shown in Table 3.4a and gel picture (Figure 3.4). No blaSPM
gene was amplified in this isolates. The antibiotic resistance rates were higher for MBL
producing isolates than for non-MBL-producing P. aeruginosa isolates (Table 3.4d). All
MBL positive isolates were resistant to ceftazidime and all of these isolates were 100%
sensitive to colistin (Table 3.4d). Most of the resistant isolates harboring MBL genes
were collected from urine and wound specimens (Table 3.4b). As seen in Table 3.4c, 20
of the 23 isolates from the surgical ward, eight of the 15 isolates from the medical ward
and six of the nine isolates from the orthopedic ward were amplified for blaIMP, blaVIM,
blaGIM, blaNDM and blaSIM genes. Only seven isolates from other wards tested positive
for these genes.
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Table 3.4a: Prevalence of ESBL and MBL genes among P. aeruginosa isolates
(n = 65)
Class Type of genes Positive No.
ESBL gene
positive (n = 33)
blaVEB 25
blaTEM 5
blaCTX-M 3
MBL gene
positive (n = 41)
blaIMP 20
blaVIM 14
blaGIM 4
blaNDM 2
blaSIM 1
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Table 3.4b: The distribution of P. aeruginosa isolated from various clinical specimens (n= 65)
specimens
Gene types
blaIMP blaVIM blaNDM blaSIM blaGIM blaTEM blaCTX-M blaVEB
No. +ve +ve +ve +ve +ve +ve +ve +ve
Urine 35 10 9 1 0 1 3 2 18
Wound 13 5 3 0 0 1 1 0 3
In dwelling medical devices 10 2 1 0 0 0 0 0 4
Sputum 4 1 0 1 1 0 0 1 0
Blood 3 2 1 0 0 1 1 0 0
Total 65 20 14 2 1 3 5 3 25
102
Table 3.4c: The distribution of P. aeruginosa from different wards (n= 65)
Wards
Gene types
No. blaIMP blaVIM blaNDM blaSIM blaGIM blaTEM blaCTX-M blaVEB
Surgery 23 12 6 0 0 2 1 2 13
Medical 15 1 2 2 1 1 1 1 3
Orthopedic 9 3 3 0 0 0 2 0 3
Neurosurgery 5 2 1 0 0 0 1 0 2
Paediatric 5 1 2 0 0 0 0 0 1
ICU 5 0 0 0 0 0 0 0 1
Gynaecology 2 1 0 0 0 0 0 0 2
ENT 1 0 0 0 0 0 0 0 0
Total 65 20 14 2 1 3 5 3 25
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Table 3.4d: Comparison of the antibiotic resistance rates of MBL and ESBL gene PCR-positive and PCR-negative
among P. aeruginosa isolates (n= 65)
Number (%) of resistant isolatesAntibiotics
ESBL producer
(n = 33)
Non ESBL producer
(n = 32)
MBL producer
(n = 41)
Non MBL producer
(n =24)
Total isolates
(n = 65)
33(100%)32(100%)41(100%)24(100%)65(100%)Imipenem
β-lactams
33(100%)32(100%)24(100%)24(100%)65(100%)Meropenem
33(100%)29(91%)41(100%)22(92%)62(95%)Ceftazidime
33(100%)6(19%)31(76%)8(33%)39(60%)Piperacillin/
Tazobactam
33(100%)8 (25%)30(73%)11(46 %)41(63%)Aztreonam
21(64%)20(63%)21(5%)20(83%)41(63%)Amikacin
Non- β-lactams 33(100%)28(88%)40(98%)21(88%)61(94%)Gentamicin
33(100%)27(84%)40(98%)20(83%)60(92%)Ciprofloxacin
0(0%)2(6.0%)0(0%)2(8.0%)2(3.0%)Colistin
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Figure 3.4 Metallo beta lactamase gene identification Gel pictures:
1. CLASS A GENES:
1.1   2.0% gel electrophoresis for CTX-M gene
1.3 2.0%gel electrophoresis for VEB gene1.2 2% gel electrophoresis for TEM gene
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2. CLASS B GENES
2.1 2.0% Gel electrophoresis for IMP gene
2.2 2.0% Gel electrophoresis for VIM gene
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2.3 2.0% gel electrophoresis for NDM gene
2.4 2.0% gel electrophoresis for GIM gene
2.5 2.0% gel electrophoresis for SIM gene
APPENDIX V
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Chapter 4
Discussion
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4.1 Overview of antibiotics resistant profile of P. aeruginosa clinical isolates
P. aeruginosa is the leading cause of pneumonia and septicemia with attributable
deaths reaching 30% in immunocompromised patients (Scarff & Goldberg, 2008).
P. aeruginosa is an important pathogen associated with serious healthcare-
associated infections and is an important cause of morbidity and mortality among
hospital patients (Hauser & Sriram, 2005). This organism is a highly prevalent
opportunistic pathogen. One of many concerning characteristics of P. aeruginosa is
its low antibiotic susceptibility. It has a propensity to develop resistance during
therapy, even evolving an MDR phenotype. P. aeruginosa develops resistance to
antibiotics either through the mutation of chromosomally encoded genes or by the
horizontal gene transfers of antibiotics resistant determinants, therefore serial
culture and susceptibility testing is advisable during therapy (Li & Nikaido, 2009).
In the last few decades, the incidences of multidrug-resistant P. aeruginosa strains
have been increasing worldwide thus limiting therapeutic options (Bonomo &
Szabo, 2006). The incidence of multidrug resistant P. aeruginosa often changes
dramatically between communities and hospitals in the same area, and among many
patients and populations in the same hospital (Wroblewska et al., 2006; Marcel et
al., 2008). These variations faced by physicians in clinical treatment are responsible
for effective clinical management on the antibiotic choice to be effectively and
correctly used according to the data on the prevalence and resistance pattern.
Treatment of P. aeruginosa infections is complicated by the intrinsic and acquired
resistance of this bacterium to many commonly used antimicrobial agents (Lister, et
al., 2009). Therapeutics of P. aeruginosa is a challenge for treatment of healthcare-
associated infections and the choice of suitable antipseudomonal agents for
treatment is significant in optimizing clinical effect (Micek et al., 2005; Lister et
al., 2009). Surveillance programs should be conducted periodically to evaluate the
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susceptibility pattern of these bacteria against prescribed antibiotics since the
emergence of resistance remains silent for periods and takes time to become
apparent. These antibiotics should be prescribed with caution so that antibiotic
resistance can be avoided (Jombo et al., 2010). The in vitro sensitivity studies also
help in the cost-effective prescription of different brands of the antibiotic to
different patients with varying socioeconomic backgrounds (Masood, 2010).
Overall, susceptibility patterns in different regions should be conducted so that the
profiles of specific regions are maintained and monitored accordingly. This will
therefore act as a guide toward the formulation of a comprehensive monitoring
program of chemotherapy. For this reason, testing of the antimicrobial
susceptibility pattern is required not only for therapy but also to monitor the spread
of resistant organisms or resistance genes throughout the hospital and community.
In some cases, the presence of a resistance gene is highly predictive for clinical
outcome of antimicrobial therapy. Therefore, determination of the antimicrobial
susceptibility pattern and identification of the causes of this drug resistance in our
Medical Centre are crucial to deﬁne the molecular and genetic bases of the MDR
mechanisms in order to combat these infectious diseases.
In this study, 88 P. aeruginosa clinical isolates were collected from the University
of Malaya Medical Centre. Most of the isolates were collected from urine
specimens, which accounted for 47 of the total isolates. This is not surprising as
almost all patients going in for major surgery are catheterized. This was supported
by Olayinka et al. (2004) who reported that the use of indwelling catheters leads to
an inherent risk for infection (Olayinka et al., 2004). In this study, only 19 wound
specimens were collected because there are many complications after operative
surgery, which use broad-spectrum antibiotics as prophylaxis. These are mostly
colonized by P. aeruginosa in the lower intestinal tract. Colonization of this
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bacterium also depended on aseptic dressing and good clinical management
(Humphreys, 2009; Zuanazzi et al. ,2010). Twelve specimens were collected from
indwelling medical devices that represented healthcare-associated infections for
patients admitted in intensive care units during the period of the medication in the
hospital as healthcare-associated infections as shown in Tables 3.1a and 3.1b.
Healthcare-associated infections caused by P. aeruginosa pose a serious problem in
clinical settings due to the high prevalence of infection, particularly in intensive
care units and cases of multi-drug resistance (Falagas et al., 2005a; Lagatolla et al.,
2006).
A number of studies have been performed to determine the effectiveness of several
antibiotics to these bacteria (Livermore et al., 2001; Nadeem Sajjad Raja, 2007;
Olayinka et al., 2004; Wroblewska et al., 2006). In the current study,
piperacillin/tazobactam, ceftazidime, aztreonam, amikacin, gentamicin,
ciprofloxacin, meropenem, imipenem and colistin were chosen to represent the
primary antibiotic classes used for treatment of P. aeruginosa infections. The
susceptibility pattern of the above mentioned antipseudomonal drugs against P.
aeruginosa clinical isolates were determined using E-test® as a quantitative
measure for antimicrobial susceptibility. The antibiotic resistance analysis  showed
increased resistance to gentamicin (94.0%), followed by ciprofloxacin and
ceftazidime (92%), imipenem (74.0%), amikacin (66.0%), piperacillin/tazobactam
(58.0%), aztreonam (56.0%) and colistin (7.0%) compared to P. aeruginosa ATCC
27853 as is illustrated in Figure 3.2e. These findings indicated that P. aeruginosa
isolates exhibited high resistance to most antimicrobial agents examined, except
colistin, which showed low levels of resistance and was still active against this
organism. These results are in agreement with many studies that demonstrated high
rates of antibacterial resistance towards P. aeruginosa, where they showed similar
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resistance to the antibiotics examined in this study (El Amin et al., 2005; Marra et
al., 2006; Sivanmaliappan & Sevanan, 2011). Raja & Singh (2007) and
Pathmanathan et al. (2009) showed a low rate of resistance in the last three years
(Raja & Singh, 2007; Pathmanathan et al., 2009). Whereas, the current study
disagrees with previous studies except in the case of colistin. Inappropriate and
incorrect administration of antimicrobial agents in empiric therapies could be one
of the reasons for this alarming phenomenon. This confirmed the increasing rate of
resistance due to the empirical therapy of P. aeruginosa infection and high pressure
of this drug choice. Colistin has become the drug choice for MDR Pseudomonal
infections, in spite of its very limited pharmacokinetic and pharmacodyanamic data
being available (Tam et al., 2005; Sobieszczyk et al., 2004).
4.2 Resistant mechanism of P. aeruginosa clinical isolates and gene
expression trends
In the present study, we aimed to  evaluate the chromosomally encoded resistance
mechanisms among 88 P. aeruginosa clinical isolates by observing the expression
levels of ampC cephalosporinase, the multidrug efflux pumps, the oprD outer
membrane porin and the penicillin binding protein (PBP2, PBP3) that contribute to
both intrinsic and acquired resistance and to study the relationship with antibiotics
resistance patterns. Nucleic acid-based detection systems present rapid and
sensitive methods to detect the presence of resistance genes and play a critical role
in the elucidation of resistance mechanisms.
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4.2.1 Expression of multidrug efflux pump genes
The genome analysis of P. aeruginosa revealed the presence of 11 RND-type efﬂux
pumps (www.pseudomonas.com). The MexAB–OprM, MexCD–OprJ, MexEF–
OprN and MexXY pumps have been shown to be of clinical importance. These
contribute to the development of multiple resistances to all strategic
antipseudomonal antibiotics and are mediated genetically by different components
of efflux systems. It also belongs to the resistance–nodulation–division (RND)
family. They were investigated in P. aeruginosa to determine the respective mRNA
transcription levels in P. aeruginosa clinical isolates. These were measured by
quantitative real time PCR on CFX96™ PCR detection systems (BioRad, Hercules,
CA) targeting the mexB, mexY, mexZ, mexCD and mexEF genes.
In the present study, mexB mRNA expression of 88 P. aeruginosa clinical isolates
as a marker for MexAB-OprM expression showed overexpression in up to 78% in
the isolates that were resistant to piperacillin/tazobactam, ceftazidime, aztreonam,
amikacin, gentamicin, ciprofloxacin, meropenem and imipenem drugs as shown in
Table 3.3e. This number is much higher than those obtained previously by
multicenter Spanish study for isolates resistant to all ﬁrst line agents (all β-lactams
and aminoglycosides) that showed overexpression of mexB in only 25% of isolates
(Cabot et al., 2011). Another study conducted at a tertiary teaching hospital located
in São Paulo, Brazil showed overexpression of mexB gene in 27.1% of P.
aeruginosa isolates that were resistant to antimicrobials and demonstrated
overexpression of mexB in 62.5% of the isolates that were meropenem resistant
(Xavier et al., 2010). This study confirmed the contributions of MexAB–OprM
overexpression to intrinsic resistance to a number of antimicrobials including
piperacillin/tazobactam, ceftazidime, aztreonam, amikacin, gentamicin,
ciprofloxacin, and carbapenems antibiotics.
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MexXY-OprM is the second eﬄux pump system that contributes to intrinsic and
acquired resistance to antimicrobials, and is capable of pumping out amikacin,
ciprofloxacin, gentamicin, cefotaxime, meropenem, cefepime and erythromycin
(Tomas et al., 2010). In the current study, mRNA expression analysis in 88 P.
aeruginosa clinical isolates demonstrated that more than 80% showed up-regulation
of mexXY-oprM among the isolates that were resistant to gentamicin, amikacin,
ciprofloxacin, ceftazidime, piperacillin/tazobactam, meropenem and imipenem as
shown in Table 3.3e. These findings are in agreement with a previous study carried
out by Hocquet et al. (2006) who found overexpression of mexXY-oprM in 84% of
the isolates that were resistant to aminoglycosides, fluoroquinolones, ceftazidime,
piperacillin/tazobactam and carbapenems (Hocquet et al., 2006). This was also
shown in many other studies where reduced susceptibility to various antibiotics
known to be substrates for the MexXY-OprM pump were demonstrated (Wolter et
al., 2004; Islam et al., 2004; Hocquet et al., 2006; Llanes et al., 2004; Hocquet et
al., 2008; Xavier et al., 2010; Cabot et al., 2011).
In the results of this study, the mRNA expression of P. aeruginosa clinical isolates
showed 90%, 86% and 84% overexpression of mexY gene in the isolates that were
resistant to amikacin, gentamicin and ciprofloxacin respectively. Of those, more
than 96% also showed reduced oprD transcription (Table 3.3e). These results are
in agreement with Xavier et al. (2010), who reported that 86.7% of the isolates that
were resistant to amikacin, gentamicin and ciprofloxacin expressed mexY and of
those, 79.2% also showed reduced oprD transcription (Xavier et al., 2010). In
addition, the up-regulation of MexXY-OprM was highly significant isolates that
were resistance to aminoglycoside drugs, particularly amikacin and gentamicin.
These findings were also in concordance with previous studies by Poole (2007),
Vila and Martines (2008) and Toma et al. (2010). They reported that most of the
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aminoglycoside drugs were significant substrates for MexXY-OprM (Poole 2007;
Tomas et al., 2010; Vila & Martinez, 2008). In addition, the current study was
consistent with other studies, which suggested the up-regulation of mexXY also
conferred reduced susceptibility to aminoglycosides detected in 6 of the 7 clinical
isolates and was responsible for the decreased antimicrobial efficacy of
aminoglycoside among clinical isolates. This is due to the longer aminoglycoside
treatment periods in a clinical setting where there is a higher risk of occurrence of
resistance and possibly therapeutic failure (Hocquet et al.,2008; Cabot et al., 2011;
Hocquet et al., 2003; Wolter et al., 2004). The highest prevalence of mexY
overexpression (84%) was found among isolates that were resistance to
ciprofloxacillin. These incidences of isolates hyperproducing MexXY-OprM were
inﬂuenced by the use of aminoglycosides and ﬂuoroquinolones drugs (Hocquet et
al., 2008; Islam et al., 2004). Besides that, the mexY overexpression (80%) was
noted in isolates that were resistant to meropenem and imipenem (Table 3.3e).
These support the results of the previous studies which emphasized the capability of
P. aeruginosa to develop dual resistance to carbapenems and ﬂuoroquinolones due
to independent mechanisms of resistance of different classes of antibacterial agents
and stress the requirement for the judicious utilization of treatment when dealing
with P. aeruginosa to avoid development of multidrug resistance (Wolter et al.,
2004; Islam et al., 2004).
The mRNA expression analysis in P. aeruginosa isolates that were resistant to
meropenem, imipenem, ciprofloxacin, ceftazidime and amikacin demonstrated
overexpression of mexZ gene ranging from 61% to 69%. In addition, mRNA
expression levels in isolates resistant to the above antibiotics were also associated
with high overexpression of mexY gene ranging from 80% to 90%. Previous studies
confirmed that mutation in genes encoding repressors and activators of efflux
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pumps lead to pump expression with the most frequent target being the repressor
gene mexZ leading to MexXY-OprM overproduction (>80%) which confers
resistance to aminoglycosides, quinolones and carbapenem drugs (Wolter et al.,
2004; Islam et al., 2004; Henrichfreise et al., 2007).
In this study, we observed a significant down-regulation of oprM in the isolates that
were resistant to amikacin and gentamicin (>62%) as shown in Table 3.3e.
However, >86% of and 72% of the isolates overexpressed MexXY and MexAB-
OprM. These findings were in consent with others studies, which confirmed that the
MexXY efflux system lacks a cognate outer membrane protein and that OprM can
substitute for the missing channel protein function. The MexXY and MexAB-OprM
pump contribute to aminoglycoside resistance in a low ionic strength environment,
which confirms the over expression of MexAB-OprM. MexAB-OprM expression is
the growth phase is regulated but MexXY is not, which sustains the propositions
that OprM has a second promoter, even though the oprM mRNA levels were even
lower than the P. aeruginosa wild type strain. The MexXY and MexAB-OprM
systems are possibly co-regulated as they expressed high levels of mexY. This is
because oprM has a secondary promoter and MexXY utilized outer-membrane
proteins other than OprM, such as OpmG, OpmI and OpmH (Evans & Poole, 1999;
Evans et al., 2001; Li et al., 2003a; Okamoto et al., 2002; Jo et al., 2003).
The mRNA expression analysis in P. aeruginosa isolates that were resistant for
ciprofloxacin demonstrated 63% down-regulation for oprM, which was associated
with 78% overexpression of mexB and 84% hyperexpression of mexY genes as
illustrated in Table 3.3e. This support that mexY require OprM in order to form a
functional pump for export the antibiotics. OprM was proposed because it is always
expressed at low but detectable levels from a secondary promoter independent of
MexAB (Kohler et al. ,1999c; Li et al., 2000b). This also concurs with Aires et al.
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(1999) and Mine et al. (1999), who reported that MexXY efﬂux system share the
OprM channel with MexAB thus confirming the significance of efflux mechanisms
in the isolates resistant to ciprofloxacin (Aires et al., 1999; Mine et al., 1999). This
is due to MexXY efﬂux pump lacking an outer-membrane protein of its own, and
OprM can substitute the missing function and selected in fluoroquinolone resistant
strains demonstrating a multidrug resistance phenotype that was originally
attributed to reduced outer membrane permeability (Masuda, et al., 2000a).
MexEF-OprN is the third efﬂux system which can export ﬂuoroquinolones (Kohler
et al., 1999b; Maseda et al., 2000). Fluoroquinolones are the choice for mutant
selection of multidrug efflux pumps in vivo and in vitro, including MexEF-OprN
(Join-Lambert et al., 2001). This supports our results, where mRNA expression
analysis in isolates that were resistant to ciprofloxacin showed that 68% of them
overexpressed MexEF-OprN as shown in Table 3.3e. Overproduction of MexEF-
OprN assists in development of resistance to the carbapenems due to regulatory
links between this pump and the porin, OprD (Ko¨hler et al., 1997). The results of
this study confirm a dual resistant phenotype in which the overexpression of
MexEF-OprN was noted in 68% of the isolates that were resistant to both imipenem
and ciprofloxacin drugs and in 70% of isolates that were resistant to meropenem as
shown in Table 3.3e. This dual resistance increases an anxiety concerning the
promotion of carbapenem resistance during the utilization of fluoroquinolones. The
present study results showed that 84% of the isolates that were resistant to
ciprofloxacin drugs were overexpressed mexY which correlated with 68% of the
same isolates showing upregulated expression of mexEF (Table 3.3e). These
findings are consistent with others that confirm function of overproduction of
MexEF-OprN in dual resistance of these strains to the fluoroquinolones as being
attributed to up-regulation of the MexXY efflux pump (Poole & Srikumar, 2001;
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Wolter et al., 2004). On the other hand, the function of MexXY in the isolates that
were resistant to fluoroquinolones has gathered interests, even though reports
demonstrate a relationship between overproduction of this pump in laboratory-
selected mutants with reduced sensitivity to the fluoroquinolones (Masuda et al.,
2000a; Jeannot et al., 2005; Islam et al., 2004).
Several studies have showed the participation of the MexEF-OprN, MexCD-OprJ,
and MexAB-OprM efflux systems in fluoroquinolone-resistant clinical isolates
(Schweizer, 2003; Jombo et al., 2010; Li & Nikaido, 2009). These findings are
consistent with the results of this study that illustrated 68%, 48% and 78% of the
isolates that were resistant to ciprofloxacin overexpressed the mexEF, mexCD and
mexB genes. Therefore, the dual resistance to the carbapenems and
fluoroquinolones remains a big problem because carbapenems and
fluoroquinolones remains the main antimicrobials for treating infections due to
multidrug-resistant P. aeruginosa, but the development of resistance may
signiﬁcantly compromise their efficacy.
Previous studies reported that fluoroquinolones, β-lactams and meropenem are
substrates for the MexCD-OprJ system, although this efﬂux pump is not
constitutively expressed under usual growth circumstances (Maseda et al., 2000;
Poole et al., 1996a). This coincides with the results of this study, in which the
overexpression mexCD-oprJ was noted in 48% of the isolates that were resistant
for ciprofloxacin and ceftazidime, in 55% of the isolates that were resistant for
aztreonam and meropenem and in 54% of the isolates that were resistant to
imipenem as is illustrated in Table 3.3e. These numbers are higher than previously,
reported where only 31% of the carbapenem resistant isolates overexpressed the
MexCD-OprJ efﬂux pump (Rodriguez-Martinez et al., 2009). The mechanisms
leading to carbapenem resistance appear to be more complex and are very likely
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multifactorial, involving overproduction of AmpC or overexpression of the efﬂux
pumps MexAB-OprM, MexXY-OprM and MexCD-OprJ (El Amin et al., 2005). In
the Rodriguez-Martinez et al. (2009) study no isolate overexpressed all three efﬂux
pumps, whereas our results demonstrated up-regulation for AmpC in >65% of the
isolates that were resistant to carbapenems and more than 71% of these isolates
also showed overexpression of mexB and mexY. In addition, up to 55% of the
isolates that were resistant to carbapenems demonstrated over expression of mexCD
as shown in Table 3.3e.
OprM functions with all RND transporter/membrane fusion protein complexes
studied including MexCD and MexEF, which is expressed at low levels (Gotoh et
al., 1998b; Gotoh et al., 1998a; Maseda et al., 2000). Another study demonstrated
the functional replacement between OprJ and OprM, and the role of the inner
membrane-associated components MexCD (Srikumar et al., 1997). The same
observation was made in this study where oprM down-regulation was associated
with overexpression of mexCD and mexEF in the resistant isolates for the examined
antibiotics (Table 3.3e). These findings also concur with other studies that
demonstrated that OprM could function with all RND transporter/MPF complexes
studies to date, including MexCD and MexEF in the efflux pumps of the antibiotics
(Gotoh et al., 1998a; Masuda et al., 2000b).
4.2.2 Analysis of AmpC expression
AmpC type β-lactamases (also called cephalosporinases) are commonly found from
extended-spectrum cephalosporin-resistant Gram-negative bacteria. AmpC type β-
lactamases are encoded on the chromosome of many Gram-negative bacteria,
notably P. aeruginosa; they can be hyperexpressed through derepression (Jacoby,
2009). AmpC overproduction by P. aeruginosa can be difficult to analyze owing to
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the multiple resistance mechanisms usually expressed by MDR P. aeruginosa, but
AmpC overproduction is major factor in persistent bacteremia and inappropriate
therapy. Furthermore, AmpC overproductions play also an important role in the
multi-drug resistance phenotype among P. aeruginosa. The results of the current
study demonstrated 65% of the isolates that were resistant to antibiotics examined
exhibited up-regulated ampC gene expression as shown in Table 3.3e. This is
considered much higher than the results obtained by Cabot et al. (2011) study that
demonstrated only 24.2% of isolated exhibited ampC overexpression. One factor
possibly contributing to this difference is the resistance level for the different
antibiotics used as our isolates showed higher rates of antimicrobial resistance.
Another important issue to consider for an understanding of resistance dynamics
are the interconnections between the different resistance mechanisms. Previously
reported prevalences of the different combinations of resistance mechanisms are
mexY (13.2%), mexB (12.6%), mexF (4.2%) and mexD (2.2%) overexpression
where in our study the values were mexY (82%), mexB (73%), mexF (68%) and
mexD (48%) considerably higher as shown in Figure 3.3.
The derepression of the chromosomal AmpC cephalosporinase and the up-
regulation of the MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM
efflux systems confer fluoroquinolone resistance, and resistance to some β-lactams
and aminoglycosides (Henrichfreise et al., 2007). This is clear with results of the
current study which demonstrated that more than 60% of the isolates that were
resistant to antimicrobial agents mentioned above showed up-regulation of an
ampC and this was associated with more than 71%, 76%, 63% and 47% of these
resistant isolates overexpressing mexB, mexY, mexEF and mexCD mRNA
respectively, as shown in Table 3.3e.
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It has been reported that AmpC β-lactamase is able to cause very little activity
alone against carbapenems but when combined with other resistance mechanisms
can play a considerable role in reducing susceptibility to carbapenems (Okamoto et
al., 2001; Quale et al., 2006). Additionally, the association of distinct mechanisms
such as AmpC overproduction and porin down-regulation also play an important
role in the carbapenem resistance phenotype among P. aeruginosa isolates (Xavier
et al., 2010). Previous studies demonstrated interaction of down-regulation of
OprD and up-regulation of AmpC which appeared to be the cause for decreased
meropenem and imipenem susceptibility, while further efﬂux pump overexpression
leads to full meropenem resistance (Henrichfreise et al., 2007; Tomas et al., 2010;
Cabot et al., 2011). In the present study, 66% of the isolates that were resistant to
carbapenems overexpressed ampC. Of those, 100% showed decreased oprD
expression. In the study of Xavier et al. (2010), 52.2% were resistant to
carbapenems and in those isolates 20% overexpressed AmpC. Of these, 90.0%
showed decreased oprD expression and this is an important finding. This is related
to interplay of different resistance mechanisms that play an important role in the
carbapenem resistance phenotype among the P. aeruginosa clinical isolates studied
as shown in Table 3.3e.
This study further confirms that chromosomal AmpC β-lactamase confers
resistance to most cephalosporins and penicillins (piperacillin/tazobactam) in P.
aeruginosa with high significance (p < 0.05) as shown in Table 3.3e and 3.3f. This
finding is in line with other studies, which reported that P. aeruginosa clinical
isolates that were resistance to piperacillin/tazobactam drug showed overexpression
of the chromosomal AmpC β-lactamase gene (Quale et al., 2006; Xavier et al.,
2010; Juan et al., 2006). In these studies, the up-regulation of the P. aeruginosa
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chromosomal cephalosporinase ultimately leads to constitutive hyperexpression of
AmpC and high-level antipseudomonal β-lactam resistance.
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4.2.3 Analysis of OprD expression
The mechanism of carbapenem (imipenem and meropenem) resistance is usually
multifactorial, and may be mediated via several distinct mechanisms involving
overexpression of efﬂux pump, AmpC overproduction or decreased levels of the
outer membrane porin OprD (Pfeifer et al., 2010; Wang et al., 2010; Ozer et al.,
2012). The loss of OprD has been reported as the most consistent ﬁnding in
carbapenem-resistant isolates (Pai et al., 2001). As reported by Quale et al. (2006),
down-regulation of oprD was found in all isolates resistant to imipenem and
meropenem, because the entry of carbapenems involves the outer membrane
protein OprD, and its decreased expression is commonly shown in carbapenem-
resistant isolates (Quale et al., 2006). There are several reports of antibiotic
resistance acquired through loss or functional change of porins in a large number of
organisms, such as Neisseria gonorrhoeae, E. coli, P. aeruginosa; Enterobacter
aerogenes and Klebsiella pneumoniae (Poole 2002; Achouak et al., 2001). Farra et
al. (2008) reported that decreased transcription of oprD was observed equally in
transconjugants and in clinical strains that were imipenem resistant and possibly
observed as elevated MICs noted for meropenem (Farra et al., 2008). In the current
study, 100% of the isolates that were resistant to imipenem and meropenem showed
down-regulation of oprD (Table 3.3e). The results reported in the this study are also
consistent with previous investigators (Giske et al., 2008a; Gutierrez et al., 2007;
Livermore, 2001a; Cabot et al., 2011), who reported that the mechanism of
resistance to imipenem and meropenem in clinical strains is associated with low
expression of oprD which increases the MIC level to these drugs.
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4.2.4 Penicillin-binding proteins (PBPs)
In Acinetobacter baumannii, the reports on resistance mechanisms mainly focused
on outer membrane impermeability, production of beta lactamases and production
of efflux pumps. However, crucial to bacterial survival are penicillin-binding
proteins (PBPs), which play an important function in the synthesis of
peptidoglycan, a fundamental component of the bacterial cell wall. PBPs catalyze
the last step of polymerization (transglycosylation) and by cross-linking the
transpeptidation of peptidoglycan, the bacteria can acquire β-lactam resistance by
changing their PBPs and studies showed an association between down-regulation of
PBPs and resistance in A. baumannii (Vashist et al., 2011). A study by El Amin et
al. (2005) on P. aeruginosa clinical isolates that were resistant to imipenem and
meropenem depicted that down-regulation of oprD did not always associate with
the degree of meropenem and imipenem resistance and the divergences might not
be clarified by the pattern of efﬂux pump gene expression or OprD alterations. For
this reason, it was believed that additional mechanisms were involved in
meropenem and imipenem resistance (El Amin et al., 2005). Another probable
resistance mechanism may be the alterations in the penicillin-binding proteins
(PBPs) and PBPs are one of the most likely mechanisms for carbapenem resistance
offer than enzymes (Farra et al., 2008). The results of the current study
demonstrated that 80% of the P. aeruginosa clinical isolates that were resistant to
imipenem and meropenem showed down-regulation of PBP2, while up to 91% of
these isolates showed down-regulation of PBP3 (Table 3.3e). However, Farra et al.
(2008) reported, in their study, that decreased expression of PBP2 and PBP3 was
noted in all strains in comparison to PA018SR, except for the clinical strain, which
showed increased expression of both PBPs. Therefore, the increased expression of
PBP2 and PBP3 genes is possibly not significant for resistance to carbapenems
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(Farra et al., 2008). Previous studies reported that PBP2 contributes signiﬁcantly to
β-lactam antibiotic resistance, and down-regulation of PBP3 has effects on a
number of genes in Pseudomonas, involved in antibiotic resistance (Blazquez et al.,
2006; Legaree et al., 2007). The present study shows that imipenem and
meropenem resistance among clinical P. aeruginosa isolates not only occurred due
to OprD down-regulation but was also linked with down-regulation of other genes
such as PBP2 and PBP3. This implies that down-regulation of the oprD gene
significantly contributes to imipenem and meropenem resistance, which increases
the MIC to these drugs. While, PBPs can be one of the most likely mechanisms for
carbapenem resistance among clinical P. aeruginosa isolates, the mechanisms of
resistance to carbapenem (imipenem and meropenem) as a result of the interplay
between diminished production of OprD, increased activity of AmpC, and several
efﬂux systems has been illustrated to contribute high-level resistance to these
agents (Quale et al., 2006; Henrichfreise et al., 2007).
4.3 Detection the prevalence of metallo-beta lactamase producing P.
aeruginosa
In the current study, we aimed to evaluate the different mechanisms associated with
reduced susceptibility to imipenem and meropenem compared to other examined
antibiotics. The mechanism of carbapenem (imipenem and meropenem) resistance
is usually multifactorial, involving overexpression of efﬂux, AmpC overproduction
or decreased outer membrane OprD levels or by acquired β-lactamases, included
extended spectrum types (ESBLs) and carbapenemases (Pfeifer et al., 2010; Wang
et al., 2010; Ozer et al., 2012). Therefore, this study was carried out to detect the
prevalence of MBL producing P. aeruginosa in the University Malaya Medical
Center (UMMC) in Kuala Lumpur, Malaysia, to discover the associated risk factors
and probable treatment alternatives. The early detection of MBL producing P.
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aeruginosa may avoid the future spread of these multi-drug resistant strains. In the
present study, 41 out of 65 imipenem and meropenem resistant P. aeruginosa
isolates from various clinical specimens were MBL producers. Out of 41 strains,
MBL genes were amplified in 20 isolates for blaIMP, in 14 isolates for blaVIM, in 4
isolates for blaGIM, in 2 isolates for blaNDM and only in one isolate for blaSIM (Table
3.4a). No blaSPM genes were detected in this study. The detection of blaIMP and
blaVIM is in agreement with a previous study that carried out at the University
Malaya Medical Center (UMMC) in Kuala Lumpur, Malaysia (Khosravi et al.,
2010). It demonstrated that 32 out of 90 imipenem resistant P. aeruginosa clinical
isolates tested positive for the presence of MBL genes including blaIMP and blaVIM
and none of the isolates tested positive for other MBL genes (Khosravi et al.,
2010). However, another study also carried out in same medical centre showed that
only one P. aeruginosa out of 50 imipenem resistant P. aeruginosa isolates was
MBL gene PCR positive (Ho et al., 2002). The results of this study are interesting
in that this is the ﬁrst study to show that imipenem and meropenem resistant P.
aeruginosa isolates harbor blaSIM, blaGIM and blaNDM.
P. aeruginosa isolates producing metallo-β-lactamases (MBLs) were ﬁrst reported
from Japan in 1991 and since then have been described in various parts of the
world, including Asia, Europe, Australia, South America and North America
(Poirel et al., 2007).
A number of studies have been carried out regarding the prevalence of MBL-
producing isolates among carbapenem resistant P. aeruginosa and varying
percentages have been reported worldwide, ranging from 10% in Turkey (Ozgumus
et al., 2007) and up to 36% in Southeast Asia (Huang et al., 2007). In addition,
there are frequent reports from Asian and the Pacific countries, such as Malaysia,
Singapore, Bangladesh, Hong Kong, Taiwan and Japan (Khosravi et al., 2010;
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Nasrin et al., 2011; Koh et al., 2004; Hemalatha et al., 2005). Previous studies
pointed out that the most common and widespread acquired MBLs are those of the
IMP and VIM types, which exhibit a worldwide distribution and are widespread in
Asian countries (Yan et al., 2001; Yatsuyanagi et al., 2004; Khosravi et al., 2010;
Hwa et al., 2009). This is in agreement with the results of this study that found
most imipenem and meropenem resistant isolates harbor IMP and VIM types.
Recently, the New Delhi metallo-β-lactamase (NDM) has been reported from
diverse locations such as the UK, the USA, Japan, India, Singapore, Australia and
most recently the Middle East and this represents an emerging public health threat
(Muir & Weinbren, 2010; Karthikeyan et al., 2010; Rolain et al., 2010). NDM is
contributing resistance to almost all β-lactam antibiotics, including carbapenems,
and was recently identiﬁed in Escherichia coli and Klebsiella pneumonia isolates
from a Swedish patient who visited New Delhi, India (Yong et al., 2009).
Kumarasamy et al. (2010) have lately reported the appearance and spread of 180
cases of patients infected with bacteria carrying the NDM encoding gene from
India, Pakistan and the UK. Fascinatingly, most patients from the UK had
journeyed to Pakistan or India within 1 year and had been hospitalized in these
countries, indicating that these organisms were acquired from a local source in Asia
(Kumarasamy et al., 2010).
In 2010, other cases were reported worldwide, including in the USA, Canada,
Europe, Japan, Africa, Oman and Australia (Rolain et al., 2010). Consequently, the
detection of two NDM positive isolates in this study suggested possibilities of
spread via international tourists in this country. All 41 MBL producing P.
aeruginosa strains were resistant not only to carbapenems (imipenem and or
meropenem), but also to ceftazidime, which was used as a marker for MBL
production. Furthermore, the MBL producing isolates were found to be most
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resistant to piperacillin-tazobactum (76%), followed by aztreonam (73%) and it was
found that the MBL producer P. aeruginosa strains were more resistant to other
antimicrobial agents than non-MBL producers (Table 3.4d). These results are in
concurrence with those by Navneeth et al. who reported that 100% of isolates were
resistance to the piperacillin/tazobactum combination and demonstrated that MBLs
confer resistance not only to carbapenems but also to other β-lactams and are
poorly inhibited by the presence of β-lactamase inhibitors such as tazobactam,
clavulanic acid and sulbactum (Navaneeth et al., 2002). The results in this study
also coincide with Hirakata et al. (1998), who reported potent antimicrobial activity
of aztreonam against MBL positive isolates (Hirakata et al., 1998). This confirms
that P. aeruginosa strains harboring MBL genes have emerged in our health
facility, which needs more attention in infection control measures.
The present study demonstrated that 33 out of 65 of the imipenem and meropenem
resistant P. aeruginosa isolates were positive for ESBL genes. Out of these 33
isolates, ESBL genes were amplified in 25 isolates for blaVEB, in 5 isolates for
blaTEM and in 3 isolates for blaCTX-M. No blaSHV and blaPER genes were detected
(Table 3.4a). The presence of blaVEB, blaTEM and blaCTX-M genes in P. aeruginosa
isolates in this study was demonstrated in Malaysia for the ﬁrst time. The most
frequently encountered ESBLs gene in our study was blaVEB (25 of 65), which is
similar to (30 of 75) ESBLs producing isolates of P. aeruginosa which was
reported by Jiang et al. (Jiang et al., 2006).
The first report of the presence of blaCTX-M ESBLs in P. aeruginosa was provided
by Al Naiemi et al. (Al Naiemi et al., 2006). The blaCTX-M ESBLs supply P.
aeruginosa with an extra potent resistance mechanism with potential serious
clinical implications, further compromising therapeutic choices. The incidence of
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blaCTX-M has gained endemic proportion in several countries (Livermore et al.,
2007).
Our study reported 50% ESBL production among P. aeruginosa isolates examined.
These findings are much higher than the results of previous studies that showed low
rates, 3.7% in Woodford et al. (2008) study, 4.2% in Lim et al. (2009) study, 7.7%
in Jacoby (1997) study, 20.3% in Aggarwal et al. (2008) study, 35.85% in Ullah et
al. (2009), 39.41% in Mirsalehian et al. (2010) study, of ESBL production in P.
aeruginosa isolates examined. These observations suggested that ESBLs are
increasingly found in P. aeruginosa, which could also be a reservoir for the spread
of these enzymes (Livermore, 1995).
ESBLs confer resistance of P. aeruginosa to the third generation cephalosporins in
100% of isolates examined in this study, which was much higher than that reported
by Uma et al. In the present study, we observed an increased resistance of this
ESBL producer P. aeruginosa isolates to the examined antibiotics except colistin,
which were in accordance with previous reports (Aggarwal et al., 2008; Jayakumar
& Appalaraju, 2007; Arya et al., 2005).
P. aeruginosa carries a notably higher mortality rate than other pneumonia
pathogens. Because of its multiple mechanisms of antibiotic resistance, therapy has
always been challenging. This problem has been magnified in recent years with the
emergence of multidrug-resistant (MDR) pathogens often unharmed by almost all
classes of antimicrobials. The increasing use of the antimicrobial and
environmental stresses leading to chronic infections of individual airways is due to
change in colony morphology that arises during bioﬁlm production (von Gotz et al.,
2004; Häußler et al., 2003; Drenkard & Ausubel, 2002). According to von Gotz et
al., Boles et al., various types of colonial morphology in P. aeruginosa displays
phenotypic modifications in motility, antibiotic resistance, bioﬁlm formation,
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adherence properties, and virulence gene expression. The creation of various
phenotypic properties may possibly contribute to the persistence and pathogenic
abilities of P. aeruginosa (von Gotz et al., 2004; Boles et al., 2004).
4.4 Clinical implication
Overall, P. aeruginosa clinical isolates in our society showed multiple resistance
phenotypes leading to limited therapeutic choices. Therefore, infections caused by
MDR P. aeruginosa have become a serious problem, especially in the healthcare-
associated settings. This problem indicates the importance of performing antibiotic
susceptibility testing before treatment.
Furthermore, infection with MDR P. aeruginosa is associated with risk factors
including severity of illness, invasive devices, a bedridden state, and in hospitalized
patients, lead to increased length of stay and increased therapeutic costs as well as
significant morbidity and mortality. The continuous efforts of clinicians,
microbiologists, pharmacists and communities should promote a greater
understanding of this problem, with better hygiene and postoperative care and
management.
Most of the P. aeruginosa clinical isolates had a high level of resistance to
examined antibiotics except colistin. Therefore, the only drug of choice in MDR
isolates is the colistin despite its toxicity. In addition, the search for anti-
pseudomonal agents with alternative mechanisms of action is very important in this
situation. In addition, it is important to practice good antibiotic prescription policies
and infection control practices to prevent the spread of genes responsible for these
resistances, which could result in the return to the pre-antibiotic era.
Efflux pumps contribute to both intrinsic and acquired resistance that can survive
the presence of antibiotics, which may select mutants that overexpress these genes.
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It was obvious that several efflux pumps genes were expressed in our isolates so
these may lead to broad-spectrum resistance.
Loss of OprD reduced the susceptibility of P. aeruginosa to antipseudomonal
carbapenems, associated with other molecular mechanisms, highlighting the
complexity by which P. aeruginosa is able to regulate expression of resistant
mechanisms, and it is difficult to relate phenotypic expression to any single
mechanism. Additionally, these strains highlight the ability of P. aeruginosa to
develop dual resistance to different classes of antimicrobial agents through
independent mechanisms of resistance and highlight the need for the judicious use
of therapy when dealing with P. aeruginosa to prevent multidrug resistance from
developing.
The prevalence of ESBLs differs with geographic location and time. ESBL
producing strains are generally found in areas of hospitals where antibiotic use is
common and the patient’s condition is critical. These resistant organisms are
clinically significant as they result in increased morbidity and mortality. In
addition, ESBL producing bacteria are commonly resistant to several classes of
antibiotics, complicating therapy. Presently, carbapenems are considered the drug
of choice for treatment of infections caused by ESBL-producing organisms. The
undesirable use of carbapenems has been linked with the appearance of
carbapenem-resistant P. aeruginosa. The increased prevalence of ESBLs is almost
certainly due to the increased use of expanded spectrum cephalosporins in hospital
settings. ESBLs organism producers are distinctive challenges to clinicians,
scientists, clinical microbiologists and infection control specialists occupied in the
discovery of new antimicrobial agents. Suitable infection control practices and
barriers are essential to prevent distribution and occurrences of ESBL-producing
bacteria. The infections detected in hospitalized patients caused by ESBLs illustrate
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either infection acquired during hospitalization or severe community acquired
infections involving hospital admission. Community-acquired infections that
contribute to ESBL-producing organisms in hospitalized patients appears to be
growing (Valverde et al., 2008). Additionally, the long-term care facilities of
residents caused by infection or colonization by the ESBL-producing organisms
may provide a means for the distribution of ESBLs among hospitals and
communities. In this respect, the occurrence of colonization by the ESBL-
producing organisms where inhabitants stay for long periods for medication appears
to be rising significantly, even though relevant data are inadequate
(Nicolas‐Chanoine & Jarlier, 2008).
The risk factors for the hospitalized patients towards infection or colonization by
the ESBL-producing organisms are comparable to those acquired by healthcare-
associated bacterial infections (Rodríguez-Baño et al., 2006). A long stay in a
hospital or intensive care unit (ICU), inclusion of different kinds of indwelling
catheters, greater severity of clinical status, performance of surgical interventions or
invasive procedures, and mechanical ventilatory support or renal replacement
therapy, have all been linked to the isolation of ESBL-producing organisms from
hospitalized patients (Jacoby & Munoz-Price, 2005; Pfaller & Segreti, 2006). The
use of antibiotics in particular, such as ﬂuoroquinolones or oxyimino-β-lactams,
represents an important additional risk factor (Jacoby & Munoz-Price, 2005). The
detection of patients colonized with the ESBL-producing organisms can be done
with an examination of the cultures from the specimens gastrointestinal tract,
especially by collecting swabs from the rectal area (Paterson & Bonomo, 2005). A
considerably high percentage of patients who develop healthcare-associated ESBL-
acquired infections associated with the preceding colonization in the
gastrointestinal tract have been noticed. On the other hand, this is technically
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demanding and requires the use of selective culture media, which is necessary for
identiﬁcation of ESBL producers among commensal Enterobacteriaceae. The
effectiveness of infection control relating to the strategy of selective
decontamination of the gastrointestinal tract of patients that are found to be
colonized with ESBL-producing organisms remains a contentious subject (Paterson
& Bonomo, 2005).
4.5 Conclusion
Eighty-eight clinical isolates from the University of Malaya Medical Center, Kuala
Lumpur, Malaysia were identified as P. aeruginosa strains based on morphology,
gram staining, pyocyanin production and biochemical tests by API20NE according
to the standard laboratory procedures. Antibiotic susceptibility testing was done
using E-test®. The antimicrobial agents tested in this work were
piperacillin/tazobactam, ceftazidime, aztreonam, amikacin, gentamicin,
ciprofloxacin, imipenem and colistin. Most of the P. aeruginosa clinical isolates
had a high level of resistance to all examined antibiotics except colistin. The
resistance mechanisms in 88 clinical P. aeruginosa isolates were evaluated using
real time PCR. The gene expression analysis of 88 P. aeruginosa isolates showed
overexpression of efflux pump genes, AmpC overexpression, down-regulation of
outer membrane porin OprD and penicillin binding proteins compared to P.
aeruginosa ATCC 27853. Therefore, the multidrug resistance phenotypes in these
clinical isolates were caused by the interaction of several different resistance
mechanisms occurring within the same strain such as overexpression of efﬂux
pumps, AmpC overproduction, decreased outer membrane porin OprD, alteration of
penicillin binding proteins. Sixty-five of the clinical P. aeruginosa isolates that
were resistant to imipenem and meropenem were then evaluated for detection of
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MBL and ESBL genes. The results obtained with these isolates demonstrated high
efflux pump overproduction, MBL and ESBL production and confirm that
resistance genes have the ability to increase resistance levels to imipenem and
meropenem in P. aeruginosa.
4.6   Future work
Multilocus Sequence Typing (MLST) could be a useful method for studying the
epidemiology of MBL-producing isolates. It is also important to develop novel
antimicrobial peptides and assess their possibility for use as anti effective agents
and to progress it through pre-clinical studies in animal models.
Furthermore, clinical studies are required to identify the epidemiological and risk
factors for MDR P. aeruginosa development and to determine the economic impact
of these infections, as well as to design the most efficacious antimicrobial
treatments and duration of therapy to maximize positive outcomes of multi drug
resistant P. aeruginosa infections. This calls for strict precautionary measures,
which includes stringent infection control practices and the judicious use of
antibiotics. These important measures might overcome the challenge of high
mortality posed by multi drug resistant P. aeruginosa and other non-fermenting
bacterial pathogens.
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APPENDIX II
EQUIPMENT AND MATERIALS
1. Electric- Binocular Microscope, CH-30 (Olympus®)
2. Automatic Micropipettes (eppendorf®).
3. Master cycler Gradient PCR (Eppendroff®).
4. Real time CFX96™ PCR (BioRad®, Hercules, CA).
5. Nano drop-2000 spectrophotometer
6. Laminar flow
7. Apparatus for agarose gel electrophoresis (BioRad ®).
8. UV transilluminator, gel doc XR system (BioRad ®, Hercules, CA)
9. Refrigerator (4°C) and freezer (–20°C & –80°C).
10. Centrifuge for 1.5 Microcentrifuge tubes (Eppendroff®).
11. Centrifuge for 50 mL tubes (BioRad®).
12. Microcentrifuge (for 0.2 mL PCR tube).
13. Vortex and shaker.
14. Tips, different sizes; (0.1-10 µL, 0.5-300µL and 300-1000µL) (eppendorf®).
15. 1.5 mL Microcentrifuge tubes (eppendorf®)
16. 0.2 mL PCR tubes (BioRad®).
17. Incubator 37ºC (MEMMERT®).
18. Conical centrifuge tube 50 mL
19. Water bath (MEMMERT®).
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B- Reagents
B.1 Gram stain reagents
1. Primary stain
Solution 1: Crystal violet                    2 g
Ethanol 95% 20 mL
Solution 2: Ammonium oxalate        0.8 g
Distilled water 100 mL
-Mix Solution 1 and Solution 2, allow to stand for at least 24 hours, and filter
before use
2. Gram’s iodine:
Potassium iodide 2 g
Iodine crystals                    1 g
Distilled water                  100 mL
3. Decolorizer: 50 mL acetone added to 50 mL ethanol.
4. Counterstain:
Safranin                            4.0 g
Ethanol 95%                  200 mL
Distilled water                800 mL
Working solution:   Stock solution    10 mL
Distilled water   90 mL
Standard biochemical reagents
Blood agar
Trypton/peptic digest of animal tissue     10 g
Brain heart infusion 500g
Sodium chloride                                       5g
Agar                                                          15g
Distilled water 1000
- Sterilize by autoclaving.
- Cool media to 45-50°C, then add preheated
(45°C) sterile blood
B.2 Preparation of sterile normal saline
8.5 g of NaCl was added to 1.0 L distilled water and mixed well. The mixture was
autoclaved at 121°C for 15 minutes.
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B.3 Preparation of sterile PBS
A total number of 5 PBS tablets were dissolved in 500 mL of distilled water and
mixed well. The mixture was autoclaved at 121°C for 15 minutes.
B.4 Preparation of 50× TAE buffer
24.2 g of Tris Base was added with 5.71 mL of glacial acetic acid and 10 mL of 0.5
M EDTA (PH 8). The mixture was topped up with distilled water to 100 mL.
Finally, the solution was autoclaved at 121°C for 15 minutes.
B.5 10X TBE Buffer (Tris-Borate-EDTA) (Fermentas®):
1X TBE buffer is composed of 89 mM Tris, 89 mM boric acid, 2 mM EDTA,
(pH 8.3), Stored at room temperature.
B.6 TE buffer (10 mM Tris·Cl, 1 mM EDTA, pH 8.0) containing 15 mg/mL
Lysozyme
1M Tris-HCL., pH 8.0                   1mL (FINAL CONCENTRATION = 10
mM)
0.5 EDTA 200 µL (FINAL CONCENTRATION = 1
mM)
Distilled water 100 mL
Lysozyme 150 g
Sterilize by passing through 0.2 Millipore micro filters.
B.7 Ethidium bromide solution:
10 mg/mL in water. Extreme care should be taken during handling this solution
as it is highly mutagenic, store in the dark at 4°C.
B.8 Preparation of McFarland standard test
Turbidity standard was prepared by adding 0.5 mL of 0.048 mol/L BaCl2 (1.175%
w/v BaCl2.2H2O) to 99.5 mL of 0.18 mol/L (0.36 N) H2SO4 (1% v/v). The density
178
of mixture was measured at 620 nm using spectrophotometer. The absorbance was
0.080-0.10 at 620 nm. The mixture was stored in the dark at room temperature for
up to 4 months.
B.9 Formaldehyde agarose denaturing gel electrophoresis
1. 1.2% agarose gel was prepared by mixing 1.5 mL of 10× formaldehyde gel
buffer with DEPC-treated water to 15 mL and 0.18 g agarose in a conical flask and
microwave until dissolved. The mixture was let cooled slightly and 0.5 µL of
ethidium bromide and 1.8 µL of 37% formaldehyde was added. The gel was then
poured in the gel cast and left to set. The gel was then soaked in 1× formaldehyde
gel running buffer for at least 30 minutes to equilibrate.
2. 6 µL of DNase treated RNA was mixed with 1 µL of RNA loading dye.
3. The mixture was then heated in a heat block at 65°C for 4 minutes.
4. After heating, the mixture was chilled immediately on ice for 3 minutes.
5. The mixture was then loaded into the formaldehyde gel. The gel electrophoresis
was done at 70 V for 40 minutes.
6. The gel was then viewed using UV Transilluminator
B. 10 Preparation of 100 bp DNA ladder
10 µL of 100 bp DNA ladder stock solution was added to 10 µL of 6× loading dye
and 40 µL of sterile ultrapure water. Finally, the mixture was gently vortexed and
centrifuged.
B.11 Preparation of 2.0% Agarose Gel
2.0 g of agarose powder was added to 100 mL of 1× TAE buffer and mixed gently.
The mixture was boiled in a microwave for 3 min until dissolved completely.
Liquid mixture was cooled and then 0.8 µL (10 mg/mL) of ethidium bromide was
added and swirled gently.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Reduction of Nitrate ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Iodole production - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Glucose acidification - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Arginine Dihydrolase ++++++++++ + - + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Urease - ++++- +++- + - - + + - - + - + - + + - - - + - - + - - + + - - + - - - - - + + + + - + + - + + + + - - + + + +
Esculin Hydrolysis ++++++++++ + - + + + + + - + + + + + - + + + - + + + + + + + + + + + + - - - - + + + + + + + - + - + - + - + +
Gelatine Hydrolysis ++++++++++ + + - + - - - + - + + + + + - - - + + + - - + + - - + + + + + + + + + + + + + - + + + + + + + + + +
B-galactosidase +++++- - - +- - - - - - - - - - - - - - - - - - - - - - - - - - - - + - + - - - - - - - - - - - - - - - - - - - -
Glucose assimilation ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + = + + + + + + + + + + + + + + +
Arabinose assimilation - - - - - - +- +- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Mannose assimilation - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Mannitol assimilation ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
N-Acetyl-Glucosamine assimilation +++++++++- - - + + + + + - + + + + + + + + + - + + + + + + + + + + - + + + + + + + + + + + + + + + + + + + + +
Maltose assimilation - - - - - - +- - - - - - - - - - - - - - - + + - - - - - - - - - - - - - - - + - - - - - - - - - - - - - - - - - - - -
Gluconate assimilation ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Caprate assimilation ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Adipate assimilation ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Malate assimilation ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Citrate assimilation ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Phenyl-acetate assimilation - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Cytochrome oxidase ++++++++++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
StrainsTest
APPENDIX III Raw data supplement
API® 20NE Result for P. aeruginosa strains
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 ATCC
Reduction of Nitrate + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Iodole production - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Glucose acidification - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Arginine Dihydrolase + + - + + + + + + + + + + + + + + - + + + + + + + + - + +
Urease + - - - - - + + + + - - + + + + - - - + - + + + + - - - +
Esculin Hydrolysis + + + - - - + - + - + - + - + + + + - + - + - + + + + - +
Gelatine Hydrolysis + + + - + - + + + + + + + + + + + + - + + + + + + + + - +
B-galactosidase - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Glucose assimilation + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Arabinose assimilation - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Mannose assimilation - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Mannitol assimilation + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
N-Acetyl-Glucosamine assimilation + + + + + + + + + + + + + + + + + + + - + + + + + + + + -
Maltose assimilation - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Gluconate assimilation + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Caprate assimilation + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Adipate assimilation + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Malate assimilation + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Citrate assimilation + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Phenyl-acetate assimilation - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Cytochrome oxidase + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
StrainsTest
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No. PATIENT
REFERENCE
No.
Minimum inhibition concentration (MIC µg/mL)
WARD SOURCE IMP MEP CAZ AZT PPT GN AK CIP CL
# PS 27853 - - 1.50 0.50 1.50 4.00 4.00 2.00 4.00 0.12 3.00
1 PS/0901-5 ORTHOPEDIC WOUND 2.00 3.00 256.00 8.00 96.00 1024.00 48.00 32.00 3.00
2 PS/0901-6 NEUROSURGERY WOUND 32.00 32.00 256.00 32.00 24.00 32.00 16.00 32.00 4.00
3 PS/0901-7 SURGERY WOUND 32.00 32.00 256.00 8.00 256.00 1024.00 8.00 32.00 3.00
4 PS/0902-1 NEUROSURGERY T/SUCTION 32.00 32.00 256.00 16.00 24.00 64.00 24.00 32.00 4.00
5 PS/0902-3 SURGERY URINE 1.50 3.00 96.00 24.00 256.00 192.00 16.00 32.00 4.00
6 PS/0903-2 PAEDITRIC URINE 32.00 32.00 48.00 16.00 256.00 1024.00 256.00 32.00 3.00
7 PS/0903-3 SURGERY URINE 32.00 32.00 256.00 256.00 32.00 1024.00 256.00 32.00 6.00
8 PS/0904-2 GYNAECOLOGY URINE 32.00 32.00 256.00 12.00 256.00 384.00 12.00 16.00 4.00
9 PS/0905-1 SURGERY WOUND 32.00 32.00 256.00 12.00 128.00 192.00 8.00 32.00 4.00
10 PS/0905-2 ORTHOPEDIC WOUND 32.00 32.00 256.00 32.00 32.00 48.00 24.00 32.00 6.00
11 PS/0906-1 NEUROSURGERY URINE 32.00 32.00 256.00 32.00 24.00 48.00 32.00 32.00 4.00
12 PS/0906-2 ORTHOPEDIC WOUND 32.00 32.00 256.00 48.00 24.00 384.00 256.00 32.00 4.00
13 PS/0811-1 NEUROSURGERY URINE 32.00 32.00 256.00 24.00 32.00 48.00 32.00 32.00 3.00
14 PS/0811-2 MEDICAL T/SUCTION 32.00 32.00 256.00 256.00 256.00 1024.00 256.00 32.00 4.00
15 PS/0812-1 SURGERY URINE 32.00 32.00 256.00 256.00 12.00 1024.00 256.00 32.00 4.00
16 PS/0812-2 SURGERY URINE 32.00 32.00 256.00 256.00 12.00 1024.00 256.00 32.00 4.00
17 PS/0812-3 PAEDITRIC CSF 32.00 32.00 32.00 24.00 256.00 8.00 8.00 125.00 4.00
18 PS/0812-4 NEUROSURGERY SPUTUM 32.00 32.00 256.00 256.00 32.00 1024.00 256.00 32.00 3.00
19 PS/0812-6 SURGERY URINE 32.00 32.00 256.00 256.00 32.00 1024.00 256.00 32.00 3.00
20 PS/0809-6 ORTHOPEDIC URINE 32.00 32.00 256.00 48.00 256.00 1024.00 24.00 32.00 2.00
21 PS/0809-7 SURGERY WOUND 32.00 32.00 256.00 16.00 256.00 1024.00 24.00 32.00 2.00
22 PS/0810-1 SURGERY URINE 2.00 32.00 256.00 256.00 256.00 384.00 24.00 32.00 2.00
23 PS/0810-2 SURGERY SPUTUM 2.00 32.00 256.00 64.00 256.00 384.00 16.00 32.00 3.00
24 PS/0810-3 MEDICAL URINE 32.00 32.00 32.00 48.00 128.00 192.00 8.00 32.00 1.00
25 PS/0810-4 MEDICAL URINE 32.00 32.00 256.00 12.00 8.00 24.00 16.00 32.00 2.00
26 PS/0811-4 SURGERY Tissue 1.00 3.00 256.00 4.00 16.00 1024.00 48.00 3.00 2.00
27 PS/0811-5 SURGERY URINE 32.00 32.00 256.00 64.00 256.00 1024.00 24.00 32.00 2.00
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28 PS/0811-6 MEDICAL URINE .50 3.00 4.00 16.00 256.00 24.00 4.00 32.00 .25
29 PS/0811-7 SURGERY URINE 2.00 3.00 256.00 256.00 256.00 1024.00 48.00 32.00 2.00
30 PS/0809-5 ORTHOPEDIC WOUND 2.00 3.00 24.00 24.00 256.00 1024.00 256.00 32.00 3.00
31 PS/0809-4 MEDICAL URINE 32.00 32.00 256.00 16.00 16.00 1024.00 64.00 32.00 3.00
32 PS/0809-3 SURGERY URINE 2.00 3.00 256.00 32.00 256.00 1024.00 256.00 32.00 3.00
33 PS/0809-2 SURGERY URINE 32.00 32.00 256.00 192.00 256.00 1024.00 32.00 32.00 4.00
34 PS/0809-1 NEUROSURGERY URINE 1.50 3.00 256.00 256.00 256.00 1024.00 32.00 32.00 2.00
35 PS/0808-8 ORTHOPEDIC Tissue 32.00 32.00 16.00 256.00 96.00 32.00 126.00 1.50 1.50
36 PS/0808-7 ENT pus 4.00 1.00 256.00 1.00 1.00 64.00 6.00 32.00 2.00
37 PS/0808-6 SURGERY WOUND 1.50 32.00 256.00 24.00 128.00 1024.00 192.00 4.00 2.00
38 PS/0808-5 SURGERY URINE 32.00 32.00 256.00 128.00 256.00 1024.00 48.00 32.00 4.00
39 PS/0808-4 MEDICAL T/SUCTION 32.00 32.00 256.00 16.00 256.00 96.00 48.00 32.00 1.50
40 PS/0808-3 CICU T/SUCTION 32.00 32.00 32.00 48.00 256.00 2.00 4.00 .25 1.50
41 PS/0808-2 SURGERY URINE 32.00 32.00 256.00 256.00 32.00 1024.00 256.00 32.00 3.00
42 PS/0808-1 ORTHOPEDIC URINE 3.00 3.00 256.00 96.00 48.00 1024.00 256.00 32.00 3.00
43 PS/0807-3 MEDICAL WOUND 2.00 3.00 256.00 12.00 64.00 1024.00 96.00 3.00 2.00
44 PS/0807-2 SURGERY URINE 32.00 32.00 256.00 24.00 256.00 1024.00 32.00 32.00 2.00
45 PS/0807-1 SURGERY URINE 32.00 32.00 256.00 32.00 256.00 1024.00 24.00 32.00 2.00
46 PS/0806-4 SURGERY T/SUCTION 32.00 32.00 32.00 256.00 256.00 1024.00 256.00 32.00 2.00
47 PS/0806-3 ORTHOPEDIC URINE 32.00 32.00 32.00 6.00 256.00 1024.00 256.00 32.00 2.00
48 PS/0806-1 PAEDITRIC URINE 32.00 32.00 192.00 192.00 256.00 1024.00 256.00 32.00 1.00
49 PS/0806-2 GYNAECOLOGY URINE 32.00 32.00 256.00 256.00 96.00 1024.00 192.00 32.00 2.00
50 PS/0805-7 SURGERY URINE 32.00 32.00 256.00 32.00 256.00 1024.00 16.00 32.00 3.00
51 PS/0805-6 MEDICAL URINE 32.00 32.00 256.00 192.00 256.00 1024.00 24.00 32.00 1.00
52 PS/0805-5 ICU URINE 32.00 32.00 256.00 256.00 256.00 1024.00 24.00 32.00 1.00
53 PS/0805-4 SURGERY URINE 32.00 32.00 256.00 64.00 256.00 1024.00 24.00 32.00 2.00
54 PS/0805-3 MEDICAL URINE 32.00 32.00 64.00 256.00 256.00 1024.00 16.00 8.00 1.50
55 PS/0805-2 ICU lumen tip 32.00 32.00 256.00 256.00 16.00 1024.00 256.00 32.00 4.00
56 PS/0805-1 ICU WOUND 32.00 32.00 256.00 32.00 256.00 6.00 8.00 .25 3.00
57 PS/0804-3 MEDICAL URINE 1.50 3.00 256.00 64.00 256.00 1024.00 32.00 32.00 3.00
58 PS/0804-2 ENT WOUND 32.00 32.00 256.00 1.00 1.00 32.00 48.00 1.50 3.00
183
59 PS/0804-1 ORTHOPEDIC WOUND 1.50 3.00 12.00 24.00 256.00 1024.00 256.00 32.00 3.00
60 PS/0803-6 SURGERY URINE 32.00 32.00 256.00 256.00 24.00 1024.00 256.00 32.00 3.00
61 PS/0803-5 SURGERY Catheter tip 32.00 32.00 24.00 6.00 256.00 1024.00 256.00 32.00 4.00
62 PS/0803-4 PAEDITRIC peritoneal fluid 32.00 32.00 3.00 256.00 256.00 32.00 64.00 1.50 48.00
63 PS/0803-3 SURGERY URINE 32.00 32.00 256.00 256.00 24.00 1024.00 256.00 32.00 4.00
64 PS/0803-2 SURGERY URINE 32.00 32.00 256.00 24.00 16.00 48.00 32.00 32.00 3.00
65 PS/0803-1 MEDICAL SPUTUM 32.00 32.00 64.00 6.00 256.00 1024.00 64.00 32.00 3.00
66 PS/0802-6 MEDICAL Blood 32.00 32.00 64.00 24.00 256.00 1024.00 256.00 32.00 4.00
67 PS/0802-5 ORTHOPEDIC WOUND 32.00 32.00 256.00 8.00 256.00 1024.00 256.00 32.00 3.00
68 PS/0802-4 MEDICAL URINE 32.00 32.00 256.00 16.00 256.00 1024.00 256.00 32.00 1.50
69 PS/0909-1 NEUROSURGERY URINE 12.00 32.00 256.00 8.00 16.00 96.00 32.00 32.00 4.00
70 PS/0909-2 MEDICAL WOUND 32.00 32.00 48.00 16.00 256.00 1024.00 256.00 32.00 3.00
71 PS/0909-3 SURGERY Blood 1.00 3.00 256.00 16.00 64.00 1024.00 64.00 6.00 1.50
72 PS/0910-4 ORTHOPEDIC WOUND 32.00 32.00 256.00 32.00 24.00 256.00 96.00 32.00 3.00
73 PS/0910-3 MEDICAL URINE 32.00 32.00 256.00 32.00 24.00 1024.00 8.00 32.00 2.00
74 PS/0910-2 ENT URINE 32.00 3.00 256.00 16.00 96.00 1024.00 96.00 4.00 1.50
75 PS/0910-1 SURGERY SPUTUM 32.00 32.00 256.00 16.00 96.00 1024.00 96.00 4.00 2.00
76 PS/0911-4 ORTHOPEDIC Blood 32.00 32.00 256.00 48.00 256.00 1024.00 256.00 32.00 3.00
77 PS/0911-2 PAEDITRIC URINE 32.00 32.00 256.00 12.00 256.00 1024.00 128.00 32.00 2.00
78 PS/0911-1 MEDICAL URINE 32.00 3.00 256.00 32.00 96.00 1024.00 3.00 32.00 1.00
79 PS/0909-6 PAEDITRIC Blood 1.50 1.00 256.00 16.00 256.00 1024.00 98.00 12.00 1.50
80 PS/0909-5 SURGERY WOUND 32.00 32.00 256.00 256.00 256.00 1024.00 12.00 32.00 6.00
81 PS/0909-4 PAEDITRIC WOUND 3.00 1.50 256.00 16.00 128.00 1024.00 128.00 16.00 6.00
82 PS/0908-3 MEDICAL URINE 3.00 32.00 256.00 32.00 48.00 1024.00 256.00 32.00 4.00
83 PS/0908-2 ORTHOPEDIC WOUND 32.00 32.00 32.00 8.00 256.00 1024.00 256.00 32.00 4.00
84 PS/0907-4 ICU URINE 32.00 32.00 256.00 256.00 64.00 1024.00 256.00 32.00 2.00
85 PS/0907-3 MEDICAL URINE 3.00 3.00 16.00 0.25 0.94 1.00 0.64 32.00 2.00
86 PS/0907-2 MEDICAL SPUTUM 32.00 32.00 256.00 256.00 256.00 8.00 3.00 1.00 .50
87 PS/0907-1 SURGERY URINE 32.00 32.00 256.00 256.00 24.00 1024.00 256.00 32.00 12.00
88 PS/0906-4 MEDICAL Blood 32.00 32.00 48.00 16.00 256.00 1024.00 256.00 32.00 4.00
Abbreviations of antibiotics: IMP= imipenem (S ), MPM= meropenem (S , CAZ= ceftazidime
( S , AZT= aztreonam ( S , PPT= piperacillin/tazobactam ( S , GN=
gentamicin ( S , AK= amikacin ( S , CIP=ciprofloxacin ( S AND CL= colistin
( S . PS: (P. aeruginosa). MIC=  minimum inhibition concentration break point for P. aeruginosa according to CLSI
(Wikler,2008).
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No. mRNA expression level (fold)levels mRNA transcription levels
WARD SOURCE MexB MexY MexZ MexC
D
MexE
F
AmpC OprD OprM PBP2 PBP3
# P. aeruginosa ATCC 27583 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
1 ORTHOPEDIC WOUND 2.84 18.07 4.21 4.64 2.23 .56 .50 .18 .31 .50
2 NEUROSURGERY WOUND 2.13 .42 .45 482 51.60 12.19 .41 .20 .21 .71
3 SURGERY WOUND 0.80 4.46 .31 6.13 4.25 19.03 .11 .07 .08 .57
4 NEUROSURGERY T/SUCTION 2.88 4.31 .42 2.56 3.25 .61 .33 .20 .26 .05
5 SURGERY URINE 4.10 40.50 7.29 .42 .23 632 1.28 2.01 .40 .25
6 PAEDITRIC URINE 2.41 25.48 4.73 4.37 .63 12.94 .47 .36 .00 .19
7 SURGERY URINE 2.61 8.87 2.31 .50 .30 .64 .27 .46 .40 .17
8 GYNAECOLOGY URINE 0.51 .83 .26 .34 .73 14.92 .22 .07 .22 .31
9 SURGERY WOUND 3.44 21.62 3.88 .98 2.75 13.41 .27 .35 .82 .75
10 ORTHOPEDIC WOUND 2.03 .33 .46 2.43 2.06 .60 .31 .32 .55 .03
11 NEUROSURGERY URINE 11.50 4.44 .42 15.75 23.91 .63 .46 .35 .58 .15
12 ORTHOPEDIC WOUND 4.26 11.12 3.10 4.37 11.13 .52 .46 .35 .61 .67
13 NEUROSURGERY URINE 2.30 10.31 5.70 2.43 3.15 18.54 .74 .51 .18 .84
14 MEDICAL T/SUCTION 2.62 43.49 3.77 3.35 40.41 .99 .25 .18 .22 .49
15 SURGERY URINE 2.63 7.06 2.69 19.98 159.7 .44 .23 .33 .23 .08
16 SURGERY URINE 2.23 4.28 2.04 2.50 2.35 .26 .18 .17 .06 .04
17 PAEDITRIC CSF 3.60 4.49 4.77 2.40 2.96 .84 .57 .49 .57 .33
18 NEUROSURGERY SPUTUM 2.40 5.79 2.60 5.24 9.58 17.58 .49 3.75 .41 .07
19 SURGERY URINE 2.07 4.99 2.04 22.18 15.27 .26 .21 .19 .07 .02
20 ORTHOPEDIC URINE 2.20 5.68 .02 2.00 4.23 16.69 .13 .28 .12 .41
APPENDIX III Raw data supplement
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21 SURGERY WOUND .55 7.78 2.84 2.90 2.00 13.75 .19 .14 .20 .09
22 SURGERY URINE 6.98 4.61 7.43 7.50 12.03 12.27 .49 3.68 1.51 .21
23 SURGERY SPUTUM 3.84 7.01 8.22 3.89 52.44 12.81 .20 2.47 5.24 .31
24 MEDICAL URINE 4.30 4.58 4.67 6.80 8.43 .09 .37 6.73 3.25 .53
25 MEDICAL URINE 2.17 .02 6.38 52.69 2.93 12.99 .47 2.53 19.88 .16
26 SURGERY Tissue 2.44 49.14 4.88 2.91 4.42 .61 .43 .53 .54 .66
27 SURGERY URINE 3.42 13.85 5.27 .36 2.89 28.92 .48 .67 .44 .37
28 MEDICAL URINE 6.14 15.81 2.83 5.24 7.93 12.03 1.07 .64 .28 .25
29 SURGERY URINE 2.40 1731 408 .05 2.29 12.99 .56 .48 1.10 4.13
30 ORTHOPEDIC WOUND 2.50 8.81 .10 22.19 9.18 19.58 .10 3.14 .20 .42
31 MEDICAL URINE 0.74 4.34 .74 2.85 6.18 .58 .12 .72 .30 .48
32 SURGERY URINE 50.06 410.0 7.52 .35 .40 15.23 3.54 18.59 3.73 6.37
33 SURGERY URINE 4.67 69.49 4.63 5.28 2.96 147.0 .12 .58 .67 .08
34 NEUROSURGERY URINE 2.47 83.16 6.82 .60 .20 .22 .17 3.30 .10 .14
35 ORTHOPEDIC Tissue 2.70 20.43 2.84 .51 .42 13.71 .28 7.49 .09 .05
36 ENT pus 11.60 9.47 4.73 .20 .11 16.21 .69 12.47 .83 .54
37 SURGERY WOUND 2.14 10.56 2.13 2.99 7.55 .17 .11 .70 .25 .26
38 SURGERY URINE 20.82 45.61 14.52 2.03 2.62 102.2 .08 11.10 .30 .44
39 MEDICAL T/SUCTION 10.98 4.53 .15 2.47 3.52 114.6 .36 7.10 .38 .37
40 CICU T/SUCTION .23 .18 .50 .10 .42 237.4 .16 .41 .15 .15
41 SURGERY URINE 3.81 52.99 .43 .36 .66 14.92 .83 3.63 .50 .28
42 ORTHOPEDIC URINE 0.56 13.97 .05 .48 .72 13.41 .58 1.06 .34 .14
43 MEDICAL WOUND 0.26 5.86 .15 .40 .70 16.94 .17 .22 .08 .02
44 SURGERY URINE 0.46 4.11 .02 .38 .27 17.00 .32 .44 .33 .26
45 SURGERY URINE 0.37 8.71 .00 2.45 .00 14.50 .19 .45 .51 .04
46 SURGERY T/SUCTION .49 16.78 .26 .78 2.10 19.70 .41 .38 .13 .04
47 ORTHOPEDIC URINE .26 7.92 .21 .00 .00 13.70 .14 .15 .82 .04
48 PAEDITRIC URINE 2.50 23.48 .30 .94 .07 12.90 .28 1.16 .16 .04
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49 GYNAECOLOGY URINE 0.73 .00 .05 .82 .40 11.40 .36 .65 .12 .06
50 SURGERY URINE 2.77 8.51 2.48 4.88 2.21 18.64 .14 .29 .14 .08
51 MEDICAL URINE 2.30 4.74 2.85 9.33 6.77 12.85 .73 .53 .48 .17
52 ICU URINE 4.90 .04 3.86 4.33 6.23 15.82 .26 .77 2.78 .05
53 SURGERY URINE 0.64 25.99 .62 .38 .39 13.29 .42 .22 .08 .13
54 MEDICAL URINE 8.01 32.54 2.70 2.43 2.35 1806 .46 3.71 .12 .13
55 ICU lumen tip 6.29 13.19 4.16 2.25 2.96 12.99 .40 .03 .69 .13
56 ICU WOUND 5.08 .00 5.94 .03 .11 14.37 .07 .74 .89 1.12
57 MEDICAL URINE 3.33 31.84 2.23 6.69 54.51 .43 .17 2.41 .30 .37
58 ENT WOUND 6.80 4.75 4.87 11.40 13.55 .82 .21 2.71 1.62 .67
59 ORTHOPEDIC WOUND 3.95 4.31 3.48 .09 .22 16.13 .31 .41 .74 .41
60 SURGERY URINE .50 .37 .58 8.44 3.58 10.41 .04 .39 .63 .27
61 SURGERY Catheter tip 0.03 5.75 .10 2.14 2.73 15.74 .07 .13 .19 .03
62 PAEDITRIC peritoneal fluid 0.65 105 314 858 371 12.67 .07 .02 1.57 3.91
63 SURGERY URINE 0.61 35.54 .32 2.68 2.90 12.63 .63 .57 .45 .15
64 SURGERY URINE 0.01 29.89 .32 .51 .25 17.12 .35 2.67 .37 .12
65 MEDICAL SPUTUM 2.32 6.84 .25 2.78 2.06 12.26 .11 .04 .08 .15
66 MEDICAL Blood 2.33 20.89 .99 .88 2.00 .29 .03 4.55 .22 .18
67 ORTHOPEDIC WOUND 2.33 27.31 2.97 72.04 4.86 .54 .07 3.82 .67 .60
68 MEDICAL URINE 5.88 74.39 3.67 177.6 165.6 .63 .18 1.52 .55 .47
69 NEUROSURGERY URINE 6.81 230.8 8.95 4.02 10.13 16.94 .93 1.21 .83 1.38
70 MEDICAL WOUND 4.73 279.8 8.94 28.18 21.07 16.87 .67 .99 .35 1.49
71 SURGERY Blood 2.06 4.95 8.38 .23 .12 .88 .15 .44 .35 1.90
72 ORTHOPEDIC WOUND 9.86 123.1 8.96 5.20 4.78 12.86 .47 2.34 1.56 .97
73 MEDICAL URINE 4.32 24.63 3.87 3.26 6.14 .20 .45 2.52 .94 .59
74 ENT URINE 38.37 .49 2.91 .31 .54 12.40 .41 1.06 1.14 1.42
75 SURGERY SPUTUM 102 .54 2.03 522 3.26 .81 .83 5.15 .05 9.76
76 ORTHOPEDIC Blood .35 .59 2.62 2.80 4.20 .53 .05 .18 1.18 .54
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77 PAEDITRIC URINE 3.72 4.76 2.55 4.78 18.13 17.56 .53 1.29 3.28 .42
78 MEDICAL URINE 2.15 123 272.8 .14 .23 12.37 .11 .47 4.12 3.12
79 PAEDITRIC Blood .39 4.40 14.33 .47 .73 .21 .06 .73 .46 .90
80 SURGERY WOUND 17.10 .01 5.03 7.30 12.30 .18 .57 1.89 4.67 2.57
81 PAEDITRIC WOUND 4.81 14.35 15.64 .72 .32 12.13 .40 .67 2.09 1.61
82 MEDICAL URINE .03 .35 .63 207.1 130.7 .82 .02 .17 .40 .45
83 ORTHOPEDIC WOUND 5.24 29.52 6.64 11.81 2.96 73.88 .26 .69 4.91 .32
84 ICU URINE 2.05 821.7 914 2.41 7.92 .95 .16 .85 1.99 .56
85 MEDICAL URINE .47 .64 .74 .64 .51 .01 .64 .29 3.62 2.30
86 MEDICAL SPUTUM .69 .73 .58 16.37 19.42 .16 .16 .71 .82 .01
87 SURGERY URINE .61 222.5 137 2.75 15.89 13.78 .04 .54 .39 .69
88 MEDICAL Blood 2.27 329.2 947 14.49 8.79 12.56 .02 .52 2.66 1.21
The mRNA transcription levels of gene expression of multidrug resistant isolates in comparison to P. aeruginosa ATCC 27583
(n=88)
APPENDIX IV
PCR amplification of genes
1. Gradient qRT-PCR oprD gene
1.1 Amplification conditions
1.1 Melting curve
Real-time RT-PCR-Standard curves of OprD gene
Amplification conditions
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2. Standard curve of qRT-PCR oprD gene
2.1 Amplification conditions
2.2 Standard curve
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3. Standard curve of qRT-PCR mexB gene
3.1 Amplification conditions
3.2 Standard curve
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4 Reference gene (rpoD)
4.1 Amplification conditions
Melting peak
.4.2 Amplification conditions
Melting curve
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Reresnative examples for the statistical analysis (Chi and Fisher's exact test)
Crosstabs
Notes
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
GENTA1 *
MEXY1 88 91.7% 8 8.3% 96 100.0%
GENTA1 * MEXY1 Cross tabulation
Count
MEXY1
Totaldown up
GENT
A1
S 2 0 2
I 2 1 3
R 12 71 83
Total 16 72 88
Chi-Square Tests
Value df
Asymp.
Sig. (2-
sided)
Pearson Chi-
Square
14.515(a
) 2 .001
Likelihood Ratio 11.040 2 .004
Linear-by-Linear
Association 14.221 1 .000
N of Valid Cases 88
a  4 cells (66.7%) have expected count less than 5. The minimum expected count is .36.
GENTA1: GENTAMICIN
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Crosstabs
Notes
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
IMIP1 *
PBP31 88 91.7% 8 8.3% 96 100.0%
IMIP1 *
OPRD1 88 91.7% 8 8.3% 96 100.0%
IMIP1 * PBP31
Crosstab
Count
PBP31
Totaldown up
IMIP
1
S 16 7 23
R 58 7 65
Total 74 14 88
Chi-Square Tests
Value df
Asymp.
Sig. (2-
sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-
Square 4.911(b) 1 .027
Continuity
Correction(a) 3.551 1 .060
Likelihood Ratio 4.433 1 .035
Fisher's Exact
Test .043 .034
Linear-by-Linear
Association 4.855 1 .028
N of Valid Cases 88
a  Computed only for a 2x2 table
b  1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.66.
IMIP1: IMIPENEM
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IMIP1* OPRD1
Crosstab
Count
OPRD1
Totaldown up
IMIP
1
S 20 3 23
R 65 0 65
Total 85 3 88
Chi-Square Tests
Value df
Asymp.
Sig. (2-
sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-
Square 8.777(b) 1 .003
Continuity
Correction(a) 5.263 1 .022
Likelihood Ratio 8.357 1 .004
Fisher's Exact
Test .016 .016
Linear-by-Linear
Association 8.678 1 .003
N of Valid Cases 88
a  Computed only for a 2x2 table
b  2 cells (50.0%) have expected count less than 5. The minimum expected count is .78.
IMIP1: IMIPENEM
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Pseudomonas aeruginosa is considered as one of the leading causes of nosocomial infections.  The 
start of antimicrobial therapy is often empirical and selective pressure on panel of antibiotics; therefore, 
it is important to know the susceptibility pattern of pathogens in order to select the most appropriate 
antibiotic. The aim of the current study is to update the rational empirical antimicrobial therapy 
recommendations. Antimicrobial resistance was done using the E-test method. Urine and wound swab 
samples were the highest encountered isolates; results were interpreted according to National 
Committee for Clinical Laboratory Standards guidelines. A total of 88 clinical isolates of P. aeruginosa 
were collected randomly from April 2009 to March 2010 from the University of Malaya Medical Center. P. 
aeruginosa isolated from various clinical samples has lost susceptibility and showed increasing 
resistance to Gentamicin with 94.3%, followed by (ciprofloxacin) 92%, (ceftazidime) 89.8%, (imipenem) 
73.9%, Pipracilline/tazobactam 61.4%, (aztreonam) 52.3%, and (amikacin) 50% and only susceptible to 
colistin with 92%. In conclusion, most of the isolates showed high levels of resistance to examined 
antibiotics except colistin and this may indicate the importance of antibiotic susceptibility testing and 
optimal treatment by combination of drugs. 
 
Key words: Pseudomonas aeruginosa, antimicrobial resistance, nosocomial infections, Malaysia.  
 
 
INTRODUCTION 
 
Pseudomonas aeruginosa is considered as one of the 
leading nosocomial pathogens worldwide (Strateva and 
Yordanov, 2009). It is mostly the causes of morbidity and 
mortality cases. A problem is made worse when 
nosocomial pathogens acquire antibiotic resistance 
(Lagamayo, 2008). The emergence of this organism has 
a significant impact on treatment outcomes and poses a 
challenge to the provision of health care and cost-
effectiveness.  
Unfortunately, the resistance to antipseudomonal 
agents is on the rise (Rubin et al., 2008). P. aeruginosa is  
 
 
 
*Corresponding author. E-mail: yasim@um.edu.my. Tel: 03-
79492152. 
known to readily develop multi-drug resistance to various 
classes of antimicrobial agents, the extensive use of 
antimicrobial agents and the evolutionary antimicrobial 
resistance strategies of bacteria have resulted in the 
emergence of pan-drug resistant bacteriathat is, bacteria 
with evidence resistance against antipseudomonal 
penicillin's, cephalosporin's, carbapenem, monobactam, 
aminoglycosides, fluroquinolone and polymyxins (Babic 
et al., 2006). In this regard, the current study aims to 
update the rational empirical antimicrobial therapy recom-
mendation. P. aeruginosa isolates were considered to be 
multidrug resistant if the isolate was resistant to at least 
three of the following eight drugs: Pipracilline/ 
tazobactam, ceftazidime, aztreonam, amikacin, 
gentamicin, ciprofloxacin, imipenem and colistin. These 
agents were selected as  representatives  of  the  primary  
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Figure 1. Antibiotic resistance of P. aeruginosa. 
 
 
 
antibiotic classes used to treat P. aeruginosa infections. 
 
 
MATERIALS AND METHODS 
 
Study location 
 
P. aeruginosa were collected randomly from April 2009 to March 
2010 from the University of Malaya Medical Center. 
 
 
Bacterial isolate 
 
A total of 88 P. aeruginosa clinical isolates isolated from various 
samples collected from different wards of University of Malaya 
Medical Center. P. aeruginosa colonies were identified based on 
morphology, grams staining, pyocyanin production and biochemical 
test by API20NE test (bioMérieux, Marcy-l’Etoile, France).  
According to the manufacturer’s instructions using standard 
laboratory procedures (Osterhout et al., 1991). 
 
 
Antibiotic susceptibility testing 
 
The susceptibility of various antibiotics against clinical isolates of P. 
aeruginosa was determined using E-test (BIOMERUX) in 
accordance with the guidelines of the Clinical and Laboratory 
Standards Institute (Tholen, 2006). P. aeruginosa ATCC 27853 
were utilized as quality control strains. The antimicrobial tested in 
this study were pipracilline/tazobactam, ceftazidime, aztreonam, 
amikacin, gentamicin, ciprofloxacin, imipenem and colistin. 
The minimum inhibitory concentration (MIC) for each antibiotic 
was determined on Mueller- Hinton agar by the E-test® method 
according to 2006 CLSI, guidelines. Overnight cultures of P. 
aeruginosa on Mueller-Hinton broth were diluted to an initial cell 
density of 107 cfu/ml with fresh Mueller-Hinton broth. Inoculums of 
105 cfu to achieve a bacterial suspension equivalent to a 0.5 
McFarland turbidity standard. Two different E-test® antimicrobial 
strips  placed in opposite gradient directions on Mueller-Hinton agar 
plate by sterile forceps, printed MIC values are faced upward, [that 
is, that the bottom surface of the strip containing the antimicrobial 
gradient is in contact with the agar.  
The plates incubated in an inverted position at 37°C  for 20 to 24 
h and after incubation. The MICs were read in the intersection point 
of inhibitory eclipse according to the manufacturer’s 
recommendation. 
 
 
RESULTS 
 
P. aeruginosa isolated from various clinical samples 
showed increasing resistance to Gentamicin with 94.3%, 
followed by (ciprofloxacin) 92%, the (ceftazidime) 89.8%, 
the (imipenem) 73.9%, pipracilline/tazobactam 61.4%, 
(aztreonam) 52.3%, and (amikacin) 50% and only 
susceptible to colistin with 92 % (Figure 1). 
Most clinical isolates of P. aeruginosa were isolated 
from urine samples (53.4%), followed by wound (21.5 %), 
sputum 5.6%, blood 5.6%, tissue 2.2% and 1.13% for 
other samples (Table 1) Specimens were isolated from 
different hospital wards. 31 were obtained from surgery 
ward, 20 from general medicine wards, 13 from 
orthopedics wards, 7 from paediatric wards, 7 from 
Neurosurgery wards, 4 from intensive care units, 1 from 
Cardiac intensive care units, 3 from ENT and 2 from 
Gynecology wards (Table 2). In the present studies the 
highest resistant rate of P. aeruginosa infections were 
observed in the surgical department for all antibiotics 
except colistin that showed the least of resistance 
followed by the Department of Medicine and Orthopedic 
(Table 3). The MICs of different antibiotics against P. 
aeruginosa based on the site of the specimen appear 
highly resistant with urine and wound specimen to be 
most of the antibiotic except colistin (Table 4).   
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Table 1. The distribution of P. aeruginosa from various clinical specimens. 
 
Source/Site No of isolates % 
Urine 47 53.4 
Wound 19 21.6 
Sputum 5 5.6 
T/suction 5 5.6 
Blood 5 5.7 
Tissue 2 2.3 
Pus 1 1.1 
Lumen tip 1 1.1 
Catheter tip 1 1.1 
Peritoneal fluid 1 1.1 
CSF 1 1.1 
Total 88 100 
 
 
 
Table 2. Distribution of specimens based on wards. 
 
Wards Specimen type 
wound T/suction Urine CSF sputum Tissue Pus Lumen tip Catheter Peritoneal fluid Blood Total 
Orthopedic 8 0 3 0 0 1 0 0 0 0 1 13 
Neurosurgery 1 1 4 0 1 0 0 0 0 0 0 7 
Surgery 5 1 20 0 2 1 0 0 1 0 1 31 
Paeditric 1 0 3 1 0 0 0 0 0 1 1 7 
Gynaecology 0 0 2 0 0 0 0 0 0 0 0 2 
Medicine 2 2 12 0 2 0 0 0 0 0 2 20 
Cicu 0 1 0 0 0 0 0 0 0 0 0 1 
Ent 1 0 1 0 0 0 1 0 0 0 0 3 
ICU 1 0 2 0 0 0 0 1 0 0 0 4 
Total 19 5 47 1 5 2 1 1 1 1 5 88 
 
 
 
DISCUSSION  
 
P. aeruginosa emerged as an important pathogen 
and responsible for nosocomial infections that is 
one of the important causes of morbidity and 
mortality among hospital patients. 
In this study, 88 isolates of  P.  aeruginosa  from  
clinical samples received from University of 
Malaya Medical Centre were studied. These num-
bers represent the multidrug resistance isolates. 
The two similar studies, show low rate of 
resistance in the last three years however this 
study confirm the increasing rate of resistance 
rate    of    colistin     (Raja    and    Singh,     2007;  
Pathmanathan et al., 2009).  
Most of the isolates in current study were 
collected from urine samples, accounted for 
53.4% of the total isolates; this is not surprising as 
the fact that almost all patients going in for major 
surgery would be get catheterized. Another study 
has   been   shown   that   the  use   of   indwelling  
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Table 3. Antibiotic resistance of P. aeruginosa based on wards. 
 
Antibiotics ORTH. NEURO. SURG. PAED. GYNAE. MEDIC. CICU ENT ICU Total 
Imipenem 
S 4 1 7 2 0 6 0 2 0 22 30.8% 14.3% 22.6% 28.6% 0% 30 % 0.0% 66.7% 0.00% 25.0% 
M 0 1 0 0 0 0 0 0 0 1 0.0% 14.3% 0.0% 0.0% 0% 0% 0.0% 0.00% 0.0% 1.1% 
R 9 5 24 5 2 14 1 1 4 65 69.2% 71.4% 77.4% 71.4% 100% 70 % 100.0% 33.3% 100.0% 73.9% 
Total 13 7 31 7 2 20 1 3 4 88 100.0% 100.0% 100.0% 100.0% 100% 100.0% 100.0% 100.0% 100.0% 100.0% 
           
Ceftazidime 
S 0 0 0 1 0 2 0 1 0 4 0.0% 0.0% 0.0% 14.3% 0.0% 10.0% 0.0% 33.3% 0.0% 4.5% 
M 1 0 0 0 0 0 0 0 0 1 
7.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.1% 
R 12 7 31 6 2 18 1 2 4 83 92.3% 100.0% 100.0% 85.7% 100.0% 90.0% 100.0% 66.7% 100.0% 94.3% 
Total 13 7 31 7 2 20 1 3 4 88 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
           
Amikacin 
S 0 1 6 1 1 8 1 1 1 20 0.0% 14.3% 19.4% 14.3% 50.0% 40.0% 100.0% 33.3% 25.0% 22.7% 
M 3 5 11 0 0 3 0 1 1 24 23.1% 71.4% 35.5% 0.0% 0.0% 15.0% 0.0% 33.3% 25.0% 27.3% 
R 10 1 14 6 1 9 0 1 2 44 76.9% 14.3% 45.2% 85.7% 50.0% 45.0% 0.0% 33.3% 50.0% 50.0% 
Total 13 7 31 7 2 20 1 3 4 88 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
           
Pipracilline/ 
tazobactam 
S 4 6 11 0 0 6 0 2 2 31 30.8% 85.7% 35.5% 0.0% 0.0% 30.0% 0.0% 66.7% 50.0% 35.2% 
M 2 0 1 0 1 1 0 1 0 6 15.4% 0.0% 3.2% 0.0% 50.0% 5.0% 0.0% 33.3% 0.0% 6.8% 
R 7 1 19 7 1 13 1 0 2 51 53.8% 14.3% 61.3% 100.0% 50.0% 65.0% 100.0% 0.0% 50.0% 58.0% 
Total 13 7 31 7 2 20 1 3 4 88 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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Table 3. Cont. 
 
Antibiotics ORTH. NEURO. SURG. PAED. GYNAE. MEDIC. CICU ENT ICU Total 
Ciprofloxacin 
S 0 0 0 0 0 1 1 0 1 3 0.0% 0.0% 0.0% 0.0% 0.0% 5.0% 100.0% 0.0% 25.0% 3.4% 
M 1 0 1 1 0 1 0 1 0 5 7.7% 0.0% 3.2% 14.3% 0.0% 5.0% 0.0% 33.3% 0.0% 5.7% 
R 12 7 30 6 2 18 0 2 3 80 92.3% 100.0% 96.8% 85.7% 100.0% 90.0% 0.0% 66.7 75.0% 90.9% 
Total 13 7 31 7 2 20 1 3 4 88 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
           
Colistin 
S 11 7 28 5 2 20 1 3 4 81 84.6% 100.0% 90.3% 71.4% 100.0% 100.0% 100.0% 100.0% 100.0% 92.0% 
M 1 0 2 1 0 0 0 0 0 4 7.7% 0.0% 6.5% 14.3% 0.0% 0.0% 0.0% 0.0% 0.0% 4.5% 
R 1 0 1 1 0 0 0 0 0 3 7.7% 0.0% 3.2% 14.3% 0.0% 0.0% 0.0% 0.0% 0.0% 3.4% 
Total 13 7 31 7 2 20 1 3 4 88 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
           
Gentamicin 
S 0 0 0 0 0 1 1 0 0 2 0.0% 0.0% 0.0% 0.0% 0.0% 5.0% 100.0% 0.0% 0.0% 2.3% 
M 0 0 0 1 0 1 0 0 1 3 0.0% 0.0% 0.0% 14.3% 0.0% 5.0% 0.0% 0.0% 25.0% 3.4% 
R 13 7 31 6 2 18 0 3 3 83 100.0% 100.0% 100.0% 85.7% 100.0% 90.0% 0.0% 100.0% 75.0% 94.3% 
Total 13 7 31 7 2 20 1 3 4 88 
 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
           
Aztreonam 
S 4 1 3 0 0 2 0 2 0 12 30.8% 14.3% 9.7% 0.0% 0.0% 10.0% 0.0% 66.7% 0.0% 13.6% 
M 2 2 7 5 1 9 0 1 0 27 15.4% 28.6% 22.6% 71.4% 50.0% 45.0% 0.0% 33.3% 0.0% 30.7% 
R 7 4 21 2 1 9 1 0 4 49 53.8% 57.1% 67.7% 28.6% 50.0% 45.0% 100.0% 0.0% 100.0% 55.7% 
Total 13 7 31 7 2 20 1 3 4 88 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
The abbreviations ORTH, NEURO, SURG, PAED, GYNAE, MEDIC, CICU, ENT, ICU designated for orthopedic , neurosurgery, surgery ,pediatrics, gynaecologyl, medicinal, cardic intensive 
care unit, ear nose throat, intensive care unit, respectively. 
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Table 4. Antibiotic susceptibility pattern of pseudomonas aeruginosa isolates based on site of specimens. 
 
Source Imipenm Ceftazidim Amikacin Aztronam Pipracillin/tazobactam Ciprofloxacin Colistin Gentamicin 
Urine S M R S M R S M 
Wound 12 1 34 1 0 46 10 17 
Sputum 6 0 13 0 1 18 5 4 
T/suction 0 0 5 1 0 4 2 0 
Blood 0 0 5 0 0 5 1 2 
Tissue 2 0 3 0 0 5 0 0 
Pus 1 0 1 0 0 2 0 1 
Lumen tip 1 0 0 1 0 0 1 0 
Catheter tip 0 0 1 0 0 1 0 0 
Peritoneal fluid 0 0 1 0 0 1 0 0 
CSF 0 0 1 1 0 0 0 0 
 
 
 
catheters lead to an inherent risk for infection 
(Olayinka et al., 2004). 
Isolates  collected from wound infections re-
present (21.59 %), the wound infections different 
from patient to patient, in addition from one 
hospital to another, from one surgical procedure 
to other (Humphreys, 2009), in many cases 
hospital patients used broad-spectrum antibiotics 
as prophylaxis are mostly colonized by P. 
aeruginosa in the lower intestinal tract (Zuanazzi 
et al., 2010). 
Blood and sputum represent 5.6% of the 
isolates isolated in the present study. This may be 
referred due to the empirical therapy of P. 
aeruginosa infection and high pressure of this 
drugs choice, there is a concordance in the highly 
susceptibility to as the low number of this samples 
sent in during the study period. Furthermore, P. 
aeruginosa is the main cause for pneumonia and 
septicemia with attributable deaths reaching 30% 
in immunocompromised patients (Scarffand and 
Goldberg, 2008). 
The incidence of multidrug resistant P. 
aeruginosa often changeable dramatically 
between communities, hospitals in the same  area  
and among many patient, populations in the same 
hospital (Wroblewska et al., 2006; Marcel et al., 
2008). This variation faced by physician in the 
clinical treatment to be responsible for madding 
clinical management on the antibiotic choice to be 
effectively and correctly use according to the 
update data on the prevalence and resistance 
pattern. 
The antibiotic policy guidelines preparation is 
the need to avoid any bitter experience of misuse 
of this class of drug therapy, the team efforts of 
the members comprising consultants, prescribing 
physicians, and members of health services team 
should participate in producing an effective plan to 
make better decisions in this regards (Masood, 
2010). In addition, surveillance programs should 
be conducted periodically to evaluate the sensi-
tivity and susceptibility of these bacteria against 
prescribed antibiotics. Since the emergence of 
resistance remains silent for some periods and 
takes time to become apparent, these antibiotics 
should be prescribed with cautions so that the 
bitter experience of antibiotic resistance can be 
avoided (Jombo et al., 2010). These in vitro 
sensitivity   studies   also   help   in  cost-effective; 
prescribing different brands of the antibiotic to the 
different patients with varying socioeconomic 
back-grounds (Masood, 2010). Overall, resistance 
patterns in different regions should be conducted 
so that the profiles of the specific region are 
maintained and monitored accordingly. This will 
therefore act as a guide towards the formulation of 
a comprehensive monitoring program of 
chemotherapy. 
In conclusion, most of the clinical isolates had a 
high level of resistance to examined antibiotics 
except colistin. Inappropriate and incorrect 
administration of antimicrobial agents in empiric 
therapies could be one of the reasons of this 
alarming phenomenon. This problem indicates 
importance of performing antibiotic susceptibility 
testing. What is most worrying is the fact that 
there is a prevalence of a multiresistant 
phenotype that was only sensitive to colistin. The 
emergence and rapid spread of multidrug-
resistant isolates of P. aeruginosa are of great 
concern worldwide. It is necessary to limit the 
overuse of antibiotics and to implement a new 
antibiotic policy and continuous efforts of clinician, 
microbiologist,   pharmacist   and    community   to  
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promote greater understanding of this problem, better 
hygiene, postoperative care and management. 
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